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Sub-lethal preconditioning stimuli can confer neuronal tolerance by triggering the activation of 
endogenous survival pathways that limit or resist subsequent injury.  Recent evidence has 
demonstrated that neuroprotection is paradoxically dependent on the sub-lethal activation of cell 
death mediators.  As intracellular Zn2+ accumulation has been closely associated with neuronal 
cell death pathways, I tested the hypothesis that neuronal tolerance is also dependent on sub-
lethal Zn2+ signals.  I found that preconditioning triggered an immediate transient rise in 
neuronal free Zn2+, while lethal excitotoxicity led to a delayed accumulation of the metal.  The 
sub-lethal rise in Zn2+ was necessary and sufficient in attenuating subsequent Zn2+-dependent 
toxicity in preconditioned neurons.  Chelating Zn2+ during the preconditioning stimulus restored 
the lethal excitotoxic accumulation in neuronal Zn2+ and abolished neuronal tolerance.  These 
data suggested that preconditioning-induced Zn2+ could trigger mechanisms for preventing 
subsequent Zn2+-dependent cell death.  Indeed, preconditioning triggered protein kinase C 
(PKC)-dependent Zn2+-regulated gene expression in neurons.  Examination of the mechanism 
involved in modulating Zn2+-regulated gene expression revealed a surprisingly early role for 
PKC in directly modifying the intracellular source of Zn2+.  A conserved PKC phosphorylation 
site was identified at serine 32 of the metal binding protein metallothionein, which was important 
in modulating Zn2+ regulated gene expression and ultimately conferring neuronal tolerance.  In 
addition to modulating gene expression, Zn2+ signals may also be important in mediating the 
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acute cellular response to stress.  Here, I found a critical role for the transient Zn2+ rise in 
modulating changes in voltage-gated potassium channel activity and localization following 
ischemia.  Together, these data strongly suggest that a transient rise in neuronal free Zn2+ is an 
important early signal in conferring neuronal tolerance and in mediating acute cellular adaptive 
responses to stress.  Thus, Zn2+ is a previously unrecognized, highly regulated signaling 
component in the initiation of survival pathways in neurons.   
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1.0  GENERAL INTRODUCTION 
1.1 THESIS OVERVIEW 
Zinc has been referred to as the “calcium of the 21st century”, reflecting its diverse roles in 
normal cell physiology and, in turn, its deregulation as a contributor to cellular pathological 
changes (Frederickson et al., 2005).  Relatively abundant in the mammalian brain, Zn2+ plays a 
critical role as a structural component of numerous proteins and transcription factors, and has 
recently emerged as a neuromodulator and intracellular signaling factor (Frederickson and Bush, 
2001; Yamasaki et al., 2007).  The concentration of intracellular free, or “chelatable” Zn2+, is 
maintained in the picomolar range under normal conditions due to exquisite regulation by metal 
binding proteins, a family of Zn2+ efflux transporters, and compartmentalization into organelles 
(Frederickson, 1989; Sensi et al., 1997).  However, an accumulation of free Zn2+, likely mediated 
by liberation of the metal from intracellular stores (Aizenman et al., 2000b) along with 
translocation from presynaptic vesicles (Koh et al., 1996), plays an important role in ischemic 
neurodegeneration (Weiss et al., 2000).   
 
Neuronal tolerance to lethal ischemic cell death can be conferred by sub-lethal 
preconditioning stimuli, which activate endogenous survival pathways that limit or resist 
subsequent lethal injury (Kitagawa et al., 1990).  Interestingly, increasing evidence suggests that 
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preconditioning stimuli induce the sub-lethal activation of cell death factors that trigger survival 
pathways, which can prevent lethal injurious signaling (O'Duffy et al., 2007).  In light of this 
idea, I hypothesized that a sub-lethal rise in neuronal free Zn2+ would activate endogenous 
protective mechanisms to prevent subsequent Zn2+-dependent injury.  In this dissertation, I 
establish a novel role for Zn2+ as an important, early signal in the initiation of survival pathways 
critical to neuronal tolerance.  The results from these studies offer insights into endogenous 
mechanisms that protect neurons in the face of lethal cellular injury.     
1.2 THE SIGNIFICANCE OF STROKE 
Stroke is the second leading cause of death worldwide and the third leading cause of death in the 
United States, accounting for about 10% of all deaths (Rothwell, 2001). However, mortality data 
do not capture the true burden of stroke, as there are more than 3.5 million survivors of stroke in 
the US alone (Lo et al., 2003).  In fact, most strokes are not fatal, but instead result in severe 
limitations with activities of daily living as well as serious long-term disability, such as 
dementia, depression, epilepsy, falls, and fractures (Rothwell, 2001; Lo et al., 2003).  Strokes 
occur due to an occlusion or hemorrhage of blood vessels supplying the brain.  Ischemic strokes, 
caused by a loss of blood flow to an area of the brain due to an occluded vessel, occur more 
commonly than hemorrhagic strokes, which are due to vessel rupture (Lo et al., 2003).  
Regardless of etiology, strokes ultimately result in neuronal dysfunction and death, manifesting 
in a spectrum of neurological deficits that reflect the location of the compromised brain area.  
Although a large body of research has implicated several molecular cascades as possible 
neuroprotective therapeutic targets, the translation of experimental results into clinical practice 
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remains challenging and, thus far, largely unsuccessful.  Studies aimed at understanding 
endogenous molecular mechanisms of neuronal protection may provide novel therapeutic targets 
and intervention strategies for stroke.    
1.3 EXCITOTOXICITY MODELS ISCHEMIC NEURONAL DEATH 
The cellular and molecular mechanisms of stroke pathophysiology are centered around three 
fundamental overlapping pathways of neuronal cell death:  excitotoxicity, oxidative and 
nitrosative stress, and apoptosis (Lo et al., 2003).  Of these, excitotoxicity, a term first coined by 
Olney referring to neuronal injury elicited by glutamate and structurally-related excitatory amino 
acids (Olney, 1986), has received much attention over the past 25 years.  Excitotoxic neuronal 
cell death consists of two components: a reversible early component mediated by an influx of 
extracellular Na+ and Cl- causing marked neuronal swelling, and a delayed component mediated 
by the influx of Ca2+ (Choi, 1987) predominantly through ionotropic N-methyl-D-aspartate 
(NMDA) receptors (Simon et al., 1984; Goldberg et al., 1987).  This delayed rise in cellular Ca2+ 
can mediate neurotoxicity by impairing mitochondrial function, producing reactive oxygen 
species (ROS) and other free radicals, and activating destructive lipases and proteases (Choi, 
1988; Kristian and Siesjo, 1998).    
 
Although several voltage-gated and ligand-gated ion channels may contribute to the 
influx of Ca2+, the NMDA receptor is particularly important in mediating acute ischemic injury 
(Simon et al., 1984; Choi, 1988).  This is illustrated by the finding that:  i) in experimental 
models of stroke, extracellular glutamate levels rise in the microdialysate and blockade of 
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NMDA receptors can reduce infarct size (McDonald et al., 1987), ii) NMDA receptor 
antagonists are neuroprotective in temperature controlled animal models of focal ischemia (Yang 
et al., 1994), and iii) knockout mice deficient in NMDA receptor subunits showed decreased 
infarct size after focal cerebral ischemia (Morikawa et al., 1998).  As such, in the present studies, 
acute exposure of NMDA is used to model ischemia-mediated neuronal death in cultured 
neurons (Choi, 1990).  It is noteworthy, however, that NMDA receptor antagonists have failed in 
a large number of stroke clinical trials due to their severe toxic side effects and their inability to 
significantly reduce stroke morbidity (Muir, 2006).  Thus, complete understanding of the 
signaling pathways involved in the ischemic pathophysiology may uncover novel alternative 
therapeutic interventions.  Deregulation of other ions may be equally, if not more, important than 
Ca2+ in mediating neuronal death following ischemic injury.         
1.4 ROLE OF ZINC IN ISCHEMIC NEURONAL DEATH 
1.4.1 Physiological roles for Zn2+  
Zinc is the second most prevalent trace element in the body and is very abundant in the brain 
(overall content of ~150M) with highest concentrations in forebrain regions including the 
hippocampus, amygdala, and cortex (Choi and Koh, 1998; Weiss et al., 2000). Since its 
discovery in brain almost 55 years ago (Maske, 1955), Zn2+ has been shown to play critical roles 
in protein structure, enzymatic activity, and gene regulation (Choi and Koh, 1998; Frederickson 
et al., 2005).  Zn2+ can associate with over 300 enzymes, where it can interact strongly with 
electronegative sulfur, nitrogen, and oxygen moieties in multiple coordination geometries, 
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serving catalytic and structural roles in maintaining active peptide conformations (Choi and Koh, 
1998).  In addition to metalloenzymes, Zn2+ is most known for its ability to bind and stabilize 
proteins involved in gene regulation in domains called zinc fingers, zinc clusters, and zinc twists 
(Vallee et al., 1991).  Because of the critical role Zn2+ plays in protein structure and function, it is 
not surprising that chronic dietary Zn2+ deficiency manifests in multi-systemic dysfunction 
including growth failure, skin changes, delayed wound healing, immune system impairment, 
neurosensory disorders, and lack of sexual development (Prasad, 1995).         
 
Besides the structure and function of proteins, brain Zn2+ may also be important in 
modulation of neuronal activity (Frederickson et al., 2005).  Approximately 10% of neuronal 
Zn2+ is selectively stored in presynaptic vesicles of certain glutamatergic neuronal terminals by 
the neuronal specific zinc transporter 3 (ZnT3).  Because of this, much attention has been given 
to determining whether synaptic Zn2+ release is activity dependent (Paoletti et al., 2009).  The 
most convincing evidence for activity-dependent Zn2+ release was provided by Qian and Nobles, 
who used a membrane-impermeant form of the Zn2+-selective indicator FluoZin-3 to show 
extracellular Zn2+ in mossy-fiber synapses of wild-type, but not ZnT-3 knock-out mice following 
individual action potentials (Qian and Noebels, 2005, 2006). Zn2+ released from presynaptic 
neurons has several potential post-synaptic targets.  Zn2+ is a potent inhibitor of NMDA 
receptors (Vogt et al., 2000; Li et al., 2001a; Li et al., 2001b; Kim et al., 2002; Qian and 
Noebels, 2005) and GABA receptor subtypes (Westbrook and Mayer, 1987; Hosie et al., 2003).  
Zn2+ can potentiate glycine receptors at submicromolar concentrations and inhibit them at 
submillimolar concentrations (Bloomenthal et al., 1994; Laube et al., 1995).  In addition to 
modulating ionotropic pathways, synaptic Zn2+ has also been reported to transactivate receptor 
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tyrosine kinase b (TrkB; Huang et al., 2008b) and regulate metabotropic activity through the 
activation of a recently described “Zn2+ receptor” (Besser et al., 2009).  However, since the exact 
amplitude and time course of synaptic Zn2+ remain unclear (Kay, 2003), the functional 
importance of vesicular Zn2+ is yet to be fully established.   
 
Perhaps a more relevant role of physiologic Zn2+ is its emergence as an intracellular 
signal.  Yamasaki and colleagues recently found evidence for intracellular Zn2+ release in mast 
cells within minutes of extracellular stimulation of the high affinity immunoglobulin E receptor 1 
(FcR1), a phenomenon they called a “zinc wave” (Yamasaki et al., 2007).  Rapid Ca2+ influx 
and mitogen-activated protein/extracellular signal-regulated kinase (MEK) activity were required 
for the Zn2+ rise, although neither the Ca2+ ionophore ionomycin nor a MEK activator was 
sufficient in eliciting a Zn2+ wave (Yamasaki et al., 2007).  A likely role for such intracellular 
Zn2+ signals is the modulation of protein phosphorylation.  While increased cellular Zn2+ can 
activate many kinase pathways including p70 S6 kinase (Kim et al., 2000), extracellular signal-
regulated kinase (Park and Koh, 1999; Kim et al., 2006), and p38 (McLaughlin et al., 2001; 
Bossy-Wetzel et al., 2004), the reports indicate a target upstream in the signaling cascade rather 
than direct effect of Zn2+ on these kinases.  Furthermore, activation of Zn2+-dependent kinase 
cascades was examined in the context of large exogenous Zn2+ exposure or cellular toxicity.  On 
the other hand, physiologically relevant nanomolar concentrations of Zn2+ have been shown to 
inhibit protein tyrosine phosphatase (PTP) activity (Maret et al., 1999; Haase and Maret, 2003, 
2005).  Interestingly, inhibition assays in these studies were performed with a truncated form of 
the phosphatase containing only the catalytic domain, suggesting that the inhibitory action of 
Zn2+ is through direct interaction with this highly conserved domain of PTPs (Haase and Maret, 
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2003; Alonso et al., 2004).  Thus, a major physiological role for Zn2+ may be in the modulation 
of cell signaling cascades, especially those involving protein phosphorylation.   
1.4.2 Regulation of neuronal Zn2+     
Despite relatively high Zn2+ content in the brain, the extracellular Zn2+ concentration is normally 
below 500 nM and the intracellular “free” Zn2+ is generally less than 1 nM (Weiss et al., 2000).  
Intracellular free Zn2+ is tightly regulated though the opposing actions of the solute-linked carrier 
39 (SLC39) family (also known as Zrt- and Irt-like proteins or Zips; Eide, 2004) and the SLC30 
family (also known as ZnTs; Palmiter and Huang, 2004).  Zip and ZnT proteins appear to have 
opposing roles in Zn2+ homeostasis, as Zips increase cytoplasmic Zn2+, while ZnTs promote Zn2+ 
efflux from the cytoplasm into intracellular compartments or across the plasma membrane 
(Liuzzi and Cousins, 2004).  Mechanisms and energetics of transport by these proteins are not 
well characterized, but are believed to be mediated by facilitated diffusion, secondary active 
transport, or symporters (Liuzzi and Cousins, 2004). 
 
Of the 14 Zip family members (Eide, 2003), Zip1 mRNA has been found in almost all 
tissues (Dufner-Beattie et al., 2003) including in neuronal cell bodies and white matter tracts of 
rat brain (Belloni-Olivi et al., 2009).  Zip4 mRNA was also found in the brain but was restricted 
to choroid plexus and brain capillaries (Belloni-Olivi et al., 2009), and may suggest that the brain 
can respond to changes in dietary Zn2+.  Although the functions of brain Zips have not been 
carefully studied in the brain, Zip1 and Zip4 mediate Zn2+ uptake across the plasma membrane in 
prostate cells and in intestinal luminal cells, respectively (Gaither and Eide, 2001; Franklin et al., 
2003; Dufner-Beattie et al., 2004).   
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Opposing the actions of Zips are the nine members of the mammalian ZnT family 
(Palmiter and Huang, 2004).  ZnT1 is a ubiquitous member of the SLC30 family found on the 
plasma membrane of neurons (Tsuda et al., 1997) and glia (Sekler et al., 2002; Nolte et al., 
2004).  ZnT1 was discovered by Palmiter and Findley for its ability to confer Zn2+ resistance to 
highly Zn2+ sensitive baby hamster kidney (BHK) cells (Palmiter and Findley, 1995).  ZnT1 
overexpression in these cells increased radioactive 65Zn efflux across the plasma membrane and 
reduced the cytoplasmic concentration of Zn2+, supporting an export function for the protein 
(Palmiter and Findley, 1995).  Recent evidence suggests that in addition to exporting Zn2+, 
neuronal ZnT1 may confer resistance to Zn2+ toxicity by also regulating routes of Zn2+ entry, 
such as through voltage-gated Ca2+ channels (Ohana et al., 2006).  However, a direct interaction 
between ZnT1 and Ca2+ channels has yet to be demonstrated.  
 
Expression of ZnT1 has been shown in several brain regions, including cerebellum, 
cerebral cortex, and olfactory bulb, corresponding to areas containing synaptic Zn2+ and, thus, 
requiring significant Zn2+ homeostasis (Sekler et al., 2002).  The first physiologically relevant 
role for neuronal ZnT1 came from a report that showed increased ZnT1 expression in 
degenerating hippocampal neurons following Zn2+-dependent ischemic injury in the gerbil 
(Tsuda et al., 1997).  Similar to lethal injury, sub-lethal Zn2+ exposure has been reported to 
induce ZnT1 expression in astrocytes (Nolte et al., 2004).  Thus, the upregulation of ZnT1 may 
be an important adaptive response to cellular injury. The remaining ZnT family members are 
localized to intracellular membranes, where they play limited tissue-specific functions in Zn2+ 
sequestration (Liuzzi and Cousins, 2004).  Of these, the most extensively studied ZnT is 
neuronal ZnT3, which transports Zn2+ into synaptic vesicles of certain glutamatergic neurons 
 8 
(Wenzel et al., 1997).  Immunohistochemical analysis of ZnT3 expression revealed a staining 
pattern identical to that produced by Timm staining for vesicular Zn2+ (Palmiter et al., 1996; 
Wenzel et al., 1997).  Timm staining, first described in 1958 as a “sulfide-silver procedure” 
(Timm, 1958) and optimized for visualizing Zn2+ (Danscher, 1984; Danscher et al., 1997), is the 
process of silver-amplifying sulfide-loaded tissue by autometallography, allowing for 
visualization of zinc-sulfide crystal lattices.  ZnT3 immunoreactivity is evident on membranes of 
Zn2+-rich Timm stained synaptic vesicles (Wenzel et al., 1997).  ZnT3 knock-out (ZnT3-KO) 
mice express no histochemically reactive (vesicular) Zn2+ (Cole et al., 1999).  Despite 
completely lacking vesicular Zn2+, ZnT3-KO mice do not have impaired spatial learning, 
memory, or sensorimotor functions (Cole et al., 2001), but may be more susceptible to kainate-
induced seizures (Lee et al., 2000; Lee et al., 2003).  Thus, while a significant role of vesicular 
Zn2+ has not yet been established, the ZnT3-KO mouse will be an invaluable tool in designing 
new experiments to uncover previously unexplored mechanisms in synaptic Zn2+ signaling.    
 
Metallothioneins also play a major role in regulating intracellular Zn2+ homeostasis by 
binding, releasing, and distributing Zn2+.  Metallothioneins are a family of non-enzymatic, 
cysteine-rich, metal-binding polypeptides (61-68 amino acids) found throughout mammalian 
tissues (Aschner, 1996; Haq et al., 2003; Penkowa, 2006).  MTs are well-known for their metal-
binding properties as they are structurally composed of two globular metal-binding domains ( 
and ) containing a total of 20 cysteine residues, allowing them to bind up to seven Zn2+ or Cd2+ 
ions or up to 12 Cu2+ ions (Haq et al., 2003).  These cysteine residues in MTs occur in unique 
Cys-X-Cys, Cys-X-Y-Cys, and Cys-Cys motifs, where X and Y represent non-cysteine amino 
acids (Kagi and Schaffer, 1988).  Interestingly, analysis of the association of Zn2+ with the 
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apoprotein thionein revealed three classes of binding affinities that vary by several orders of 
magnitude.  Four Zn2+ ions were bound tightly (log Kd = 11.8), making the thionein a strong 
chelating agent; one Zn2+ was relatively weakly bound (log Kd = 7.7), making metallothionein a 
Zn2+ donor; and the remaining two Zn2+ ions were with intermediately bound (log Kd ~ 10) 
(Krezel and Maret, 2007).  This suggests that MT molecules are not saturated with seven Zn2+ 
ions under normal physiological conditions and can actively participate in cellular Zn2+ buffering 
and distribution (Krezel and Maret, 2007).  Thus, MT is a dynamic protein with species 
containing varying amounts of Zn2+ due to the constant transfer of Zn2+ to thioneins and other 
metalloenzymes (Yang et al., 2001; Krezel and Maret, 2007).  Further, because of the unique 
Zn2+ coordination environment of MT, the redox environment of the cell may ultimately dictate 
cellular Zn2+ availability (discussed further in Section 1.4.6; Maret and Vallee, 1998).   
 
Three major MT isoforms are expressed in the adult mammalian central nervous system.  
The precise cellular localization of MT I, II, and III is still a matter of debate due to the lack of 
isoform-specific antibodies leading to conflicting results between in vivo and in vitro studies and 
between mRNA and protein expression assays (Hidalgo et al., 2001).  The general consensus, 
however, is that the MT I and MT II are the predominant astrocytic isoforms (where they are 
expressed over seven-fold higher than in neurons; Hidalgo et al., 1994; Kramer et al., 1996b; 
Kramer et al., 1996a; Suzuki et al., 2000), while MT III is predominantly expressed in neurons 
(Masters et al., 1994; Hidalgo et al., 2001).  Interestingly, MT III was first identified in pursuit of 
putative mechanisms underlying Alzheimer’s disease neuropathology.   Abundant MT III 
expression, which was then identified as growth inhibitory factor (GIF) due to its ability to 
inhibit neurotrophic factors and neurite outgrowth, was found in normal brain astrocytes, but not 
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in Alzheimer’s disease brains (Uchida et al., 1991).  However, since then, the association 
between MT III and Alzheimer’s disease has not fully developed (Erickson et al., 1994; Carrasco 
et al., 2006).  Instead, MTs are thought to play a major role in heavy metal detoxification and 
Zn2+ homeostasis, as previously discussed.  Interestingly, expression of MT I and II is highly 
inducible in response to a range of stimuli in addition to Zn2+ and Cd2+, including hormones, 
cytokines, oxidative agents, inflammation, and ischemia (Bremner et al., 1987; Sato and 
Bremner, 1993; Vasak and Hasler, 2000; Trendelenburg et al., 2002).  Because of this, MTs have 
been implicated in mediating a more general cellular response to injury (West et al., 2008).  
Exciting recent reports have shown that following brain injury, astrocytes are able to secrete MT 
into the extracellular space, which is internalized by neurons promoting cell survival (Ambjorn et 
al., 2008; Chung et al., 2008; West et al., 2008).  Thus, MTs play diverse roles in regulating 
cellular Zn2+ homeostasis, heavy metal detoxification, and intercellular response to injury.   
1.4.3 Zn2+-regulated gene expression    
A major role for physiologic Zn2+ is the regulation of the proteins that control the intracellular 
concentration of the metal.  The inducible metallothionein isoforms, MT I and MT II, are 
regulated in a coordinated manner through the activation of gene transcription (Penkowa, 2006). 
The promoter regions of MT I/II genes contain several cis-acting DNA elements, including 
metal, glucocorticoid, anti-oxidant, and interleukin-6/signal transducers and activator of 
transcription (STAT) responsive elements (MREs, GREs, AREs, and IL-6 RE) that can bind 
trans-acting transcription factors involved in the regulation of both constitutive and inducible 
MT expression (Haq et al., 2003; Penkowa, 2006).  Metal response element transcription factor 1 
(MTF-1) is the predominant gene regulatory protein mediating constitutive as well as metal- and 
 11 
oxidative stress-induced MT I/II expression (Heuchel et al., 1994; Dalton et al., 1996).  MTF-1 is 
a 72.5 kDa, ubiquitous zinc-finger transcription factor in the Cys2His2 family that binds to DNA 
sequence motifs, known as metal response elements (MREs), at the consensus site TGCRCNC 
(Stuart et al., 1984).  MRE sequences are present in five, non-identical copies (MREa-MREe) in 
the 5’ flanking region of the MT I/II gene (Larochelle et al., 2001a).  MTF-1 mediated MRE 
activation sufficiently upregulates MT I/II in response to Zn2+ or Cd2+ (Stuart et al., 1984; Stuart 
et al., 1985), oxidative stress (Dalton et al., 1994), and hypoxia (Murphy et al., 1999).  Following 
Zn2+, acute hypoxia, or oxidative stress induced by H2O2 or tert-butylhydroquinone, MTF-1 
translocates from the cytoplasm to the nucleus and acquires tight DNA-binding ability (Dalton et 
al., 1996; Dalton et al., 1997; Andrews, 2000; Smirnova et al., 2000).  However, following 
exposure to other heavy metals, most notably Cd2+, the DNA-binding ability of MTF-1 is 
inhibited in cell-free DNA binding assays, despite induction of MTF-1-dependent MT gene 
transcription in vivo (Heuchel et al., 1994; Palmiter, 1994; Bittel et al., 1998; Murata et al., 1999; 
Zhang et al., 2001).  This paradox was solved by demonstrating that transcriptional activation 
following Cd2+ requires Zn2+-saturated metallothionein (Zhang et al., 2003).  Cd2+, which binds 
to metallothioneins with higher affinity than Zn2+, can displace Zn2+ from the metal-binding 
protein, making Zn2+ available for MTF-1 activation (Zhang et al., 2003).  Activation of gene 
transcription also requires the occupancy of the Zn2+ fingers with Zn2+ (Westin and Schaffner, 
1988) and the interaction among three distinct transcriptional activation domains in the C-
terminal region of MTF-1 (Radtke et al., 1995).  While most of the evidence characterizing Zn2+-
regulated gene expression has been performed studying MT gene activation, changes in ZnT1 
expression can also be induced by Zn2+ or Cd2+ (Andrews, 2000).  Constitutive and metal-
induced activation of the ZnT1 gene also required MTF-1 (Langmade et al., 2000).  On the other 
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hand, while the organization of the promoter regions of all MT genes is conserved, the MT III 
gene was found to contain a ‘silencing element’ in the 5’ flanking regions upstream from the first 
cluster of putative MREs (Watabe et al., 1997; Chapman et al., 1999), eliminating Zn2+-
regulation.  Closer inspection of this silencing element of the rat MT III promoter revealed that it 
contained a quadruplicate CTG sequence approxiametely 400 base-pairs upstream of the 
translation start site (Chapman et al., 1999).  CTG-repeat elements have been shown to act as 
repressors on a number of heterologous promoters independent of its orientation and proximity 
to the gene, and thus may account for the silencing effect on the promoter region of the MT III 
gene (Chapman et al., 1999).  Overall, these studies suggest that Zn2+ regulated, MTF-1/MRE-
mediated gene expression plays an important role in coordinating the expression of proteins 
involved in intracellular Zn2+ homeostasis.  In this dissertation, I show that Zn2+ regulated gene 
expression can be stimulated by sub-lethal ischemia in neurons and thus may be an important 
endogenous mechanism conferring tolerance to subsequent Zn2+-dependent injury.   
1.4.4 PKC modulation of Zn2+-regulated gene expression  
Zn2+ regulated gene expression has been shown to be dependent on a number of kinase cascades, 
especially protein kinase C (PKC; LaRochelle et al., 2001b; Adams et al., 2002; Saydam et al., 
2002).  PKC is a family of serine/threonine kinases, which consists of at least 10 isozymes 
(Newton, 2001).  These isozymes have been classified into three groups according to their 
structure and cofactor regulation.  Conventional PKCs (α, β1, β2, and γ) are directly activated by 
calcium or diacylglycerol (DAG); novel PKCs (δ, ε, σ, φ, and μ) are independent of calcium but 
responsive to DAG; and atypical PKCs are independent of calcium and DAG but require 
membrane phospholipids for activation (Newton, 2001).  Interestingly, PKC is also a Zn2+-
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metalloenzyme, containing four Zn2+ atoms bound to two cysteine-rich repeats in the regulatory 
domain of the N-terminus (Quest et al., 1992).  Nanomolar concentrations of Zn2+ activated 
PKC, and the cell-permeant Zn2+ chelator N,N,N’,N’-tetrakis (2-pyridalmethyl)ethylenediamine 
(TPEN) inhibited PKC activation (Csermely et al., 1988b, a).  Furthermore, oxidation of the 
Zn2+-binding cysteine residues led to release of PKC-bound Zn2+, which was sufficient in 
activating the enzyme (Knapp and Klann, 2000).  Oxidative release of PKC-bound Zn2+ has been 
shown to cause a substantial increase in intracellular free Zn2+ in cardiomyocytes (Korichneva, 
2005).  Thus, Zn2+ may play a critical regulatory role in PKC activity.  In turn, PKC may also 
play an important role in the regulation of intracellular Zn2+ concentration. Activators of PKC 
are sufficient stimulants of Zn2+-regulated gene expression (Imbra and Karin, 1987; Garrett et al., 
1992), while PKC inhibitors can interfere with metal-induced MRE activation (Yu et al., 1997a).  
Despite evidence suggesting that PKC activity can modulate of Zn2+-regulated gene expression, 
the mechanism of action of the kinase in this process is unclear (LaRochelle et al., 2001a; Adams 
et al., 2002; Saydam et al., 2002; Jiang et al., 2004).  It has been shown that MTF-1 is 
constitutively phosphorylated at serine and tyrosine residues and that metal exposure increases 
its level of phosphorylation by a mechanism involving PKC (LaRochelle et al., 2001a; Saydam 
et al., 2002).  Treatment with kinase inhibitors decreased MTF-1/MRE-mediated gene 
transcription (LaRochelle et al., 2001a), and inhibition of dephosphorylation resulted in elevated 
constitutive and induced MT expression (Chen et al., 2001).  However, studies have shown that 
although MTF-1 can be phosphorylated in unstimulated cells, metal exposure does not increase 
its phosphorylation state or its ability to bind DNA (Jiang et al., 2004).  Further, kinase inhibition 
does not affect metal-induced MTF-1 nuclear translocation, MTF-1 DNA binding, or the 
formation of a stable MTF-1-chromatin complex (Larochelle et al., 2001a; Jiang et al., 2004).  
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Thus, modulation of Zn2+-regulated gene expression by signaling kinases may be cell-type 
specific, and may not target MTF-1 directly (Jiang et al., 2004).  It is certainly possible that 
modulation of Zn2+-regulated gene expression by PKC may not be mediated by post-translational 
modification of MTF-1.  In this dissertation, I identify MT as a previously unrecognized target 
for PKC phosphorylation, and examine its effect on neuronal Zn2+-regulated gene expression.     
1.4.5 Zn2+ translocation in ischemic cell death 
As the intracellular concentration of Zn2+ is kept in the picomolar range through the actions of 
several regulatory processes mentioned in earlier sections, an increase of free intracellular Zn2+ 
in neurons can have deleterious consequences.  During the height of the debate regarding the 
exact roles for Ca2+, glutamate, and excitotoxicity in mediating neuronal death following 
ischemia, Zn2+ emerged as another cation important in ischemia pathophysiology.  Using TSQ 
(N-[6-methoxy-8-quinolyl]-P-toluenesulfonamide) and acid fuschin to simultaneously stain the 
presence of Zn2+ and degenerating neurons, respectively, Tonder and colleagues were first to 
suggest a translocation of Zn2+ from mossy fibers terminals to degenerating dentate hilar neurons 
2-24 hrs following 20 min of cerebral ischemia (Tonder et al., 1990).  This observation, coupled 
with reports suggesting that the amount of Zn2+ stored in synaptic vesicles (~300 M) was 
sufficient in killing neurons (Yokoyama et al., 1986; Frederickson et al., 1988), led to the Zn2+ 
translocation hypothesis.  This hypothesis proposes that the extracellular release of vesicular 
Zn2+ and its uptake by postsynaptic neurons is responsible for the toxic accumulation of neuronal 
Zn2+ following ischemia (Frederickson et al., 1989; Choi and Koh, 1998; Lee et al., 1999). More 
direct evidence came from Koh and colleagues who showed that intraventricular injection of the 
membrane-impermeant Zn2+ chelator, ethylenediaminetetraacetic acid (EDTA) saturated with 
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Ca2+ (CaEDTA), blocked the accumulation of neuronal Zn2+ and prevented neuronal death 
following transient global cerebral ischemia (Koh et al., 1996).  While Zn2+ was known to be 
toxic to neurons when applied exogenously (Choi et al., 1988; Weiss et al., 1993; Koh and Choi, 
1994), these reports were first to implicate endogenous accumulation of Zn2+ in ischemic 
neuronal death.   
  
Extracellular Zn2+ can lead to toxic intracellular Zn2+ accumulations by entering through 
voltage-sensitive Ca2+ channels (VSCC; Weiss et al., 1993), NMDA channels (Koh and Choi, 
1994), or Ca2+-permeable a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) / 
kainate channels (Ca2+-A/K; Yin and Weiss, 1995; Yin et al., 1998).  Of these, Ca2+-A/K 
channels exhibit the highest Zn2+ permeability (Sensi et al., 1999) and may be the primary route 
of Zn2+ entry following ischemia (Yin et al., 2002).  In hippocampal slices, ischemia-induced 
Zn2+ accumulation and subsequent neurodegeneration can be attenuated with a Ca2+-A/K channel 
inhibitor but not NMDA or VSCC channel antagonists (Yin et al., 2002). Hippocampal 
pyramidal neurons, which are especially sensitive to ischemic injury, express Ca2+-A/K channels 
on distal dendritic branches (Lerma et al., 1994; Yin et al., 1999; Ogoshi and Weiss, 2003).  
Unlike all other heterotetrameric AMPA receptors, Ca2+-A/K channels lack the GluR2 subunit 
(Dingledine et al., 1999; Kwak and Weiss, 2006).  GluR2 subunits contain an arginine (R) in its 
pore-forming domain due to RNA editing of a genomically encrypted glutamine (Q) codon 
(Sommer et al., 1991).  The arginine is functionally dominant because it dictates gating kinetics, 
channel conductance, channel assembly and importantly, Ca2+ permeability (Burnashev et al., 
1992; Geiger et al., 1995; Greger et al., 2003).  Edited GluR2(R) subunits form Ca2+-
impermeable channels, whereas unedited GluR2(Q) channels are Ca2+ permeable (Geiger et al., 
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1995; Jonas and Burnashev, 1995).  Generation of mice with unedited GluR2(Q) produced 
fulmitant seizures and death by three weeks of age (Brusa et al., 1995).  Interestingly, GluR2 
expression can be modulated by ischemic injury, as ischemia has been shown to induce GluR2 
down-regulation (Gorter et al., 1997; Opitz et al., 2000) and disrupt Q/R editing (Peng et al., 
2006).  This modulation of GluR2 subunits render AMPA channels Ca2+ permeable, allowing 
entry of toxic Ca2+ and Zn2+ during ischemia (Pellegrini-Giampietro et al., 1992; Gorter et al., 
1997; Opitz et al., 2000; Sensi and Jeng, 2004).  Thus, regulation of Ca2+-A/K channel 
composition may play a critical role in ischemic injury.  
  
Regulation of Ca2+-A/K channel composition following ischemic injury may involve 
Zn2+.  In an in vivo model of ischemia, application of CaEDTA 30 minutes prior to global 
ischemia attenuated the ischemic downregulation of GluR2, the delayed rise in neuronal Zn2+, 
and neuronal death (Calderone et al., 2004).  Ischemic downregulation of GluR2 may occur by 
Zn2+-dependent expression of the nine Zn2+-finger transcription factor restrictive element-1 
silencing transcription factor (REST-1), which suppresses neuronal-specific targets including 
GluR2 (Calderone et al., 2003; Calderone et al., 2004).  Application of CaEDTA 48-60 hours 
following global ischemia, presumably after GluR2-lacking A/K channels are already expressed, 
only attenuated the late rise in neuronal Zn2+ and cell death (Calderone et al., 2004).  These data 
suggest that Zn2+ entry through Ca2+-A/K channels contributes to the accumulation of the metal 
following ischemia.        
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1.4.6 Intracellular sources for ischemic Zn2+  
Several key observations have shown that Zn2+ translocation cannot fully account for the 
accumulation of free Zn2+ following ischemia.  Zn2+ accumulation in degenerating neurons 
following global ischemia is observed in areas that are not highly innervated by glutamate- and 
Zn2+-releasing fibers, such as thalamic neurons (Koh et al., 1996).  Thus, intracellular sources of 
Zn2+ must play a major role in lethal Zn2+ accumulation in these brain regions.  More 
importantly, if presynaptic Zn2+ was the only source of toxic Zn2+ that contributed to ischemic 
injury, then animals without presynapic Zn2+ would not be susceptible to Zn2+-dependent 
toxicity.  Mice lacking the zinc transporter ZnT3 show no histochemically reactive Zn2+ in 
presynaptic vesicles, but still undergo significant Zn2+ accumulation in degenerating CA1 and 
CA3 neurons following kainate-induced seizures (Lee et al., 2000).  These data suggest that 
lethal neuronal injury can induce intracellular Zn2+ accumulation and neurodegeneration in the 
absence of presynaptic vesicular Zn2+.  While CaEDTA nearly completely abolished the Zn2+ 
accumulation and neuronal cell death, suggesting an extracellular source of Zn2+, CaEDTA has 
been since shown to deplete intracellular Zn2+ compartments, including synaptic vesicles 
(Frederickson et al., 2002).  The membrane-impermeant Zn2+ chelator CaEDTA may chelate and 
trap extracellular Zn2+, giving rise to a steep Zn2+ gradient across the plasma membrane resulting 
in “pulling” of free Zn2+ from the neuronal cytoplasm.  Taken together, these reports suggest that 
accumulation of intracellular Zn2+ following neuronal injury may not be solely dependent on 
translocation of the metal from presynaptic neurons.   
 
As Zn2+ accumulation can occur in the absence of vesicular Zn2+, liberation of Zn2+ from 
intracellular stores may be a significant mechanism of cell injury, especially in brain regions 
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with little or no synaptic Zn2+. Vallee and colleagues suggest that Zn2+ binding and release in 
cells are dynamic processes that are dependent on the redox status of the cell (Jacob et al., 1998; 
Jiang et al., 1998).  Of the Zn2+ metalloproteins, only those with Zn2+/sulfur coordination 
environments are susceptible to oxidative mobilization of Zn2+ during excitotoxicity (Maret, 
1995).  These coordination environments allow for tight binding of Zn2+ and for the mobilization 
of redox-inert Zn2+ (Berg and Shi, 1996) by biological oxidants.  Of the thiol-Zn2+ 
metalloproteins in neurons, MT III is a likely source of injury-induced mobilized Zn2+.  Despite 
binding Zn2+ with high thermodynamic stability (Kd = 1.4 X 10-13 M for human MT, pH 7.0; 
Maret and Vallee, 1998), the redox potential for MT is very negative (-366 mV), causing even 
mild cellular oxidants to release Zn2+ from the metal-binding protein (Maret and Vallee, 1998).  
Consistent with this, exposure of neurons to oxidative stress promotes the release of Zn2+ from 
intracellular stores, an event critical to initiation of neuronal apoptosis (Aizenman et al., 2000b).  
Further, nitric oxide (NO) and subsequent peroxynitrite (ONOO-) formation, two powerful 
cellular oxidants contributing to ischemic “nitrosative stress” (Lo et al., 2003), also liberate 
neuronal Zn2+ from intracellular stores triggering neurodegeneration (Cuajungco and Lees, 1998; 
Bossy-Wetzel et al., 2004; Zhang et al., 2004).   NO has been shown to more readily release Zn2+ 
from MT III than other MT isoforms due to the unique presence of consensus motifs for catalytic 
nitrosylation and the preferential reactivity of S-nitrosothiols with MT III through 
transnitrosylation, allowing direct transfer of NO between sulfhydryl groups that result in 
sequential release of Zn2+ ions (Chen et al., 2002).  Thus, liberation of Zn2+ from intracellular 
stores, especially neuronal MT III, may be a significant source of the Zn2+ rise following 
ischemia.  In this dissertation, I provide evidence supporting a major role for metallothionein as 
the primary source and sink for free Zn2+ in neurons.         
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1.4.7 Zn2+-dependent signaling in ischemia 
Accumulation of neuronal Zn2+, likely mediated by a combination of Zn2+ translocation from 
presynaptic vesicles and Zn2+ liberation from intracellular stores, can trigger subsequent 
neurodegenerative signaling following ischemia.  Zn2+-induced cell death involves several serial 
and parallel signaling events, has features of both apoptosis and necrosis (Kim et al., 1999b), and 
is likely mediated by oxidative and nitrosative stress (Kim et al., 1999a; Noh et al., 1999; Kim et 
al., 2002; Sensi et al., 2002).  The diversity of cell death signaling attributed to Zn2+ may depend 
on the intensity of Zn2+ exposure, as brief exposure to high concentrations of Zn2+ lead to signs 
of necrotic, caspase-independent cell death, while longer exposures to lower Zn2+ concentrations 
trigger apoptotic, caspase-dependent cascades (Kim et al., 1999a; Kim et al., 1999b; Lobner et 
al., 2000).   
 
In addition to concentration-dependent signaling, accumulation of Zn2+ following 
ischemia may trigger divergent signaling mechanisms along multiple temporal profiles.  While a 
delayed rise in neuronal Zn2+ in degenerating neurons following ischemia has been well 
described (Koh et al., 1996; Park et al., 2000), recent reports suggest that an early Zn2+ rise 
following ischemia onset also contributes to ischemic injury (Stork and Li, 2006; Medvedeva et 
al., 2009).  In hippocampal neurons loaded with both Zn2+ and Ca2+ indicators, an accumulation 
of neuronal Zn2+ within the first minutes following ischemia was detected before, and shown to 
contribute to, Ca2+ deregulation (Medvedeva et al., 2009).  Interestingly, previously utilized Ca2+ 
probes actually bind Zn2+ with higher affinity, and what was previously attributed to Ca2+ 
deregulation may be in fact due to Zn2+ (Stork and Li, 2006).  Two important reports (Stork and 
Li, 2006; Medvedeva et al., 2009) used oxygen-glucose deprivation in hippocampal slices to 
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model ischemia, but neither examined the source of the early Zn2+ rise, leaving the possibility 
that areas of brain deficient in Ca2+-A/K channels or vesicular Zn2+ may not undergo an early 
ischemic Zn2+ rise.  Nevertheless, this early Zn2+ accumulation in ischemic neurons may trigger 
neurodegenerative signaling previously attributed to Ca2+.   
 
Mechanisms involved in Zn2+-dependent ischemic neuronal death are incompletely 
understood, and may resemble the complexity in Ca2+-mediated cell death pathways.  However, 
central to Zn2+-dependent neuronal cell death are roles for mitochondria and oxidative stress.  
Exogenously-applied Zn2+ can be taken up by mitochondria (Manev et al., 1997; Sensi et al., 
2000) leading to changes in mitochondrial potential (m), release of reactive oxygen species 
and pro-apoptotic proteins, and induction of mitochondrial swelling (Sensi et al., 1999; Jiang et 
al., 2001; Dineley et al., 2005).  These effects on mitochondria could also be produced following 
oxidant-induced liberation of intracellular Zn2+ (Sensi et al., 2003; Bossy-Wetzel et al., 2004).  
In vivo, Zn2+ chelation by CaEDTA prior to global ischemia attenuates the activity of large 
multi-conductance mitochondrial channels, prevents the cytosolic accumulation of mitochondrial 
proapoptotic proteins, and ultimately decreases the apoptotic cell death execution protein, 
caspase-3 (Calderone et al., 2004; Bonanni et al., 2006).  Mitochondria are widely implicated in 
oxidative- and nitrosative-stress mediated neuronal injury, as deficits in the electron transport 
chain are linked to ROS generation (Adam-Vizi, 2005, but see Brennan et al., 2009).  Zn2+ 
exposure leads to increased levels of superoxides and lipoperoxides (markers for oxidative 
injury) and the resultant neurotoxicity is attenuated by antioxidants (Kim et al., 1999a; Kim et 
al., 1999b).  However, under these conditions, the source of ROS is likely to be mediated by 
PKC dependent, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation 
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(Noh et al., 1999; Noh and Koh, 2000; Brennan et al., 2009).  Aside from mitochondria and 
oxidative stress, other Zn2+-dependent cell death signaling events have also been described, 
including regulation of Zn2+-dependent transcription factors (Park and Koh, 1999), induction of 
p75 neurotrophin receptor-mediated pathways (Park et al., 2000), and activation of kinases (Noh 
et al., 1999; McLaughlin et al., 2001; Du et al., 2002; Bossy-Wetzel et al., 2004) and poly-ADP-
ribose polymerase (PARP-1) (Sheline et al., 2003).  Thus, Zn2+-dependent neurodegeneration 
may be mediated by several diverging and redundant cellular processes that only have begun to 
be elucidated.     
1.5 PRECONDITIONING OFFERS INSIGHT INTO STROKE 
NEUROPROTECTION 
Preconditioning refers to the activation of endogenous adaptive processes by sub-lethal stimuli 
that can increase cellular tolerance to subsequent, lethal injury (Obrenovitch, 2008).  Tolerance 
to lethal ischemic injury was first described by preconditioning cardiac myocytes with brief sub-
lethal ischemic episodes (Murry et al., 1986).  This phenomenon was subsequently shown to also 
be present in the brain (Kitagawa et al., 1990).  Preconditioning triggers an adaptive cellular 
response that is characterized by specific time frames of tolerance induced relative to 
preconditioning stimulus and subsequent lethal ischemia.  Acute tolerance is short-lasting (~1 hr) 
and is mediated by post-translational protein modifications.  In contrast, delayed tolerance can be 
detected 24 hr following preconditioning and can last for days, requiring gene expression and 
protein synthesis (Lo et al., 2003; Obrenovitch, 2008).   
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Activation of several transcription factors have been shown to mediate neuronal 
tolerance, including activating protein 1 (AP1), cyclic AMP responsive element-binding protein 
(CREB), nuclear-factor B (NF-B), and the redox regulated transcriptional activator SP1 
(Blondeau et al., 2001; Ryu et al., 2003; Meller et al., 2005).  However, the most evidence for a 
role in mediating neuronal tolerance has been found for the hypoxia-inducible factor (HIF) 
isoforms (Bergeron et al., 2000; Bernaudin et al., 2002b).  HIF is a heterodimer consisting of  
and  protein subunits.  Under normal conditions, the HIF1 isoform is targeted for degradation 
by an oxygen-sensitive prolyl hydroxylase, which allows for the interaction between HIF1and 
ubquitin ligase (Gidday, 2006).  Hypoxia inactivates the hydroxylase enzyme, stabilizing HIF1 
and allowing it to enter the nucleus, where it can dimerize with HIF1and promote transcription 
of genes that enhance tolerance (Bergeron et al., 2000).  Hypoxia can also activate HIF1 
transcription, further promoting the activation of HIF-sensitive genes (Semenza, 2001).  HIF 
target genes that may play a role in neuronal tolerance are those related to angiogenesis, such as 
vascular endothelial growth factor (VEGF), and blood and iron metabolism, such as 
erythropoietin (Sharp and Bernaudin, 2004).  In addition to these genes, studies using 
oligonucleotide-based DNA microarrays have described general families of genes that are 
particularly affected by preconditioning, including genes related to cell metabolism, immune 
response, ion channel activity, and blood coagulation (Stenzel-Poore et al., 2004).  Thus, despite 
the multitude of stimuli, transducers, and effectors involved in various models of tolerance, the 
overall implication of neuronal preconditioning is the development of a genetically 
reprogrammed, primed brain that can effectively limit cellular injury after ischemia. 
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Preconditioning may represent the most powerful mechanism described to date for 
limiting infarct size other than timely reperfusion.  Preconditioning-induced tolerance has been 
demonstrated clinically in retrospective case-controlled studies that showed that patients with 
transient ischemic attacks (TIAs) have decreased morbidity following stroke (Weih et al., 1999).  
Understanding the molecular mechanisms involved in the preconditioning-induced 
neuroprotection may help develop novel therapeutic strategies not only for limiting morbidity 
following stroke, but also following high-risk surgical procedures that involve the potential for 
hemodynamic compromise (Dirnagl et al., 2009).  In this dissertation, I present evidence 
suggesting that a transient Zn2+ rise may be a previously unexplored early signaling event critical 
for the development of delayed neuronal tolerance.   
1.6 NEURONAL TOLERANCE IS CONFERRED BY CELL DEATH MEDIATORS 
A variety of stress stimuli known to cause ischemic brain injury, when exposed at sub-lethal 
levels have been reported to trigger neuronal tolerance, including ischemia, hypoxia, metabolic 
inhibitors, excitotoxins, and inflammatory cytokines (Gidday, 2006).  Generally, a particular 
stress stimulus can either be too weak to elicit any response, sufficient to precondition neurons 
and confer tolerance, or too robust and therefore lethal (Dirnagl et al., 2003).  Similarly, the 
intensity or duration of conserved cellular mediators may be critical in determining cell fate.  
Indeed, recent evidence suggests that pro-survival mechanisms conferring neuroprotection in 
ischemic preconditioning may involve sub-lethal activation of cell death pathways.  For example, 
antioxidants and protease inhibitors, which limit cell death following lethal stimuli, can 
paradoxically increase vulnerability to subsequent lethal injury when administered during the 
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preconditioning period (McLaughlin et al., 2003).  Thus, the ultimate fate of neurons may not 
depend on which molecules are activated following a particular insult, but rather the extent and 
duration of their activity.  Below, I highlight several examples of such mediators that are 
particularly relevant to my dissertation work.   
1.6.1 Caspase-3 
Cysteine aspartic acid-specific proteases (caspases) are a family of proteolytic enzymes that 
cleave hundreds of targeted proteins during apoptosis including structural proteins, DNA repair 
enzymes, and cleavage-activated kinases (Taylor et al., 2008).  The family is divided into 
initiators (such as caspase-8), which can auto-activate and cause the proteolysis of other 
caspases, and effectors (such as caspases-3, -6 and -7), which are activated by other caspases and 
carry out substrate proteolysis and cell death (Taylor et al., 2008).  Activation of caspases 
eventually leads to, or is accompanied by, cellular changes of apoptosis, including membrane 
blebbing, DNA fragmentation, chromatin condensation, and formation of apoptotic bodies (Kerr 
et al., 1972).  Caspase activation has been shown to play an important role in ischemic 
neurodegeneration as genetic or pharmacological inhibition of caspases is neuroprotective in 
experimental stroke (Endres et al., 1998; Le et al., 2002).  Caspase-3 mRNA, protein, and 
cleavage products can be detected in animal models of stroke at varying time points following 
insult depending on the extent of ischemia and reperfusion injury (Asahi et al., 1997; Namura et 
al., 1998).  Caspase-3 inhibition prior to, or following, cerebral ischemia markedly reduced 
neuronal injury due to ischemia and reperfusion injury (Fink et al., 1998).  Thus, caspase-3 plays 
a significant role in ischemic neuronal death.       
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Surprisingly, caspase-3 has also been implicated in neuronal tolerance.  Our laboratory 
was first to show that preconditioning led to caspase cleavage in vivo and that caspase-3 activity 
was required for neuronal tolerance in vitro (McLaughlin et al., 2003).  Pro-caspase cleavage and 
caspase enzymatic activity reach maximum levels six hours following a preconditioning stimulus 
and are dependent on ROS generation and KATP channel opening (Garnier et al., 2003; 
McLaughlin et al., 2003).  Although widespread caspase-3 activation characterizes many cell 
death processes, the relatively modest preconditioning-induced caspase-3 activation is held in 
check by sequestration with caspase-binding proteins including the constitutively active heat 
shock protein 70 (HSP70) homologue HSC70 (McLaughlin et al., 2003) and the pro-survival 
inhibitor-of-apoptosis (IAP) family member cIAP (Tanaka et al., 2004).  The depletion of the 
free pool of HSC70 leads to increased synthesis of HSP70, which is observed 24 hours following 
preconditioning and is able to buffer lethal caspase-3 generation (McLaughlin et al., 2003).  
Importantly, inhibiting the activation of caspase-3 or the upregulation of HSP70 attenuates the 
neuroprotective effect of preconditioning (McLaughlin et al., 2003).   
 
Aside from upregulating survival proteins in preconditioned neurons, caspase-3 has also 
been shown to target poly(ADP-ribose) polymerase-1 (PARP-1; Szabo and Dawson, 1998; 
Garnier et al., 2003; Lee et al., 2008).  PARP-1, which accounts for >80% of nuclear PARP 
activity (Heller et al., 1995; D'Amours et al., 1999), facilitates DNA repair by mediating the 
enzymatic transfer of ADP-ribose groups from NAD+ to form branched ADP-ribose polymers on 
acceptor proteins in the vicinity of DNA strand breaks or kinks.  However, extensive PARP-1 
activation, which occurs in ischemia (Virag and Szabo, 2002), depletes NAD and ATP, leading 
to cellular energy failure and cell death (Ha and Snyder, 1999).  Caspase-3 can irreversibly 
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cleave the catalytic site of PARP-1 from its DNA binding domain, effectively inactivating the 
polymerase (Lazebnik et al., 1994; Le et al., 2002).  Accordingly, preconditioning stimulates 
caspase-dependent PARP-1 cleavage, attenuating PARP-1 activity, and protecting neurons from 
subsequent PARP-1 mediated cell death (Garnier et al., 2003).  Caspase inhibition during 
preconditioning blocked PARP-1 cleavage and severely diminished the neuronal tolerance 
(Garnier et al., 2003).  Thus, the killer protease caspase-3, when activated to sub-lethal levels, is 
a critical mediator of neuroprotection in preconditioned neurons.  Although the preconditioning-
induced caspase activation and some of its downstream targets have been characterized, little is 
known about proximal signaling events that contribute to sub-lethal caspase activation.  A recent 
report showed that preconditioning mouse cortical cultures with sub-lethal Zn2+ activated 
caspase-3-dependent PARP-1 cleavage and HSP70 upregulation (Lee et al., 2008).  Not 
surprisingly, caspase-3 and HSP70 induction were required for conferring tolerance to 
subsequent excitotoxic and Zn2+-dependent toxicity (Lee et al., 2008).  Most importantly, 
however, Lee and colleagues showed a sub-lethal accumulation of neuronal Zn2+ following 
preconditioning in vivo, which was necessary for ischemic tolerance (Lee et al., 2008).  Despite 
these findings, the mechanism underlying the rise in free Zn2+ in preconditioned neurons was not 
explained.  In this dissertation, I concentrate on upstream Zn2+-dependent signaling pathways 
involved in initaing tolerance by examining the source of the Zn2+ rise in preconditioned neurons 
and investigating preconditioning-induced Zn2+-regulated gene expression. 
1.6.2 Protein kinase C (PKC) 
As mentioned above, PKC is a family of serine/threonine kinases shown to play a role in Zn2+-
dependent cell death signaling (Noh et al., 1999; Newton, 2001).  Zn2+ overload toxicity triggers 
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a PKC-dependent activation of NADPH oxidase, which generates ROS, resulting in cell death 
(Noh and Koh, 2000).  On the other hand, PKC plays a central role in the signal transduction 
pathway following a preconditioning stimulus in multiple models of rapid and delayed, cardiac 
and neuronal tolerance (Bright and Mochly-Rosen, 2005).  The seemingly opposing actions of 
PKC may be mediated by different isoforms.  For example, in neurons PKC has been 
implicated in mediating oxidative stress, apoptosis, and inflammation following cerebral 
ischemic injury (Koponen et al., 2000; Brodie and Blumberg, 2003), while PKC has been 
identified as a critical isoform responsible for neuroprotection (Raval et al., 2003).  Although 
PKC signaling clearly mediates neuroprotection in preconditioned neurons, the mechanistic 
details of its activation and its molecular targets remain unclear.  Diverse signaling mechanisms 
involving extracellular adenosine, mitogen-activated protein kinases (MAPK), mitochondrial 
proteins, and ROS have all been hypothesized to play a role as PKC activators or targets in 
preconditioned neurons (Bright and Mochly-Rosen, 2005).  In this dissertation, I provide 
evidence suggesting that PKC plays a novel early role in the post-translational modification of 
metallothionein, facilitating intracellular Zn2+ release, and driving neuroprotection.   
1.6.3 Potassium channels 
The enhancement of voltage-gated K+ channel activity, producing K+ efflux, is a critical step in 
many apoptotic programs (Yu, 2003; Bortner and Cidlowski, 2007).  Apoptotic K+ current 
enhancement leads to a decrease in the concentration of this cation in the cytoplasm (Yu et al., 
1999), which may serve as a permissive apoptotic signal (Bortner and Cidlowski, 1999, 2007), as 
pro-apoptotic factors are activated most efficiently at reduced K+ concentrations (Hughes and 
Cidlowski, 1999).  In our laboratory, Kv2.1 was identified as the critical mediator of K+ efflux 
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during neuronal apoptosis (Pal et al., 2003).  Kv2.1 is the major component of delayed-rectifying 
K+ current in cortical neurons (Murakoshi and Trimmer, 1999), and exists in large, highly 
phosphorylated clusters on the somatic surface and proximal dendrites of cortical neurons 
(Scannevin et al., 1996).  Stimulation of a caspase-dependent neuronal apoptotic cascade by 
oxidative injury triggers the liberation of intracellular Zn2+, leading to p38 MAPK-dependent 
phosphorylation and insertion of new Kv2.1-encoded channels (McLaughlin et al., 2001; Pal et 
al., 2006; Redman et al., 2007).   
 
As lethal K+ efflux is a component of apoptotic cell death, a sub-lethal modulation of 
voltage-gated K channel activity may mediate tolerance.  Ischemia leads to profound changes in 
neuronal excitability, manifesting as an early phase of cellular hyperpolarization and depression 
of neural activity followed by a second phase of dramatic enhancement of excitability (Krnjevic, 
2008).  Changes in metabolic state or intracellular Ca2+ concentration following ischemia can 
modulate a variety of K+ channels, including KATP channels, Ca2+-activated BK channels, and 
delayed rectifier voltage-dependent K+ channels (Runden-Pran et al., 2002; Ballanyi, 2004; 
Misonou et al., 2005).  Recent evidence has shown that sub-lethal ischemic injury is associated 
with a protein-phosphatase 2B (PP2B or calcineurin)-dependent dephosphorylation of existing 
Kv2.1 channels, which is accompanied by a dispersal of somatodendritic Kv2.1 clusters and 
hyperpolarizing shifts in voltage-dependency (Misonou et al., 2005).  The latter has been 
proposed to limit neuronal excitability and thus prevent widespread excitotoxic cell death 
(Surmeier and Foehring, 2004).  Thus, the modulation of Kv2.1 following mild ischemia may be 
an important adaptive response to cellular injury.  In this dissertation, I provide evidence that 
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Kv2.1 modulation following sub-lethal ischemia requires neuronal free Zn2+ providing a novel 
target of Zn2+ in a neuroprotective pathway.   
1.7 THESIS GOALS 
The overall goal of this thesis was to establish the role of Zn2+ in endogenous neuroprotective 
signaling mechanisms involved in neuronal tolerance.  Accumulating evidence suggests the sub-
lethal activation of cell death mediators can paradoxically activate endogenous protective 
pathways in neurons.  Several downstream signaling events including caspase-3 activation, 
PARP-1 cleavage, and HSP70 upregulation have been identified.  However, upstream signaling 
events that initiate neuroprotective signaling cascades in preconditioned neurons remain unclear.  
Zn2+ has been shown to play a critical role in ischemic neuronal cell death, but has recently 
emerged as a potentially important intracellular messenger.  Thus, I hypothesized that a sub-
lethal increase in neuronal free Zn2+ is required for conferring neuronal tolerance in 
preconditioned cells.  My first goal was to characterize the increase in free Zn2+ in 
preconditioned neurons and to determine whether this Zn2+ rise contributed to attenuating 
subsequent Zn2+-dependent toxicity.  The results from these studies are presented in Chapter 2.  
PKC has been shown to be an important signaling agent in both Zn2+-regulated gene expression 
as well as in neuronal tolerance.  Accordingly, I examined the role of PKC in mediating Zn2+-
regulated gene expression in preconditioned neurons.  Results from these studies suggested a 
very early role for PKC in facilitating Zn2+ liberation from intracellular stores.  Based on these 
data, I examined whether PKC could directly modulate MT in promoting a Zn2+ rise in 
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preconditioned neurons.  These data are also presented in Chapter 2.  This chapter represents the 
contents of a manuscript that was recently published (Aras et al., 2009).   
 
Kv2.1 encoded K+ channels are modulated following sub-lethal ischemic injury and are 
thought to be important in limiting neuronal excitability following ischemia.  Because a toxic 
Zn2+ rise triggers Kv2.1 modulation in lethal neuronal injury, I hypothesized that a sub-lethal 
increase in free neuronal Zn2+ may mediate Kv2.1 modulation in neuroprotection.  The results 
from these experiments are presented in Chapter 3.  This chapter represents the contents of a 
recently submitted manuscript.  The findings of my thesis work suggest that sub-lethal 
accumulation of free Zn2+ plays important roles in diverse pathways involved in protecting 
neurons from lethal ischemic injury (Figure 1).  With this dissertation, I detail this novel 
neuroprotective role for Zn2+ and examine a previously unexplored mechanism of triggering 
Zn2+-regulated gene expression by PKC-dependent modulation of the metallothionein/Zn2+ 
interaction.  In addition, I have included a related published study in Appendix B describing the 
critical role of apoptosis signal-regulating kinase-1 (ASK-1) in the Kv2.1 mediated K+ current 
enhancement following oxidant-induced injury (Aras and Aizenman, 2005).  Appendix C 
contains a published paper in detailing the variety of methods used to assess neuronal viability in 
primary neuronal cultures (Aras et al., 2008).      
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 Figure 1 - Model of zinc-induced neuronal tolerance 
 
Figure 1.  Schematic diagram representing a proposed model in which a sub-lethal Zn2+ rise 
following preconditioning leads to the activation of Zn2+-regulated gene expression and the 
modulation of Kv2.1 channel properties.  The accumulation of free Zn2+ is facilitated by PKC-
dependent phosphorylation of MT.  The transient Zn2+ rise in preconditioned neurons may 
upregulate endogenous Zn2+ buffers, preventing subsequent lethal Zn2+-dependent cell death.        
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2.0  PKC REGULATION OF NEURONAL ZINC SIGNALING MEDIATES 
SURVIVAL DURING PRECONDITIONING 
2.1 ABSTRACT 
Sub-lethal activation of cell death processes initiate pro-survival signaling cascades.  As 
intracellular Zn2+ liberation mediates many neuronal death pathways, we tested whether a sub-
lethal increase in free Zn2+ could also trigger neuroprotection.  Neuronal free Zn2+ transiently 
increased following preconditioning and, importantly, this Zn2+ rise was both necessary and 
sufficient for conferring excitotoxic tolerance.  Lethal exposure to NMDA led to a delayed 
increase in Zn2+ that contributed significantly to excitotoxicity in non-preconditioned neurons, 
but not in tolerant neurons, unless preconditioning-induced free Zn2+ was chelated.  Thus, 
preconditioning may trigger the expression of Zn2+-regulating processes, which, in turn, prevent 
subsequent Zn2+-mediated toxicity.  Indeed, preconditioning increased Zn2+-regulated gene 
expression in neurons.  Examination of the molecular signaling mechanism leading to this early 
Zn2+ signal revealed a critical role for protein kinase C (PKC) activity in the Zn2+ rise, suggesting 
that PKC may act directly on the intracellular source of neuronal Zn2+.  As such, we identified a 
conserved PKC phosphorylation site at serine-32 (S32) of metallothionein (MT) that was 
important in modulating Zn2+-regulated gene expression and conferring excitotoxic tolerance.  
Importantly, we observed increased serine phosphorylation in immunopurified MT1, but not in 
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mutant MT1(S32A), when incubated with catalytically active PKC.  These results indicate that 
neuronal Zn2+ serves as an important, highly regulated signaling component responsible for the 
initiation of a neuroprotective pathway. 
2.2 INTRODUCTION 
The mammalian brain contains relatively high concentrations of Zn2+ (~150M; Weiss et al., 
2000), reflecting its critical role not only as a structural component of numerous proteins and 
transcription factors but also as a neuromodulator and intracellular signaling messenger 
(Frederickson and Bush, 2001; Yamasaki et al., 2007).  Most cellular Zn2+ is tightly bound to 
metal-binding proteins, limiting the amount of chelatable, “free” Zn2+ in the cytoplasm under 
physiological conditions (Outten and O'Halloran, 2001; Krezel and Maret, 2006).  Nonetheless, 
the liberation of neuronal Zn2+ from intracellular stores, mediated by oxidative and nitrative 
stress, can readily trigger cell death signaling (Aizenman et al., 2000b; Bossy-Wetzel et al., 
2004; Zhang et al., 2004).  Neurotoxicity initiated by endogenous Zn2+ liberation is mediated by 
the generation of reactive oxygen species (ROS; McLaughlin et al., 2001; Bossy-Wetzel et al., 
2004; Dineley et al., 2008), the release of cytochrome c and apoptosis-inducing factor from 
mitochondria (Sensi et al., 2003), and phosphorylation of mitogen-activated protein kinases 
(MAPK; McLaughlin et al., 2001; Du et al., 2002; Bossy-Wetzel et al., 2004).   
 
A sub-lethal, preconditioning stimulus can activate endogenous pathways that limit or 
resist subsequent lethal injury in the brain (Kitagawa et al., 1990; for recent review, see Gidday, 
2006).  While the mechanisms conferring neuronal tolerance have yet to be fully defined, 
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increasing evidence suggests that preconditioning stimuli induce the sub-lethal activation of cell 
death factors that trigger endogenous survival pathways, which, in turn, prevent subsequent 
lethal signaling (Gidday, 2006).  For example, ischemic preconditioning leads to sub-lethal 
activation of caspase-3 both in vivo and in vitro (Garnier et al., 2003; McLaughlin et al., 2003; 
Tanaka et al., 2004; Lee et al., 2008).  Importantly, caspase activation is required for the 
establishment of tolerance to lethal stimuli (McLaughlin et al., 2003).  Analogous roles in the 
establishment of neuronal tolerance have also been described for other signaling molecules 
linked to cell death including poly (ADP-ribose) polymerase-1 (PARP-1), p38 mitogen-activated 
protein kinase (MAPK), and protein kinase C (PKC; Garnier et al., 2003; Nishimura et al., 2003; 
Raval et al., 2003; Lee et al., 2008). 
 
Here, we establish endogenous intracellular Zn2+ as a necessary and sufficient early 
signal in an in vitro model of excitotoxic tolerance (see also Lee et al., 2008).  A 
preconditioning-induced increase in neuronal Zn2+ was critical in rendering neurons resistant to 
lethal excitotoxic insults that would otherwise induce Zn2+-mediated toxicity.  Examination of a 
potential Zn2+-mediated neuroprotective pathway revealed that the major source of 
preconditioning-induced Zn2+ is metallothionein (MT) and that the Zn2+ signal emanating from 
the metal binding protein can be directly modulated by PKC phosphorylation.  The results 
presented here strongly suggest that neuronal free Zn2+ serves as an upstream signaling 
component responsible for the initiation of pro-survival pathways that ultimately confer 
excitotoxic tolerance. 
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2.3 MATERIALS AND METHODS 
Materials.  Reagents were obtained from Sigma (St. Louis, MO) unless otherwise noted. 
Tissue culture supplies were purchased from Invitrogen (Carlsbad, CA), except for heat-
inactivated and iron-supplemented bovine calf serum (Hyclone, Logan, UT). Renilla luciferase 
reporter gene (pRL-TK) and Dual-Glo luciferase assay system were purchased from Promega 
(Madison, WI).  The MRE-luciferase construct (pLuc-MCS/4MREa) was kindly provided by Dr. 
David Giedroc (Indiana University, Bloomington, IN; Chen et al., 2004).  Isoform-specific 
constitutively active PKC plasmids were kindly provided by Dr. Jae-Won Soh (Inha University, 
Incheon, South Korea; Soh et al., 1999).   
 
Rat primary cortical culture and transfection.  All experiments were performed in 
cortical cultures prepared from embryonic day 16 Sprague-Dawley rats (Charles River 
Laboratories, Wilmington, MA) as previously described (Hartnett et al., 1997).  Cultures were 
utilized at 18–22 days in vitro (DIV).  For transfection, neurons were treated for 5 hours with 
2L Lipofectamine 2000 (Invitrogen, Carlsbad, CA), 100L OptiMEM (GIBCO, Grand Island, 
NY), and 1.5g DNA per well in 500L 2% serum-containing media.       
 
Preconditioning and assessment of neuronal viability. An in vitro model of ischemic 
preconditioning was previously developed in our laboratory (Aizenman et al., 2000a; 
McLaughlin et al., 2003).  Briefly, cortical cultures were treated with 3mM potassium cyanide 
(KCN) in a glucose-free balanced salt solution (150mM NaCl, 2.8mM KCl, 1mM CaCl2, 10mM 
HEPES, pH 7.2) for 90min at 37oC.  Twenty-four hours later, neurons were exposed to 100M 
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N-methyl-D-aspartate (NMDA) and 10M glycine for 60 min prepared in phenol red-free MEM, 
supplemented with 25mM HEPES and 0.01% BSA.  Neuronal viability was determined 18-24 
hours following NMDA treatment with a lactate dehydrogenase (LDH) release assay (TOX-7 in 
vitro toxicology assay kit; Sigma) and/or by cell counting, with essentially similar results (Koh 
and Choi, 1987; Aras et al., 2008).   
 
Neuronal viability in transfected neurons was assessed using a luciferase reporter assay 
(Aras et al., 2008).  Twenty-four to forty-eight hours following transfection of a luciferase 
reporter plasmid (pUHC13-3) and any other plasmids of interest, neurons were treated with 
control and experimental conditions and assayed for luciferase-mediated luminescence using a 
SteadyLite luciferase assay system (PerkinElmer, Waltham, MA).  Following 10-minute 
incubation in the luciferase reagent, luminescence was measured using a 96-well microplate 
reader (Wallac 1420, PerkinElmer Life Sciences, Waltham, MA).  Cell viability is proportional 
to luciferase activity.     
 
Intraneuronal Zn2+ imaging.  To assess the relative magnitude of intracellular free Zn2+ 
in neurons, we utilized the Zn2+-sensitive fluorescent probe, FluoZin-3 AM (Molecular Probes, 
Eugene, OR).  FluoZin-3 AM is a cell-permeant, non-ratiometric fluorescent dye that responds 
robustly to physiological changes in cellular free Zn2+ and is highly selective for this metal 
(Devinney et al., 2005).  Following treatment with chemical ischemia or an excitotoxic stimulus, 
neurons were loaded with FluoZin-3 (30min; 5M prepared in buffered solution containing 
144mM NaCl, 3mM KCl, 10mM HEPES, 5.5mM glucose, 5mg/mL bovine serum albumin; pH 
7.3).  The culture-containing glass coverslips were then immediately transferred to a recording 
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chamber (Warner, Hamden, CT) mounted on an inverted epifluorescence microscope superfused 
with phenol red-free MEM, supplemented with 25mM HEPES and 0.01% BSA.  Images were 
acquired by exciting the fluorescent dye with 490 nm light every 10 seconds for 5 minutes using 
a computer controlled monochromator (Polychrome II, TILL photonics, Martinsried, Germany) 
and CCD camera (IMAGO, TILL photonics).  Following acquisition of baseline metal levels (for 
approximately 100s), any neuronal free Zn2+ was chelated by superfusing cells with the 
membrane-permeant Zn2+ chelator N,N,N’,N’-tetrakis (2-pyridalmethyl) ethylenediamine (TPEN, 
20μM).  The magnitude of the Zn2+ fluorescence for all neuronal cell bodies in a single field (n = 
5–20 neurons) was determined by subtracting the fluorescence signal after TPEN perfusion from 
the initial baseline signal (FTPEN).  With this method, larger FTPEN values correspond to higher 
amounts of pre-existing free intracellular Zn2+ in cells (Knoch et al., 2008).   
 
Luciferase reporter assay.  Cortical neurons were co-transfected with the metal 
response element (MRE)-firefly luciferase reporter (pLuc-MCS/4MREa) and Renilla luciferase 
reporter (pRL-TK) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) as previously described 
(Hara and Aizenman, 2004).  The MRE-luciferase construct contains four tandem repeats of the 
endogenous MREa sequence (GGCTTTTGCACTCGTCCCGGCT) from the human 
metallothionein-IIA (hMT-IIA) gene upstream of a basal promoter that drives transcription of 
firefly luciferase (Chen et al., 2004).  In transfected neurons, activation of MRE by Zn2+ drives 
the transcription of the firefly luciferase gene, increasing enzymatic luciferase activity.  Renilla 
luciferase, driven by the constitutively active herpes simplex virus thymidine kinase (HSV-TK) 
promoter, is a non-inducible reporter used to standardize transfection efficiency.  Neurons were 
treated 24 - 48 hours following transfection.  Following treatment, neurons were extensively 
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washed and placed in a humidified 37oC incubator for 5-24 hours until luciferase activity was 
measured.   
 
Generation of MT3 targeted short hairpin RNA (shRNA) expression plasmid.  RNA 
interference (RNAi) technology was used to knock-down endogenous MT3 in neurons.  A MT3-
shRNA targeting plasmid was constructed by inserting targeting oligonucleotides into the 
pSuppressorNeo plasmid (Imgenex; San Diego, CA).  Inserted clones express RNAs under the 
U6 promoter in transfected mammalian cells as fold-back stem-loop structures that are processed 
into siRNA (Dykxhoorn et al., 2003).  The synthetic oligonucleotides (sense, 
tcgagcctgctcggacaaatgcaattcaagattgcatttgtccgagcaggttttt; antisense, ctagaaaaacctgctcggacaaatgca 
atcttgaattgcatttgtccgagcaggc) were used for the preparation of the MT3-shRNA fragment.  A 
MT1-shRNA construct was prepared using a similar strategy (sense, 
tcgagaactgcaaatgcacctccttcaagaggaggtgcatttgcagttcttttt; antisense, ctagaaaaagaactgcaaatgcacctc 
ctcttgaaggaggtgcatttgcagttc). 
 
To confirm the specificity of the MT3-shRNA plasmid, we generated MT3 and MT1 
expression vectors, each coupled to a different fluorescent probe.  The MT3 and MT1 expression 
plasmids were constructed by first amplifying the MT3 and MT1 full-length cDNAs from rat 
brain and liver cDNAs, respectively.  Specific primers for MT3 (sense primer, 
agaagcttgccaccatggaccctgagacctgccc; antisense primer, gaggatcctggcagcagctgcatttct) and MT1 
(sense, agaagcttgccaccatggaccccaactgctcctg; antisense, gaggatccgcacagcacgtgcacttgtc) were used 
for the amplification.  Second, the MT3 and MT1 cDNAs obtained were inserted into the Hind 
III/BamH I sites of the pEGFP-N1 and the pDsRed2-N1 vectors, respectively, in frame.  The 
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final constructs encoded fusion proteins that fluoresced green for MT3 and red for MT1.  Third, 
Chinese hamster ovary (CHO) cells were used as an expression system to verify the specificity 
of the constructs in epifluorescence and immunoblotting experiments (Supplementary Figure 1).   
 
Site-directed mutagenesis.  Mutagenesis of the MT1-DsRed cDNA was performed with 
a QuikChange XL kit (Stratagene, La Jolla, CA) according to the manufacturer's directions. 
Primers containing the desired mutation, serine on residue 32 to alanine (S32A) or aspartic acid 
(S32D), were obtained from Integrated DNA Technologies (Coralville, IA).  The specific primers 
for MT1(S32A) used in the amplification were as follows:  sense primer, 
aaatgcacctcctgcaagaaggcctgctgctcctgctgccccgtg; antisense primer, cacggggcagcaggagcagcaggcctt 
gcaggaggtgcattt.  The specific primers for MT1(S32D) used in amplification were as follows:  
sense primer, aaatgcacctcctgcaagaaggactgctgctcctgctgccccgtg; antisense primer, 
cacggggcagcaggagcagcagtccttcttgcagcaggtgcattt.  Mutations in MT1-DsRed were confirmed by 
sequencing.  These constructs were used in neuronal transfection experiments where they were 
co-expressed with luciferase reporters.   
 
Cell-free kinase assay.  Wild-type MT1- and mutant MT1(S32A)-expressed protein 
from transfected CHO cells was immunoprecipitated by incubating cell lysates with an anti-
metallothionein rabbit polyclonal antibody (1g antibody per 1mL of cell lysate; Santa Cruz 
Biotechnology, Santa Cruz, CA) followed by a Protein A/G PLUS-Agarose immunoprecipitation 
reagent (Santa Cruz).  The immunoprecipitated substrate was incubated in 15l of kinase buffer 
(25mM Hepes, pH 8.0/2mM DTT/0.1mM vanadate), 15l of Mg/ATP (50mM MgCl2 and 50M 
ATP), and 20ng of activated PKC catalytic subunit (Calbiochem, San Diego, CA) at 30oC for 1 
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hour.  Reactions containing kinase buffer alone, kinase buffer plus Mg/ATP, and 100nM 
Ro318220 were used as controls.  The reaction was stopped with sample preparation buffer 
(62.5mM Tris-HCl, pH 6.8/25% glycerol/2% SDS/0.01% bromophenol blue/5% -
mecaptoethanol) and incubated at 95oC for 5 min before SDS/PAGE and immunoblotting.  
Immunoblotting was performed with a phospho-Serine (PKC substrate-specific) antibody (Cell 
Signaling Technology, Beverly, MA, cat #2261; 1:1000) and the metallothionein rabbit 
polyclonal antibody (1:1000).   
 
Data analysis.  Data are expressed as mean ± SEM.  Statistical analysis was performed 
using Student’s t test or ANOVA with post hoc comparisons, as indicated in figure legends.  An 
of p<0.05 was considered statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 41 
2.4 RESULTS 
Inhibitors of energy metabolism, including KCN, can be coupled with glucose-free conditions to 
model ischemia (Aizenman et al., 2000a; Garnier et al., 2003; McLaughlin et al., 2003).  Sub-
lethal KCN exposure has been shown to induce excitotoxic tolerance in cortical neurons 
(McLaughlin et al., 2003).  This in vitro preconditioning paradigm, which is used in the present 
study, expresses the hallmark features of delayed neuronal tolerance including requisite protein 
synthesis, involvement of mitochondrial KATP channels, and production of ROS (McLaughlin et 
al. 2003).   
2.4.1 Preconditioning induces a transient increase in neuronal free Zn2+. 
The cell-permeant, non-ratiometric, Zn2+-sensitive fluorescent probe, FluoZin-3 was used to 
determine whether sub-lethal chemical ischemia increases neuronal free Zn2+.  Cortical neurons 
were treated with increasing concentrations of KCN in glucose-free conditions for 90 minutes 
and immediately loaded with FluoZin-3 (5M, 30 minutes).  Neuronal TPEN-sensitive Zn2+ 
fluorescence (FTPEN) increased in a dose-dependent manner immediately following sub-lethal 
chemical ischemia (Figure 2a).  Importantly, the concentration of KCN that has been shown to 
be a successful preconditioning stimulus (3mM; McLaughlin et al. 2003) resulted in a 
statistically significant increase in FTPEN when compared to vehicle-treated cells (Figure 2a).  
This increase in neuronal free Zn2+ following preconditioning was transient, as it diminished to 
intermediate levels 4 hours post-preconditioning (not shown) and returned to baseline levels 24 
hours following preconditioning (e.g., see Figure 3c).  However, the kinetic characteristics of the 
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preconditioning-induced Zn2+ rise are not representative of the “zinc wave” phenomenon as 
recently reported for mast cells (Yamasaki et al., 2007).   
2.4.2 Excitotoxicity increases free Zn2+ in non-preconditioned neurons. 
We investigated whether intracellular Zn2+ increased following NMDA exposure in non-
preconditioned neurons and evaluated the contribution of this metal to NMDA-mediated toxicity.  
FluoZin-3 fluorescence was measured at various time points following treatment of neurons with 
an excitotoxic insult (100M NMDA plus 10M glycine, 60 minutes).  NMDA treatment led to 
a delayed increase in FTPEN, reaching significant levels 6 hours following the excitotoxic insult 
(Figure 2b).    To determine whether this delayed increase in neuronal free Zn2+ is critical for 
excitotoxic cell death, neuronal free Zn2+ was chelated with 1M TPEN during and 24 hours 
following exposure to increasing concentrations of NMDA (plus 10M glycine) in non-
preconditioned neurons.  We found that co- and post-treatment with 1M TPEN significantly 
attenuated NMDA-induced toxicity (Figure 2c).  We confirmed that this concentration of TPEN 
is non-toxic to neurons (not shown), as higher concentrations of TPEN can lead to neuronal 
toxicity (Ahn et al., 1998).  We also confirmed that pre-treatment with TPEN alone for 24 hours 
prior to NMDA exposure does not subsequently affect NMDA-induced toxicity (Figure 4a), or 
the NMDA-induced increase in Zn2+ (Figure 3c).  As an additional method for chelating 
intracellular Zn2+, cortical neurons were transfected with the metal-binding protein, 
metallothionein-3 (MT3), and subsequently exposed to 30M NMDA (plus 10M glycine).  
Overexpression of MT3 serves as a sink for free Zn2+ in neurons (e.g., see Figure 7a), and like 
TPEN, would be expected to effectively chelate NMDA-induced free Zn2+.  We found that 
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transfected neurons overexpressing MT3 had significantly reduced toxicity following NMDA 
compared to vector-expressing neurons (Figure 2c, inset).  These results indicate that the delayed 
increase in neuronal Zn2+ following NMDA contributes substantially to excitotoxicity, 
confirming previous reports (Bossy-Wetzel et al., 2004).      
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 Figure 2 - Preconditioning and excitotoxicity increase neuronal zinc 
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Figure 2.  (A) Inset, representative fluorescence traces of several vehicle and 3mM KCN-treated 
neurons in a single coverslip.  Each trace reflects the level of intracellular free Zn2+ in a single 
neuron.  Arrow depicts the beginning of superfusion with 20M TPEN to chelate Zn2+ and 
quench florescence.  Calibration:  10 arbitrary fluorescence units, 60 seconds.  Plot shows 
TPEN-sensitive Zn2+ fluorescence, expressed as FTPEN, which was determined by subtracting 
the fluorescence signal after TPEN superfusion from the baseline signal.  Data represent the 
mean (± s.e.m.) FTPEN measurements from 5-10 coverslips, each containing 5-10 neurons 
(**p<0.01 compared to 0mM KCN group; one-way ANOVA-Dunnett).  (B) Cortical neurons 
were exposed to 100M NMDA (with 10M glycine) for 60 minutes and allowed to recover for 
various times prior to FluoZin-3 loading.  Inset, examples of fluorescent images of cortical 
neurons loaded with 5M FluoZin either immediately (left panels) or 6 hours (right panels) 
following NMDA.  Images show FluoZin fluorescence from a representative field before (top 
panels) and after (bottom panels) 20M TPEN superfusion. Scale: 100m.  Plot shows FTPEN 
(mean ± s.e.m.) measurements from 5-10 coverslips, each containing 5-10 neurons (**p<0.01 
compared to 0 hr time point, one-way ANOVA-Dunnett).  (C) Neurons were treated with vehicle 
(squares) or 1M TPEN (triangles) during and 24-hours following exposure of non-
preconditioned neurons to increasing concentrations of NMDA (plus 10M glycine).  Neuronal 
viability was determined with LDH release, measured 24 hours following NMDA exposure.  
Data are expressed as mean (± s.e.m) relative toxicity from 4 independent experiments 
performed in triplicate (*p<0.05 compared to corresponding 0M TPEN group; paired two-tailed 
t-test).  Inset, neurons expressing either vector or MT3 (0.5g/well) along with a firefly 
luciferase reporter (pUHC13-3; 1.0g/well) were treated with 30M NMDA with 10M glycine 
(10min) twenty-four hours following transfection.  Twenty-four hours following treatment, 
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luciferase activity (viability; mean ± s.e.m) was measured from 4 independent experiments 
performed in quadruplicate (***p<0.001 Repeated measures ANOVA-Bonferroni Multiple 
Comparisons Test).     
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2.4.3 Preconditioning-induced Zn2+ elevation attenuates subsequent excitotoxicity-
induced Zn2+ rise. 
Previous work in our laboratory has shown that sub-lethal activation of cell death mediators 
initiates endogenous neuroprotective cascades that can buffer subsequent lethal levels of the 
same factor (McLaughlin et al. 2003).  Since preconditioning induces a sub-lethal increase in 
Zn2+, it is possible that preconditioned neurons may be tolerant to a subsequent NMDA-mediated 
elevation in Zn2+.  To test this, FTPEN was measured from preconditioned and non-
preconditioned neurons six hours following exposure to NMDA (Figure 3a).  Remarkably, the 
NMDA-induced delayed increase in neuronal Zn2+ was completely abolished in preconditioned 
neurons (Figure 3b, c).  To determine whether the preconditioning-induced free Zn2+ is required 
for the diminished NMDA-induced Zn2+, 1M TPEN was added during and 24 hours following 
preconditioning.  Following extensive washing to remove TPEN from the bathing medium, 
neurons were subsequently exposed to NMDA and assayed for the delayed increase in Zn2+ 
(Figure 3a).  We found that chelating preconditioning-induced free Zn2+ restores the excitotoxic 
delayed increase in neuronal Zn2+ (Figure 3c).  We verified that TPEN treatment without 
preconditioning had no effect on subsequent NMDA-induced Zn2+ elevation (Figure 3c).  These 
results suggest that the preconditioning-induced transient increase in neuronal Zn2+ triggers the 
expression of Zn2+-regulating processes, which, in turn, prevent or dampen subsequent increases 
in Zn2+ and Zn2+-mediated toxicity following NMDA.   
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 Figure 3 - Excitotoxic zinc rise is attenuated by preconditioning-induced increase in neuronal zinc 
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Figure 3.  (A)  Diagram representing experimental protocol designed to measure the effect of the 
preconditioning-induced increase in Zn2+ on the NMDA-induced Zn2+ rise.  (B) Representative 
FluoZin fluorescence traces of a single coverslip containing non-preconditioned neurons exposed 
to vehicle, non-preconditioned neurons exposed to 100M NMDA (with 10M glycine, 60min), 
and 3mM KCN preconditioned neurons exposed to NMDA.  Each trace reflects the level of 
intracellular Zn2+ in a single neuron.  Arrow depicts the beginning of superfusion with 20M 
TPEN to quench Zn2+ fluorescence.  Calibration:  10 arbitrary fluorescence units, 60 seconds.  
(C) Preconditioned (3mM KCN, 90 minutes) and non-preconditioned neurons were exposed to 
100M NMDA (with 10M glycine) for 60 minutes.  FluoZin fluorescence was measured from 
neurons 6 hours following NMDA.  In TPEN-treated groups, 1M TPEN was present during and 
24 hours following preconditioning, but not during or after NMDA exposure.  FTPEN (mean ± 
s.e.m.) was measured from 5-10 coverslips in each group, each containing 5-10 neurons 
(*p<0.05, **p<0.01 compared to non-preconditioned, non-NMDA treated group; p<0.05; one-
way ANOVA-Tukey).   
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2.4.4 Zn2+ is necessary and sufficient for excitotoxic tolerance. 
If chelating Zn2+ during preconditioning restores the NMDA-induced lethal increase in Zn2+, 
then Zn2+ chelation during preconditioning would also be expected to attenuate excitotoxic 
tolerance.  To test this, cortical neurons were treated with 1μM TPEN 30 minutes prior to, 
during, and 24 hours following preconditioning.  Neurons were subsequently exposed to NMDA 
and assayed for cell viability 18-20 hours following excitotoxic exposure.  In the absence of 
TPEN, preconditioning with chemical ischemia significantly reduced NMDA-induced toxicity 
(Figure 4a; McLaughlin et al. 2003).  In contrast, chelation of preconditioning-induced free Zn2+ 
restored the vulnerability of neurons to NMDA (Figure 4a).  TPEN treatment alone (without 
preconditioning) had no effect on subsequent NMDA-induced toxicity (Figure 4a).  Therefore, 
these data suggest that excitotoxic tolerance is critically dependent on the preconditioning-
induced transient increase in neuronal Zn2+. 
 
Next, to confirm the Zn2+-selectivity of the TPEN results above, we investigated whether 
Zn2+ exposure alone was sufficient to induce excitotoxic tolerance.  Cortical neurons were 
preconditioned with 30M Zn2+ in the presence of 300nM pyrithione, which selectively 
transports extracellular Zn2+ into cells.  Immediately following 18-24 hour incubation with Zn2+ 
and pyrithione, neurons were exposed to 30M NMDA plus 10M glycine for 30 minutes.  Cell 
viability was determined 24 hours following NMDA insult.  We found that 30M Zn2+ with 
300nM pyrithione afforded significant neuroprotection against NMDA toxicity (Figure 4b, c), to 
a similar degree as KCN preconditioning (e.g., see Figure 4a, inset).  In general, however, we 
found that exogenous Zn2+ administration was not an ideal preconditioning agent due to intrinsic 
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Zn2+ neurotoxicity (Choi and Koh, 1998).  Lower concentrations of Zn2+ (3, 10, and 20M), or 
30M Zn2+ without pyrithione, failed to induce tolerance, while higher concentrations of Zn2+ 
(100M) or pyrithione (1M, along with Zn2+) were themselves neurotoxic.  Further, although 
30 minute exposure of neurons to 30M NMDA led to significant toxicity (e.g., see Figure 4b, 
c), no tested combination of Zn2+ and pyrithione afforded significant neuroprotection from a 60 
minute exposure to 100M NMDA.   
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 Figure 4 - Zinc is necessary and sufficient for excitotoxic tolerance 
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Figure 4.  (A) LDH release was measured following 100M NMDA (plus 10M glycine, 
60min) exposure in 3mM KCN preconditioned and non-preconditioned neurons treated in the 
presence or absence of 1M TPEN.  Main plot shows relative toxicity (mean ± s.d.) in a 
representative experiment (performed in quadruplicate; **p<0.01 compared to non-
preconditioned, vehicle treated group; one-way ANOVA-Dunnett), while inset shows pooled 
viability data normalized to its corresponding control (n=5 independent experiments in triplicate 
or quadruplicate; *p<0.05; Paired, two-tailed t-test).  (B)  Cortical neurons were preconditioned 
with 30M Zn2+ in the presence of 300nM pyrithione or 300nM pyrithione alone (non-
preconditioned) for 18-24 hours prior to exposure to 30M NMDA (plus 10M glycine) or 
vehicle (10M glycine alone).  Phase-contrast images were obtained 24 hours following NMDA 
exposure.  White arrows point to the presence of phase-bright, viable neurons in Zn2+-
precondioned cultures following NMDA exposure.  (C) Cortical neurons were preconditioned 
with 300nM pyrithione alone (non-preconditioned), 30M Zn2+ in the presence of 300nM 
pyrithione, or 30M Zn2+/300nM pyrithione in the presence of 1M Ro318220 for 18-24 hours 
prior to exposure to 30M NMDA (plus 10M glycine) or vehicle (10M glycine alone).  
Quantification of neuronal viability was determined by counting phase-bright live neurons in 10 
random, high-power (200X) fields.  Cell counts were performed 24-hours following NMDA 
exposure and expressed as percent viability (mean ± s.e.m.; n=4-9 independent experiments, 
each performed in triplicate; **p<0.01, ***p<0.001, significantly different from non-
preconditioned condition; ANOVA/Tukey).   
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2.4.5 PKC modulates the intraneuronal Zn2+ signal. 
Preconditioning triggers a transient increase in neuronal Zn2+ that is required for the attenuation 
of a subsequent, NMDA-induced lethal Zn2+ rise.  Thus, it is conceivable that the 
preconditioning-induced Zn2+ rise triggers a neuroprotective mechanism that involves the 
activation of Zn2+ regulatory elements that prevent subsequent Zn2+ toxicity.  An increase in 
intracellular free Zn2+ activates the metal response element transcription factor-1 (MTF-1), 
which translocates to the nucleus and activates a conserved metal response element (MRE), 
located on the promoter regions of Zn2+-regulated genes (Andrews, 2001).  Thus, a MRE-
luciferase reporter construct (Chen et al., 2004; Hara and Aizenman, 2004) was utilized not only 
to monitor the level of free Zn2+ in transfected neurons, but also to determine whether the Zn2+ 
rise was sufficient to trigger Zn2+-regulated gene expression.  While PKC has been previously 
implicated in Zn2+-regulated gene expression, all prior work had been performed in non-neuronal 
cell lines (LaRochelle et al., 2001b; Adams et al., 2002; Saydam et al., 2002; Jiang et al., 2004).   
Thus, we first confirmed that PKC plays a similar role in neurons.  Cortical neurons were co-
transfected with the MRE-firefly luciferase (pLuc-MCS/4MREa) and Renilla luciferase (pRL-
TK) reporters.  Twenty-four hours following transfection, neurons were treated with one of two 
PKC inhibitors, Ro318220 and Gö6976, during metal exposure (20M Cd2+ + 50 M 
NMDA/10M glycine, 10 minutes; Hara & Aizenman 2004).  In this treatment paradigm, Cd2+ 
permeates through the NMDA receptor (Ascher and Nowak, 1988), and strongly promotes MTF-
1/MRE activation indirectly by displacing Zn2+ from MT (Zhang et al., 2003).  We found that 
both PKC inhibitors blocked Zn2+-regulated gene expression in a concentration-dependent 
manner (Figure 5a).  Next, constitutively active forms of PKC were used to determine whether 
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PKC activity could enhance metal-induced MRE activation in neurons.  The constitutively active 
PKC constructs encode a truncated protein in which the catalytic domain of PKC is preserved 
and the regulatory N-terminal domain is deleted (Soh et al., 1999).  Forty-eight hours following 
transfection, neurons expressing a vector plasmid, constitutively active PKC1, or constitutively 
active PKC, along with the MRE-firefly and Renilla luciferase reporters were exposed to 
vehicle or Cd2+ and assayed for MRE activation.  We found enhanced basal and metal-induced 
MRE activation in neurons expressing constitutively active PKC isoforms compared to vector 
expressing neurons (Figure 5b).  Collectively, these data strongly implicate PKC activity in 
modulating the intracellular free Zn2+ signal and Zn2+-regulated gene expression in neurons.   
 
To determine whether PKC plays a role in preconditioning-induced Zn2+-regulated gene 
expression, neurons expressing the two luciferase reporter genes were exposed to KCN in the 
presence or absence of 1M Ro318220.  Ro318220 is a cell-permeable, competitive, and 
relatively selective inhibitor of PKC.  We first observed that preconditioning led to a significant 
activation of the MRE, similar to the positive control, 100M Zn2+ (Figure 5c, left).  PKC 
inhibition during preconditioning significantly attenuated Zn2+-regulated MRE activation (Figure 
5c, left) to a similar degree as during metal exposure (compare Figure 5c left to 5a).  To confirm 
the PKC selectivity of Ro318220, neurons expressing the MRE firefly and Renilla luciferase 
reporters were stimulated with KCN preconditioning in the presence of 1M H-89.  H-89 is a 
cell-permeable, selective, and potent inhibitor of PKA.  We found that, in contrast to Ro318220, 
H-89 had no effect on preconditioning-induced MRE activation (Figure 5c, left).  These data 
suggest that a signaling cascade involving PKC is necessary for Zn2+-dependent gene expression 
in preconditioned neurons.   
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PKC plays a central role in the signal transduction pathway in multiple models of 
neuronal tolerance (Raval et al., 2003; Bright and Mochly-Rosen, 2005; Dave et al., 2008).  To 
confirm that PKC plays a critical role in excitotoxic tolerance in our model, cortical neurons 
were exposed to 1M Ro318220 30 minutes prior to, during, and 24-hours following 
preconditioning. Cell viability was determined 24 hours following excitotoxic NMDA exposure.  
Indeed, PKC inhibition during preconditioning significantly blocked excitotoxic tolerance 
(Figure 5c, right).  Thus, PKC plays a major role in preconditioning-induced Zn2+-regulated gene 
expression and is required for excitotoxic tolerance.     
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 Figure 5 - Critical role of PKC in zinc-regulated gene expression in neurons 
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Figure 5.  (A) MRE-firefly (fLuc; 1g/well) and Renilla luciferase (rLuc; 0.5g/well) -
expressing neurons were stimulated with 20M Cd2+ plus 50M NMDA and 10M glycine 
(10min) or vehicle in the presence or absence of increasing concentrations of the PKC inhibitors, 
Gö6976 and Ro318220.  Relative MRE-fLuc/rLuc values (mean ± s.e.m., n=4-7 independent 
experiments in quadruplicates) were normalized to the control response in the absence of any 
PKC inhibitor (100%).  (B) Neurons were transfected with MRE-firefly (0.375g/well) and 
Renilla luciferase (0.375g/well) expressing plasmids in conjunction with plasmids encoding 
vector alone, constitutively active PKC-1, or constitutively active PKC-0.75g/well).  Forty-
eight hours later, neurons were stimulated with 3M Cd2+ plus 50M NMDA and 10M glycine 
(10min) or vehicle.  Luciferase activity (MRE-fLuc/rLuc; mean ± s.e.m) was measured in 3-6 
independent experiments performed in quadruplicate (**p<0.01 compared to vector-expressing 
neurons stimulated by Cd2+).  (C)  Left (filled bars), neurons expressing the MRE-firefly 
(1g/well) and Renilla luciferase (0.5g/well) reporters were stimulated with 100M Zn2+ 
(10min), KCN preconditioning (3mM, 90 min), or KCN in the presence of either 1M Ro318220 
or 1M H-89, and subsequently assayed for luciferase activity 24 hours following treatment.  
Relative MRE-fLuc/rLuc values (mean ± s.e.m., n=4-11 independent experiments in triplicate) 
were normalized to the response in corresponding control neurons (*p<0.05, **p<0.01, 
***p<0.001 compared to 100%; one-sample two-tailed t-test; p<0.05 one-way ANOVA-
Tukey).  Right (open bars), neuronal viability was determined with LDH release following 
NMDA exposure in preconditioned neurons in the absence or presence or 1M Ro318220.  Data 
from 4 independent experiments performed in triplicate are expressed as viability (± s.e.m.) 
normalized to corresponding control condition (p<0.05; paired, two-tailed t-test).   
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2.4.6 Preconditioning-induced Zn2+ rise is downstream of PKC activity. 
Next, we examined the temporal relationship between Zn2+ liberation and PKC activation in 
preconditioned neurons.  Previous reports have shown that acute exposure of a high 
concentration of exogenous Zn2+ can activate neuronal PKC (Noh et al., 1999).  Zn2+-overload 
neurotoxicity involves a PKC-dependent activation of NADPH-oxidase, which contributes to 
intracellular ROS generation (Noh and Koh, 2000).  In other work, Knapp and Klann (2000) 
reported that mild oxidant-induced Zn2+ released directly from the Zn2+ finger motif of the 
cysteine-rich region of PKC is sufficient to trigger the activation of the kinase, suggesting that 
PKC activation and Zn2+ release occur almost simultaneously.  Thus, the precise temporal 
relationship between PKC and Zn2+ remains unclear and may be stimulus-dependent.  Here, 
KCN-induced Zn2+ accumulation was measured in neurons that were preconditioned in the 
presence of the PKC inhibitor Ro318220.  Again, to confirm the selectivity of Ro318220 for 
PKC, H-89 was also used in these experiments.  Surprisingly, co-treatment with Ro318220 
during preconditioning completely blocked the increase in neuronal Zn2+ (Figure 6), suggesting 
that PKC activity occurs upstream of the Zn2+ rise in preconditioned neurons.  To confirm this, 
we examined the requirement of PKC in the Zn2+-induced preconditioning model.  If 
intracellular Zn2+ is indeed downstream of PKC activity in the neuroprotective cascade, then 
PKC activity would not be required for Zn2+-induced preconditioning.  Neurons were 
preconditioned with 30M Zn2+/300nM pyrithione in the presence of Ro318220, and 
subsequently exposed to lethal NDMA.  We found that neuroprotection was maintained in the 
presence of PKC inhibition (Figure 4c).  Thus, in the Zn2+-induced preconditioning model, 
application of exogenous Zn2+ can bypass PKC and directly trigger the neuroprotective cascade, 
confirming the temporal relationship of PKC activity prior to Zn2+ signaling in preconditioning.         
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2.4.7 Intracellular Zn2+ is likely the primary source of the preconditioning-induced Zn2+ 
rise. 
In addition to liberation of neuronal Zn2+ from intracellular stores, synaptic release of vesicular 
Zn2+ and its translocation to postsynaptic neurons may contribute to neuronal injury following 
ischemia (Frederickson et al., 1989; Suh et al., 2000; but see Lee et al., 2000; Kay, 2003).  We 
approached this issue two ways:  1) by targeting the main route of extracellular Zn2+ entry during 
ischemia, namely Ca2+-permeable AMPA/kainate (Ca-A/K) channels (Sensi et al., 1999; Yin et 
al., 2002; Noh et al., 2005) with the competitive AMPA/kainate channel antagonist 6-cyano-7-
nitroquinoxaline-2,3-dione (CNQX); and 2) by chelating extracellular Zn2+ using a cell-
impermeant Zn2+ chelator, tricine (N-[Tris(hydroxymethyl)methyl]glycine; Paoletti et al., 2009).  
Intracellular Zn2+ was measured in neurons preconditioned in the presence CNQX (10M), or 
tricine (1mM).  We found that co-treatment with CNQX or tricine during preconditioning had 
little effect on the increase in neuronal Zn2+ (Figure 6), suggesting that the major source of 
preconditioning-induced Zn2+ is not extracellular.  It must be noted, however, that the use of a 
higher affinity extracellular Zn2+ chelator (1mM CaEDTA) substantially decreased both baseline 
and preconditioning-induced intracellular Zn2+ levels (data not shown).  As such, other sources 
of Zn2+ may be at play in this process, although CaEDTA has been reported to eliminate 
intracellular Zn2+ signals (Lee et al., 2000; Frederickson et al., 2002).   
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Figure 6 - Preconditioning-induced PKC activation is upstream of zinc release 
 
 
 
Figure 6.  Cortical neurons were preconditioned (3mM KCN, 90min) in the presence or absence 
of 3Ro318220, 1M H-89, 10M CNQX, or 1mM tricine immediately before FluoZin-3 
loading.  FTPEN (mean ± s.e.m.) was measured from 4-18 coverslips, each containing 10-20 
neurons (*p<0.05, **p<0.01 compared to non-preconditioned vehicle-treated neurons, one-way 
ANOVA-Tukey).   
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2.4.8 PKC alters the MT / Zn2+ interaction. 
Finally, we examined a possible site of action for PKC in Zn2+-regulated gene expression in 
cortical neurons.  Our results suggest that PKC acts upstream of preconditioning-induced Zn2+ 
release and may directly target an intracellular source of the liberated Zn2+ signal.  A likely 
source of such labile Zn2+ in neurons is MT3, which is the predominant MT isoform in neurons 
(Aschner, 1996; Aschner et al., 1997; Palmiter, 1998; Hidalgo et al., 2001).  When MT3 
expression is reduced using a MT3-specific targeting plasmid that generates RNAi (MT3-
shRNA; Supplementary Figure 1), MRE activation was enhanced, suggesting that under normal 
conditions, a fraction of MT3 is devoid of Zn2+ and can serve as a sink for intracellular free Zn2+ 
(Figure 7a).  Knock-down of MT1, which is not normally significantly expressed in neurons, had 
no effect on neuronal MRE activity (Figure 7a).  In contrast, neurons overexpressing MT3 or 
MT1 have excess Zn2+-binding capacity, resulting in reduced levels of free Zn2+ released to 
trigger MRE activation (Figure 7a).  Thus, MT3 may be a substantial source of labile Zn2+ in 
cortical neurons in vitro, and could potentially be one of the sites of PKC action during 
preconditioning.   
 
Scansite (http://scansite.mit.edu), a computer program that predicts protein 
phosphorylation sites (Obenauer et al., 2003) was used to search for potential PKC 
phosphorylation target motifs on MT.  All MT isoforms examined, regardless of species, 
contained a highly conserved, putative PKC phosphorylation site (serine 32 for MT1/2, serine 33 
for MT3).  In order to determine the role of this conserved site in Zn2+-regulated gene 
expression, site-directed mutagenesis was used to create mutant forms of MT, in which the 
amino acid of the putative PKC phosphorylation site, serine (S), was substituted for either a non-
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phosphorylatable alanine (A) or a phospho-mimicking charged aspartic acid (D) residue.  Since 
neurons predominantly express MT3, cells were transfected with the MT3-shRNA targeting 
vector to reduce background provided by this isoform.  In MT3-depleted neurons, 
overexpression of MT1 can restore the Zn2+-binding capacity of cells, thus permitting 
substitution of the endogenous protein (Figure 7a).  Using this approach, MRE activation was 
measured in MT3-depleted neurons expressing either wild-type MT1, a non-phosphorylatable 
mutant, MT1(S32A), or a phospho-mimicking mutant, MT1(S32D).  Forty-eight hours following 
transfection, Zn2+-regulated gene expression was stimulated with 100M Zn2+ for 10 minutes.  
Twenty-four hours following this treatment, Zn2+-induced MRE activation was significantly 
diminished in MT3-depleted, MT1(S32A)-expressing neurons, while significantly enhanced in 
MT3-depleted, MT1(S32D)-expressing neurons compared to MT3-depleted, wild-type MT1-
expressing neurons (Figure 7b).  These data suggest that neurons expressing a mutant MT, in 
which the putative PKC phosphorylation site is replaced with either a non-phosphorylatable 
residue or a phospho-mimicking charged residue, have altered efficiency in binding free Zn2+, 
resulting in modulation of Zn2+-regulated gene expression.   
 
In order to determine whether PKC could directly phosphorylate MT, we performed a 
cell-free assay in which recombinantly expressed, immunoprecipitated wild-type MT1 was used 
as a substrate for active PKC (Figure 7b, inset).  We found that wild-type MT1 exposed to active 
PKC produced increased phospho-serine immunoreactivity.  This increase in the phospho-
specific signal was abolished when the assay was performed in the presence of a PKC inhibitor 
(not shown).  Similar experiments were performed with the mutant MT1(S32A) protein yielding 
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no change in phospho-serine immunoreactivity.  Thus, active PKC can directly induce selective 
phosphorylation of MT1 at residue S32.   
 
During preconditioning, PKC may influence Zn2+-regulated gene expression by targeting 
MT at S32 and modulating the MT/Zn2+ interaction, ultimately leading to altered levels of 
neuroprotection.  To test this, MT3-depleted neurons expressing either wild-type MT1 or 
MT1(S32A) along with a luciferase reporter plasmid were preconditioned with KCN.  Twenty-
four hours following preconditioning, neurons were exposed to NMDA excitotoxicity and 
subsequently assayed for viability.  We found that KCN preconditioning was less efficient in 
conferring excitotoxic tolerance to MT3-depleted, MT1(S32A)-expressing neurons compared to 
MT3-depleted, wild-type MT1-expressing neurons (Figure 7c).  Collectively, these data strongly 
suggest that PKC can directly phosphorylate MT and influence the MT/Zn2+ interaction, 
resulting in modulation of neuronal free Zn2+ and Zn2+-regulated gene expression critical for 
preconditioning-induced tolerance. 
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 Figure 7 - PKC alters the MT/zinc interaction 
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Figure 7.  (A) Neurons were transfected with MRE-firefly (0.5g/well) and Renilla luciferase 
(0.5g/well) expressing plasmids in conjunction with a plasmid encoding vector, MT3, MT1, the 
MT3-shRNA targeting vector, the MT1-shRNA targeting vector, or the MT3-shRNA targeting 
vector with MT1 (0.5g/well).  Forty-eight hours later, neurons were stimulated with 20M 
Cd2+ plus 50M NMDA/10M glycine or vehicle and assayed for luciferase expression.  
Relative MRE-fLuc/rLuc values (mean ± s.e.m., n=3-11 independent experiments in 
quadruplicate) were normalized to the response in corresponding vehicle-treated groups and then 
to the response in vector-expressing neurons (*p<0.05, **p<0.01, ***p<0.001 compared to 
100%; One-sample two-tailed t-test.; p<0.05 one-way ANOVA-Tukey).  (B)  Neurons were 
transfected with MRE-firefly (0.375g/well) and Renilla (0.375g/well) luciferase reporters in 
addition to the MT3-shRNA targeting vector (0.375g/well) and either a wild-type MT1, a 
mutant MT1(S32A) plasmid,  or a mutant MT1(S32D) plasmid (0.375g/well).  Forty-eight 
hours following transfection, neurons were stimulated by 100M Zn2+ and assayed for luciferase 
activity.  Luciferase activity (mean ± s.e.m.) was measured from 3-11 independent experiments 
performed in quadruplicate (p<0.05; repeated measures ANOVA-Bonferroni Multiple 
Comparisons Test). Inset, wild-type MT1 and mutant MT1(S32A) proteins were 
immunoprecipitated from CHO cell lysates with a metallothionein rabbit polyclonal antibody 
(1g antibody per 1mL of cell lysate) and reacted with 15l of kinase buffer (25mM Hepes, pH 
8.0/2mM DTT/0.1mM vanadate), 15l of Mg/ATP (50mM MgCl2 and 50M ATP), and 20ng of 
activated PKC catalytic subunit at 30oC for 1 hour.  Immunoblots were probed with the phospho-
Serine (PKC substrate-specific) antibody (1:1000).  Representative immunoblot of 4 independent 
experiments is shown. (C)  Neurons were transfected with a firefly luciferase reporter (pUHC13-
3; 0.5g/well) in conjunction with the MT3shRNA targeting vector (0.5g/well) and either wild-
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type MT1 or the mutant MT1(S32A) plasmid (0.5g/well).  Forty-eight hours following 
transfection, neurons were preconditioned with 3mM KCN and subsequently exposed to 100M 
NMDA/10M glycine (60min).  Luciferase activity (viability; mean ± s.e.m.) was measured 24 
hours following NMDA exposure from 6 independent experiments performed in triplicate 
(p<0.05 repeated measures ANOVA-Bonferroni Multiple Comparisons Test).   
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2.5 DISCUSSION 
Zn2+ has been implicated as a causative trigger in many forms of neuronal cell death (Choi and 
Koh, 1998; Weiss et al., 2000; Frederickson et al., 2005).  Here, we report a different, 
neuroprotective role for intracellular Zn2+.  A sub-lethal preconditioning stimulus elicited an 
immediate increase in neuronal free Zn2+, which attenuated a subsequent excitotoxicity-induced 
increase in this metal.  Chelating Zn2+ during preconditioning restored the excitotoxic increase in 
neuronal free Zn2+ and blocked excitotoxic tolerance.  We examined the molecular signaling 
mechanism involved in excitotoxic tolerance and found that PKC activity was required for the 
preconditioning-induced increase in free Zn2+, activation of Zn2+-regulated gene expression, and 
neuroprotection.  Finally, we identified a PKC phosphorylation site on MT that can modulate 
Zn2+-regulated gene expression and neuroprotection presumably by facilitating Zn2+-release from 
MT.  Taken together, these results implicate intracellular Zn2+ in a neuroprotective pathway 
critical for excitotoxic tolerance.  A very similar role for Zn2+-mediated neuroprotection was 
recently described (Lee et al., 2008). 
 
A preconditioning-induced, sub-lethal increase in neuronal free Zn2+ prevents a 
subsequent, NMDA-induced lethal increase in Zn2+, likely by triggering the expression of Zn2+-
regulating processes.  Evidence suggesting a role for endogenous Zn2+-regulated proteins in 
neuroprotection comes from studies that used transgenic mice to examine the role of MT in 
ischemic cell death.  MT overexpressing mice showed an average of 42% smaller infarct 
volumes and better motor performance compared to control mice following focal cerebral 
ischemia (van Lookeren Campagne et al., 1999).  In contrast, MT 1/2-knock out mice develop 
approximately three-fold larger infarcts than wild-type mice (Trendelenburg et al., 2002).  
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Endogenous proteins involved in Zn2+ homeostasis, including MT1/2 and Zn2+ transporters are 
transcriptionally regulated by the Zn2+/MTF-1/MRE pathway (Andrews, 2001).  Since delayed-
onset neuronal tolerance requires de novo protein synthesis (Gidday, 2006), a potential survival 
pathway in preconditioning may involve the transcriptional upregulation of Zn2+-regulated 
proteins. Indeed, we found that preconditioning sufficiently activates a neuronal Zn2+-specific 
MRE reporter construct containing the conserved response element located on the promoter 
regions of the Zn2+-regulated genes.  Together, these data provide strong evidence for Zn2+-
triggered processes mediating neuronal survival pathways critical for preconditioning-induced 
tolerance.   
 
While the preconditioning-induced upregulation of endogenous Zn2+-regulated proteins 
may ultimately confer neuroprotection, here we focus on neuronal MT3 as a source of free 
intracellular Zn2+, which can act as an upstream signaling agent to trigger a neuronal survival 
pathway.  First, using an extracellular chelator of Zn2+ and an inhibitor of Ca-A/K channels to 
block the primary entry route for synaptically-released Zn2+, we found the preconditioning-
induced Zn2+ rise was maintained, suggesting that the major source of preconditioning-induced 
Zn2+ is intracellular.  While the use of a higher affinity extracellular Zn2+ chelator (CaEDTA) 
substantially blocked the preconditioning-induced Zn2+ rise (data not shown), CaEDTA also 
abolished baseline intracellular free Zn2+, consistent with previous reports suggesting that 
CaEDTA eliminates intracellular Zn2+ signals (Lee et al., 2000; Frederickson et al., 2002).  Thus, 
while possible, extracellular sources of preconditioning-induced free Zn2+ and enhanced Zn2+ 
uptake during preconditioning are not likely.  Second, using a highly Zn2+-sensitive molecular 
assay, we found that altering the expression of MT can modulate the levels of labile Zn2+ 
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released during metal stimulation.  This suggests that MT is the major intracellular source of free 
Zn2+ in neurons. Third, and most importantly, when endogenous MT3 is replaced with mutant 
forms of MT1, in which the putative PKC phosphorylation site on MT, serine 32, is converted to 
a non-phosphorylatable residue (S32A), we observed decreased excitotoxic tolerance conferred 
by KCN preconditioning.  Thus, modulation of intracellular Zn2+ homeostasis, possibly by the 
altering the ability of MT to bind free Zn2+, has a profound impact on neuronal survival.  These 
data show that MT3 is the major source of labile Zn2+ in neurons, and that MT-bound Zn2+ is the 
likely the critical source of the preconditioning-induced Zn2+ rise.   
 
Several signal transduction pathways central to the neuroprotective response following 
preconditioning have also been implicated in Zn2+-mediated signaling including p38 MAPK, 
extracellular signal regulated protein kinase (ERK), Akt, and PKC (Noh et al., 1999; Kim et al., 
2000; McLaughlin et al., 2001; Du et al., 2002; Gidday, 2006).  Of these, PKC has been shown 
to be required for both short-lasting and delayed tolerance in several models of cardiac and 
neuronal preconditioning (Raval et al., 2003; Bright and Mochly-Rosen, 2005; Perez-Pinzon et 
al., 2005; Dave et al., 2008).  Here, we found that inhibition of PKC significantly reduced 
neuroprotection in our model.  The mechanisms involved in PKC-mediated neuroprotection 
remain unclear and have been suggested to involve MAPK signaling, regulation of mitochondrial 
ATP-dependent potassium channels (KATP), and synaptic mitochondrial proteins (Bright and 
Mochly-Rosen, 2005; Dave et al., 2008).  We found that PKC is required for the KCN-induced 
Zn2+ rise and can modulate Zn2+-regulated gene expression, providing an additional, somewhat 
surprising upstream role of PKC in promoting neuronal survival.  In the exogenous Zn2+-induced 
preconditioning model, PKC activity was not required for excitotoxic tolerance, indicating that 
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Zn2+ is downstream of PKC in the neuroprotective cascade.  The precise mechanism underlying 
the activation of PKC in conferring neuronal tolerance is still unclear.  Several models of 
ischemic preconditioning have implicated a role for adenosine in triggering a PKC-dependent 
survival cascade (Bright and Mochly-Rosen, 2005).  Others have shown that reactive oxidative 
and nitrative species, which are required in delayed neuronal tolerance, can modulate the activity 
of phospholipases, leading to the activation of downstream kinases, such as PKC (Das and 
Maulik, 2003).  Alternatively, Knapp and Klann (2000) reported that mild-oxidant-induced Zn2+-
release from the cysteine-rich region of PKC can directly trigger the activation of the kinase.  
This hypothesis is supported by studies in cardiac preconditioning models, where a ROS-
dependent activation of PKC is critical in cardiac tolerance (Zhang et al., 2002; Novalija et al., 
2003).   
 
Although PKC has been previously suggested to influence Zn2+-regulated gene 
expression in non-neuronal cell lines (LaRochelle et al., 2001b; Saydam et al., 2002), its 
mechanism of action remains unclear.  Much of the literature surrounding this issue focuses on 
MTF-1 as a target of PKC phosphorylation.  MTF-1 is a 72.5kDa, ubiquitous, Zn2+-finger 
transcription factor in the Cys2His2 family that, in the presence of Zn2+, can bind to MREs at the 
consensus site TGCRCNC (Stuart et al., 1984).  MTF-1 has been shown to be phosphorylated at 
multiple sites in unstimulated cells, and can undergo an increase in phosphorylation following 
metal exposure by a mechanism involving PKC (LaRochelle et al., 2001b; Adams et al., 2002; 
Saydam et al., 2002).  However, when immunopurified endogenous MTF-1 protein from mouse 
hepatoma (Hepa) cells was used rather than overexpressed MTF-1 protein, Jiang and colleagues 
found that while MTF-1 can be phosphorylated in unstimulated cells, metal exposure does not 
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alter the phosphorylation pattern of MTF-1 (Jiang et al., 2004).  Further, kinase inhibition does 
not affect metal-induced MTF-1 nuclear translocation, MTF-1 DNA binding, or the formation of 
a stable MTF-1-chromatin complex (Larochelle et al., 2001a; Jiang et al., 2004).  Therefore, it is 
certainly possible that modulation of Zn2+-regulated gene expression by signaling kinases may 
not be mediated by post-translational modification of MTF-1.  Instead, signaling kinases, 
including PKC, may directly target unknown factors that interact with, or regulate MTF-1 (Jiang 
et al. 2004).   
 
Based on a report showing a direct interaction of the PKC kinase domain with MT2A in a 
yeast two-hybrid screen (Rao et al., 2003), we turned our attention to MT as a potential target of 
PKC phosphorylation in neurons.  First, we found that PKC activity was necessary for the 
preconditioning-induced increase in neuronal Zn2+, suggesting that PKC may target an 
intracellular source of labile Zn2+.  Second, neurons expressing constitutively active forms of 
PKC had enhanced Zn2+-regulated gene expression, similar to MT3-depleted neurons, suggesting 
that PKC activity may alter the MT/Zn2+ interaction.  Third, MT3-depleted neurons expressing 
mutant forms of MT1, consisting of either a non-phosphorylatable or a phospho-mimicking point 
mutation at a putative PKC phosphorylation site (S32) had, respectively, either diminished or 
enhanced Zn2+-induced MRE activation, similar to neurons in which either PKC activity or MT3 
expression was modulated.  Fourth, a cell-free kinase assay revealed increased serine 
phosphorylation in immunopurified wild-type MT, but not in mutant MT(S32A), when incubated 
with catalytically active PKC.  Fifth, preconditioning of MT3-depleted neurons that expressed 
MT1(S32A) conferred less neuroprotection compared to MT3-depleted neurons expressing wild-
type MT1.  Collectively, these data provide evidence for a role of PKC phosphorylation in 
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modulating Zn2+-regulated gene expression by possibly altering the MT/Zn2+ interaction.  In 
conditions that promote an increase in neuronal Zn2+, such as preconditioning, PKC activity 
could facilitate the release of Zn2+ from the metal-binding protein, which, in turn, would promote 
MTF-1/MRE activation and upregulate Zn2+-regulating processes.  This is the first study, to our 
knowledge, that directly demonstrates MT phosphorylation by PKC.  Thus, modulation of Zn2+-
regulated gene expression by direct phosphorylation of MT by PKC may resolve the conflicting 
interpretations in the literature.   
 
In summary, our results provide evidence for a central role of intracellular Zn2+ in a 
neuroprotective signaling cascade.  Preconditioning induces a transient, sub-lethal intracellular 
Zn2+ rise that is critical for not only attenuating a subsequent, lethal elevation in excitotoxic Zn2+, 
but also for conferring neurons excitotoxic tolerance.  This preconditioning-induced increase in 
neuronal Zn2+ is sufficient for triggering Zn2+-regulated gene expression via a PKC-dependent 
pathway.     
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3.0  ZINC REGULATES KV2.1 VOLTAGE-DEPENDENT GATING AND 
LOCALIZATION FOLLOWING ISCHEMIA 
3.1 ABSTRACT 
The delayed rectifier K+ channel Kv2.1 exists in highly phosphorylated somatodendritic clusters.  
Ischemia induces rapid Kv2.1 dephosphorylation and a dispersal of these clusters, accompanied 
by a hyperpolarizing shift in their voltage-dependent activation kinetics.  Transient modulation 
of Kv2.1 activity and localization following ischemia is dependent on a rise in intracellular Ca2+ 
and the protein phosphatase calcineurin.  Here, we show that neuronal free Zn2+ also plays a 
critical role in the ischemic modulation of Kv2.1.  We found that sub-lethal ischemia in cultured 
rat cortical neurons led to characteristic hyperpolarizing shifts in K+ current voltage dependency 
and pronounced dephosphorylation of Kv2.1.  Zn2+ chelation, similar to calcineurin inhibition, 
attenuated ischemic induced changes in K+ channel activation kinetics.  Zn2+ chelation during 
ischemia also blocked Kv2.1 declustering.  Surprisingly, we found that the Zn2+ rise following 
ischemia occurred in spite of calcineurin inhibition.  Therefore, a calcineurin-independent rise in 
neuronal free Zn2+ is critical in altering Kv2.1 channel activity and localization following 
ischemia.  The identification of Zn2+ in mediating ischemic modulation of Kv2.1 may lead to a 
better understanding of cellular adaptive responses to injury.  
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3.2 INTRODUCTION 
Ischemia triggers accumulation of extracellular glutamate, rise in intracellular Ca2+, and 
occurrence of repetitive waves of depolarization, leading to profound changes in neuronal 
excitability (Lee et al., 1999; Dietz et al., 2009).  Delayed rectifier voltage-dependent potassium 
(Kv) channels are important in regulating neuronal excitability (Du et al., 2000).  Of these, Kv2.1 
is a major component of delayed-rectifier potassium currents (IK) in cortical neurons (Murakoshi 
and Trimmer, 1999; Du et al., 2000; Malin and Nerbonne, 2002; Pal et al., 2003) and exists in 
large, highly phosphorylated clusters on the surface of soma and proximal dendrites (Scannevin 
et al., 1996).  Mild ischemic injury is associated with dephosphorylation of Kv2.1, dispersal of 
somatodendritic Kv2.1 clusters, and hyperpolarizing shifts in voltage-dependency (Misonou et 
al., 2005).  The latter has been proposed as a mechanism to limit neuronal excitability and thus 
prevent or limit widespread excitotoxic cell death (Surmeier and Foehring, 2004).  Such changes 
in Kv2.1 following ischemia are transient, returning to baseline conditions within hours of 
stimulus cessation, and are mediated by a rise in intracellular Ca2+ and protein phosphatase 2B 
activity (PP2B or calcineurin; Misonou et al., 2005).   
 
In addition to a rise in neuronal Ca2+, ischemic injury also leads to an accumulation of 
free Zn2+ in neurons (Galasso and Dyck, 2007).  Recent evidence suggests that the Zn2+ rise 
following ischemia may actually precede the rise in intracellular Ca2+, serving as a very early 
signal in the ischemic cascade (Medvedeva et al., 2009).  This rise in neuronal Zn2+ following 
lethal ischemic insults has been associated with irreversible neuronal injury mediated by 
mitochondrial dysfunction (Medvedeva et al., 2009), nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase activation (Suh et al., 2008; Brennan et al., 2009), generation of 
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reactive oxygen species (Dineley et al., 2008), and activation of a p75NTR-mediated death 
executer (Park et al., 2000).  In contrast to lethal injury, preconditioning with sub-lethal ischemia 
can activate endogenous signaling pathways that confer neuronal tolerance to irreversible 
ischemic damage (Kitagawa et al., 1990; Gidday, 2006).  Recent evidence suggests that a 
transient, early rise in neuronal free Zn2+ may also be important in preconditioning-induced 
neuroprotection (Lee et al., 2008; Aras et al., 2009).    Preconditioning with chemical ischemia 
triggers a transient rise in neuronal free Zn2+, which is necessary and sufficient for excitotoxic 
tolerance (Aras et al., 2009).     
 
In the present study, we find a critical role for Zn2+ in the modulation of Kv2.1 following 
preconditioning.  We first confirmed that sub-lethal chemical ischemia leads to the transient 
modulation of Kv2.1 voltage dependency and phosphorylation state.  The altered K+ channel 
activation kinetics, which have been shown to be a cellular adaptive process mediating 
neuroprotection, are dependent on a rise in neuronal free Zn2+.  Moreover, the ischemia-induced 
dispersal of Kv2.1 clusters is also Zn2+-dependent.  We find that both altered kinetics and 
localization of Kv2.1 following chemical ischemia are dependent on calcineurin, but that the 
Zn2+ rise occurs independently of this phosphatase.  Thus, Zn2+ may represent a novel early 
signal in the modulation of Kv2.1 channel activity and localization following sub-lethal chemical 
ischemia.       
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3.3 MATERIALS AND METHODS 
Rat primary neuronal cultures and preconditioning.  All experiments were performed 
in primary cortical cultures prepared from embryonic day 16 Sprague-Dawley rats (Charles 
River Laboratories, Wilmington, MA) as previously described (Hartnett et al., 1997). Briefly, 
cortices were dissociated, and the resultant cell suspension was adjusted to 670,000 cells/well 
(six-well tissue culture plates containing five, 12-mm poly-L-ornithine-treated coverslips per 
well).  Cultures were maintained at  37oC, 5% CO2 in a growth medium composed of a volume-
to-volume mixture of 80% Dulbecco’s modified minimal essential medium, 10% Ham’s F12-
nutrients, 10% bovine calf serum (heat-inactivated, iron-supplemented) with 25mM HEPES, 
24U/mL penicillin, and 24g/mL streptomycin. Non-neuronal cell proliferation was inhibited 
after 2 weeks in culture with 1–2M cytosine arabinoside, after which the cultures were 
maintained in growth medium containing 2% serum and without F12-nutrients.  Cultures were 
utilized at 18–22 days in vitro.  An in vitro model of ischemic preconditioning was previously 
developed in our laboratory (McLaughlin et al., 2003; Aras et al., 2009).  Briefly, cortical 
cultures were treated with 3mM potassium cyanide (KCN) in a glucose-free balanced salt 
solution (150mM NaCl, 2.8mM KCl, 1mM CaCl2, 10mM HEPES, pH 7.2) for 90min at 37oC.  
Preconditioning with KCN attenuates subsequent excitotoxic cell death by ~50% (McLaughlin et 
al., 2003; Aras et al., 2009).     
 
Electrophysiology. All recordings were made using the whole-cell configuration of the 
patch-clamp technique as described previously (McLaughlin et al., 2001).  The extracellular 
solution contained (in mM):  115 NaCl, 2.5 KCl, 2.0 MgCl2, 10 HEPES, 10 D-glucose; pH was 
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adjusted to 7.2 with concentrated KOH; 0.250 mM TTX was added to inhibit voltage gated 
sodium channels.  The intracellular (electrode) solution contained (in mM):  100 K-Gluconate, 
11 EGTA, 10 KCl, 1 MgCl2, 1 CaCl2 x 2H2O, 10 HEPES; pH was adjusted to 7.2 with 
concentrated KOH; 0.22 mM ATP was added and osmolarity was adjusted to 280 mOsm with 
sucrose.   All measurements were obtained under voltage clamp with an Axopatch 1C amplifier 
(Molecular Devices, Sunnyvale, CA) and pClamp software (Molecular Devices) using 2-3 
MOhm electrodes.  Partial compensation (80%) for series resistance was provided in all 
instances.  Currents were filtered at 2 kHz and digitized at 10 kHz (Digidata; Axon Instruments).  
K+ currents were evoked with a series of 200 msec voltage steps from a holding potential of –
50mV to +80mV in 10mV increments.  Before the start of the depolarization, a single pre-pulse 
to −10mV was given for 30 ms.  Peak conductance (G) was calculated from peak steady-state 
current amplitudes (I) using the equation G = I/(V-EK), where EK is the Nerst K+ equilibrium 
potential.  The conductance was plotted against the potential (V) and fitted to a single Boltzmann 
function G = Gmax/(1 + exp[-(V – V1/2)/k]), where Gmax is the maximum conductance, V1/2 is the 
potential at which the channel has half-maximal conductance, and k is the parameter that 
represents the slope of the activation curve.   
 
Immunofluorescence.  Kv2.1 labeling was performed essentially as described by 
Misonou and colleagues (2004).  Immediately following chemical ischemia, neurons were 
washed three times in ice-cold PBS and fixed with 4% paraformaldehyde for 15 minutes.  
Following three washes with PBS, neurons were permeabilized for 5 min in PBS containing 
0.3% Triton X-100.  Neurons were washed three times in PBS and then incubated in PBS 
containing 1% bovine serum albumin (BSA) for 5 min.  Following overnight incubation with 
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anti-Kv2.1 rabbit polyclonal (1:500; Alomone Labs, Jerusalem, Israel) and anti-microtubule-
associated protein-2 mouse monoclonal (MAP2; 1:500; Sigma-Aldrich, St. Louis, MO; #M9942) 
antibodies, neurons were incubated in FITC anti-mouse (1:1000; Sigma-Aldrich, St. Louis MO) 
and Cy5 anti-rabbit (1:1000; Jackson Immunoresearch, West Grove, PA) secondary antibodies at 
room temperature for 1 hr.  Coverslips containing neurons were then mounted onto glass slides 
and allowed to air-dry before imaging.  Imaging of neurons was performed on an Olympus 
Fluoview FV1000 confocal unit fitted to an Olympus BX61 microscope at 60X (PlanApo, NA 
1.4 oil) using Fluoview software (Olympus Fluoview, USA).  Laser and detector settings were 
retained for all images collected.  Multiple (5-10) optical sections (0.5m) were acquired to 
generate a collapsed image file.  Control and treatment groups were always run in parallel within 
the same immunocytochemical procedure.  Collapsed, raw images were transferred to NIH 
image processing software (ImageJ; http://rsbweb.nih.gov/ij/) for analysis.  Following 
background subtraction, neuronal somas were selected and a plot displaying a 3-dimensional 
graph of pixel intensity over a region of interest was used to display Kv2.1 localization (Figure 
10).  Clusters on the plots appeared as orange-red peaks in pixel intensity, which corresponded to 
>70% of maximal intensity (Figure 10).  A clustered cell was scored as such when its associated 
surface map revealed greater than ten orange-red peaks.  Using these plots, 75-100 cells from 3-4 
independent experiments were classified as either having clusters or not.  Although infrequent 
(<10% of total), neurons containing regions of both clustered and diffuse staining patterns were 
scored according to the predominant (>50% of cell surface) staining pattern.  
 
Immunoblotting.  Samples for biochemical analysis were prepared from neuronal 
cultures immediately following chemical ischemia.  Neurons were washed three times with PBS 
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and then incubated in lysis buffer [50mM Tris-HCl, pH 7.4, 150mM NaCl, 0.25% deoxycholic 
acid, 1% nonyl phenoxylpolyethoxylethanol (NP-40), 1mM EDTA] supplemented with protease 
inhibitor mixture (Roche Diagnostics, Indianapolis, IN), 1mM phenylmethylsulphonyl fluoride 
(PMSF), and 100M vanadate for 5min on ice.  Cell lystates were harvested and centrifuged at 
10,000 X g for 10min at 4oC.  Cell lysate samples were combined in a 1:1 ratio with sample prep 
buffer [62.5mM Tris-HCl, pH 6.8, 2% SDS, 25% glycerol, 0.01% Bromophenol Blue] and 
incubated for 5 min at 100°C to denature proteins before gel electrophoresis.  SDS/PAGE was 
carried out by standard procedures using the Mini Protean 3 System (Bio-Rad, Hercules, CA).  
Equal amounts of cell lysate (15 g) were separated on 7.5% SDS/PAGE gels and transferred 
onto a 0.2 m nitrocellulose membrane.  The membranes were blocked with 1% bovine serum 
albumin (BSA) in PBS with 0.05% Tween 20 before probing with either an anti-Kv2.1 mouse 
monoclonal (clone K89/34, NeuroMab, Davis, CA) or an anti-GAPDH mouse monoclonal 
(Novus Biologicals, Littleton, CO).  Blots were incubated with a goat anti-mouse secondary 
antibody conjugated to HRP and were visualized with a SuperSignal CL-HRP Substrate System 
(Pierce Biotechnology, Rockford, IL).   
 
Neuronal Zn2+ imaging. To assess the relative magnitude of intracellular free Zn2+ in 
neurons, we utilized the Zn2+-sensitive fluorescent probe FluoZin-3 AM (Molecular Probes, 
Eugene, OR).  FluoZin-3 AM is a cell-permeant, non-ratiometric fluorescent dye that responds 
robustly to physiological changes in cellular free Zn2+ (KD for Zn2+ 10-20nM) and is highly 
selective for this metal (Devinney et al., 2005).  The small-molecule probe fluoresces upon 
binding Zn2+ and is best suited for assessing the presence of free Zn2+ in cells rather than 
determining its precise intracellular concentration (Thompson et al., 2002; Kay, 2003).  
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Following treatment with chemical ischemia, neurons were loaded with FluoZin-3 (30min; 5M 
prepared in buffered solution containing 144mM NaCl, 3mM KCl, 10mM HEPES, 5.5mM 
glucose, 5mg/mL bovine serum albumin; pH 7.3).  The culture-containing glass coverslips were 
then immediately transferred to a recording chamber (Warner, Hamden, CT) mounted on an 
inverted epifluorescence microscope superfused with phenol red-free minimal essential medium, 
supplemented with 25mM HEPES and 0.01% bovine serum albumin.  Images were acquired by 
exciting the fluorescent dye with 490 nm light every 10 seconds for 5 minutes using a computer 
controlled monochromator (Polychrome II, TILL photonics, Martinsried, Germany) and CCD 
camera (IMAGO, TILL photonics).  Following acquisition of baseline metal levels (for 
approximately 100s), any neuronal free Zn2+ was chelated by superfusing cells with the 
membrane-permeant Zn2+ chelator N,N,N’,N’-tetrakis (2-pyridalmethyl) ethylenediamine (TPEN, 
20μM).  The magnitude of the Zn2+ fluorescence for all neuronal cell bodies in a single field (n = 
5–20 neurons) was determined by subtracting the fluorescence signal after TPEN perfusion from 
the initial baseline signal (FTPEN), as described earlier (Knoch et al., 2008; Aras et al., 2009).  
With this method, larger FTPEN values correspond to higher amounts of pre-existing free 
intracellular Zn2+ in neurons (Knoch et al., 2008; Aras et al., 2009).   
 
Statistical analysis.   Data are expressed as mean ± SEM.  Statistical analysis was 
performed using an ANOVA with post hoc comparisons, as indicated in figure legends.  An of 
p<0.05 was considered statistically significant. 
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3.4 RESULTS 
3.4.1 Sub-lethal ischemia alters potassium channel activity and Kv2.1 phosphorylation 
Transient hyperpolarizing shifts in the voltage-dependence of activation of neuronal Ik 
dramatically limit neuronal excitability and are thus thought to be an adaptive cell response to 
ischemia (Surmeier and Foehring, 2004).  Sub-lethal chemical ischemia, using potassium 
cyanide (KCN) coupled with glucose-free conditions, reliably induces Zn2+-dependent 
excitotoxic tolerance in cortical neurons (Aras et al., 2009).  To first determine whether sub-
lethal ischemia could alter K+ channel activation in cortical neurons, whole-cell K+ currents were 
measured from control and KCN preconditioned (3mM, 90 min) neurons immediately following 
treatment.  We found that sub-lethal ischemia indeed led to a hyperpolarizing shift in the voltage-
dependency of K+ channel activation (Figure 8a), similar to those reported in hippocampal 
neurons (Misonou et al., 2005).  These hyperpolarizing shifts were transient and partially 
returned to baseline conditions 24 hours following the ischemic stimulus (Figure 8a).    
 
Hyperpolarizing shifts in the voltage-dependent activation of neuronal Ik are associated 
with a dephosphorylation of the Kv2.1 channel (Misonou et al., 2004; Misonou et al., 2005).  To 
determine whether sub-lethal ischemia could dephosphorylate Kv2.1, we performed immunoblot 
experiments on cortical neurons exposed to either KCN or control conditions (Figure 8b).  The 
major forms of Kv2.1 in control-treated rat brain cultured neurons were found to exhibit a higher 
range of molecular weight bands (~95-105 kDa; Figure 8b) than predicted from the deduced 
Kv2.1 primary sequence (95.3 kDa), reflecting its constitutively multi-phosphorylated state 
(Misonou et al., 2004).  KCN led to a dramatic reduction in the molecular weight of Kv2.1, 
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representing a dephosphorylation of the channel (Figure 8b; Misonou et al., 2004).  Changes in 
the phosphorylation state of Kv2.1 are reversible and are restored to control conditions hours 
after the stimulus (Misonou et al., 2004; Misonou et al., 2005).  Indeed, twenty-four hours 
following KCN exposure, we found that Kv2.1 partially returned to its multi-phosphorylated 
state (Figure 8b). Thus, reminiscent to the response following ischemia in hippocampal neurons 
(Misonou et al., 2005), sub-lethal ischemia led to a transient dephosphorylation of Kv2.1 in 
cortical neurons, accompanied by hyperpolarizing shifts in the voltage-dependence of neuronal 
Ik.     
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Figure 8 - Chemical ischemia alters K+ channel activation properties and phosphorylation state 
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Figure 8.  (A) Inset, representative Ik currents in cortical neurons evoked with a series of 200ms 
depolarizing steps from -50mV to +80mV recorded under whole-cell voltage clamp.  A single 
30ms pre-pulse depolarization to -10mV was given before each recording to minimize rapidly-
inactivating K+ current.  Whole-cell K+ currents were measured immediately following either 
control (black traces) or 3mM KCN (red traces) exposure, or 24 hours following 3mM KCN 
(green traces).  Calibration:  2nA, 50ms.  Main plot shows the conductance-voltage (G-V) 
relationship of peak potassium current recorded from neurons in each treatment group.  Data 
points represent the mean ± s.e.m from 6-18 neurons.  (B) Neurons were exposed to either 
vehicle or 3mM KCN.  In KCN treated groups, cell lysates were harvested immediately or 24 
hours following stimulus.  Lysates were separated and transferred to nitrocellulose membranes, 
which were probed with either an anti-Kv2.1 mouse monoclonal (1:1000) or an anti-GAPDH 
mouse monoclonal (1:1000) antibody.  Representative blot of 4 independent experiments is 
shown.   
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3.4.2 Modulation of K+ channel activity is Zn2+- and calcineurin-dependent  
The hyperpolarizing shifts in K+ channel activation have been shown to be dependent on a rise in 
intracellular Ca2+ and the activation of calcineurin (Misonou et al., 2005).  Recent evidence 
suggests that Zn2+ is both necessary and sufficient for mediating neuronal tolerance triggered by 
ischemic preconditioning (Lee et al., 2008; Aras et al., 2009).  Thus, the ischemia-induced 
modulation of K+ channel activation may also be Zn2+-dependent.  To test this, whole-cell K+ 
currents were measured from neurons preconditioned in the presence of the cell-permeant Zn2+-
chelator, TPEN (N,N,N’,N’-tetrakis (2-pyridalmethyl)ethylenediamine; 1M).  It is noteworthy 
that under these conditions the neuroprotective effects of preconditioning are severely attenuated 
(Aras et al., 2009).  We found that TPEN almost completely blocked the hyperpolarizing shift in 
the voltage-dependence of activation (Figure 9).  However, when neurons were treated with 
exogenous Zn2+ and pyrithione acutely (30 and 100 M ZnCl2 with 1 M pyrithione; 2-5 min), 
the voltage-dependence of activation of Kv2.1 channels was not shifted (not shown), suggesting 
that Zn2+ may be necessary but not sufficient for the ischemic-induced modification of neuronal 
Ik.  In order to verify the role of calcineurin in this process, whole-cell K+ currents were 
measured from preconditioned neurons treated in the presence of the calcineurin inhibitor, 
FK520 (5M; IC50 49nM).  We found that, like TPEN, FK520 attenuated the preconditioning-
induced hyperpolarizing shift in the voltage-dependence of K+ channel activation (Figure 9).  
Thus, both Zn2+ and calcineurin play a role in the modulation of the voltage-dependence of 
activation of neuronal Ik following chemical ischemia.   
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 Figure 9 - Altered K+ channel activation properties are zinc- and calcineurin-dependent 
 
 
 
 
Figure 9.  Whole-cell K+ currents were measured immediately following control, 3mM KCN, or 
3mM KCN in the presence of 1M TPEN or 5M FK520.  Peak current for each neuron was 
converted to conductance and the conductance was plotted against each potential and fit to a 
Boltzmann distribution. Data points represent mean ± s.e.m. half-maximal activation voltage 
(mV) for K+ currents obtained from 8-18 neurons (**p<0.01 compared to control; One-way 
ANOVA-Dunnett).   
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3.4.3 Chemical ischemia induces Zn2+ and calcineurin-dependent Kv2.1 declustering   
Hyperpolarizing shifts in K+ channel activation and dephosphorylation of Kv2.1 are 
accompanied by a dispersal of surface Kv2.1 clusters to a more uniform localization (Misonou et 
al., 2005).  To determine whether the ischemic dispersal of Kv2.1 clusters is also dependent on a 
rise in free Zn2+, cortical neurons were exposed to KCN in the absence and presence of TPEN.  
Immediately following exposure, neurons were fixed and immunostained using antibodies 
specific for Kv2.1 and the neuronal marker, microtubule-associated protein-2 (MAP2).  Maps 
plotting the distribution of Kv2.1 within individual neuronal somata were used to determine 
whether a cell contained clusters (Figure 10a).  We found that sub-lethal ischemia led to a 
dispersal of somatic Kv2.1 clusters (Figure 10a, b).  Kv2.1 dispersal partially returned to a 
clustered localization 24 hours following ischemia (Figure 10b).  When neurons were exposed to 
KCN in the presence of TPEN, declustering of Kv2.1 was blocked (Figure 10a, b).  As controls, 
we verified that ischemia- and NMDA-mediated declustering was dependent on calcineurin by 
using FK520 (Figure 10a, b; Misonou et al., 2005; Mulholland et al., 2008).  Thus, in addition to 
calcineurin, ischemic declustering of Kv2.1 requires an increase in neuronal free Zn2+.     
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 Figure 10 - Zinc is required for the calcineurin-dependent ischemic declustering of Kv2.1 in neurons 
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Figure 10.  (A) Neurons exposed to control or 3mM KCN were fixed and immunostained with 
anti-Kv2.1 (1:500 red) and anti-MAP2 (1:500 green) antibodies.  In KCN treated groups, 
neurons were fixed immediately or 24 hours following stimulus.  Representative neurons and 
their associated surface maps from each treatment group from 3-4 independent experiments are 
shown.  Background-subtracted neuronal surface maps show relative Kv2.1 staining intensity 
values plotted along the area of the cell body.  Scale bar: 10m.  (B) Neurons were exposed to 
control, 3mM KCN (90 min), KCN in the presence of 1M TPEN or 5M FK520 (90 min), 
100M NMDA with 10M glycine (10 min), or NMDA/glycine in the presence of 5M FK520 
(10min).  Neurons were fixed and immunostained as in A.  Fluorescent images were background 
subtracted and cell surface maps were created to plot Kv2.1 staining intensity over the neuronal 
soma.  Clusters on surface maps appeared as orange-red peaks in pixel intensity.  Using these 
plots, 75-100 cells from 3-4 independent experiments were classified as either clustered or not.  
Data points represent percentage of cells with clusters compared to total cell counts (mean ± 
s.e.m.) (*p<0.05; **p<0.01 compared to control; One-way ANOVA-Dunnett). 
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3.4.4 Zn2+ accumulation is not calcineurin-dependent 
Both a rise in neuronal free Zn2+ and activation of calcineurin are required for the modulation of 
Kv2.1 following sub-lethal ischemia (Figures 9, 10).  To determine the interdependence of these 
two signaling events, we measured the preconditioning-induced Zn2+ rise in the absence and 
presence of the calcineurin inhibitor.  Cortical neurons were loaded with the Zn2+-selective 
indicator, FluoZin-3 (5M, 30 min) and imaged using live-cell wide-field microscopy.  
Intracellular TPEN-sensitive Zn2+ fluorescence rose significantly in neurons exposed to sub-
lethal chemical ischemia (Figure 11), as previously reported (Aras et al., 2009).  This KCN-
induced increase in neuronal Zn2+ remained relatively unchanged in the presence of the 
calcineurin inhibitor, FK520 (5M; Figure 11).  These data suggest that the rise in neuronal Zn2+ 
occurs independently of, or is upstream of, calcineurin activity following preconditioning.   
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 Figure 11 - Chemical ischemia induces a calcineurin-independent zinc rise 
 
 
 
Figure 11.  Cortical neurons were exposed to control or 3mM KCN in the absence or presence of 
5M FK520.  Representative fluorescence traces of several neurons in a single coverslip from 
each treatment groups are shown above corresponding bar from bar graph.  Arrow depicts the 
beginning of superfusion with 20M TPEN to chelate Zn2+ and quench fluorescence.  
Calibration:  50 arbitrary fluorescence units, 50 s. Bar graph represents mean (± s.e.m.) FTPEN 
measurements from 8-15 coverslips, each containing 10-25 neurons (**p<0.01 compared to 
control; One-way ANOVA-Dunnett).   
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3.5 DISCUSSION 
Previous reports have shown ischemic modulation of Kv2.1 critically depends on a rise in 
intracellular Ca2+ and on the protein serine/threonine phosphatase calcineurin (Misonou et al., 
2005).  In the present study, we found a novel role for Zn2+ in mediating the modulation of 
Kv2.1 channel activity following sub-lethal ischemic injury.  We first confirmed that sub-lethal 
chemical ischemia in cortical neurons leads to a hyperpolarizing shift in the voltage-dependent 
activation of neuronal Ik and associated reduction in molecular weight of total Kv2.1 protein, 
reflecting a dephosphorylation of the channel.  Changes in the voltage-dependency and 
phosphorylation state of Kv2.1 following sub-lethal ischemia in hippocampal neurons are 
transient, and recover shortly following stimulus cessation (Misonou et al., 2005).  In cortical 
neurons, we found that the ischemia-induced changes only partially recovered to baseline 
conditions 24 hours following KCN cessation.  The difference in recovery between the two 
studies may simply be due to the differences in cellular model system (hippocampal neurons 
versus mixed cortical culture) or stimulus duration (15 min versus 90 min chemical ischemia).  
Importantly, however, KCN induced sub-lethal ischemia led to characteristic changes in Kv2.1 
activity and phosphorylation previously described following ischemia (Misonou et al., 2005). 
 
A rise in neuronal Zn2+, likely mediated by a combination of Zn2+ translocation from 
presynaptic vesicles (Koh et al., 1996) and Zn2+ liberation from intracellular stores (Aizenman et 
al., 2000b), can trigger neurodegenerative signaling following ischemia (Frederickson et al., 
2005).  However, early rises in neuronal Zn2+ have also been reported to be required for 
neuroprotection following sub-lethal ischemia in both in vivo and in vitro models (Lee et al., 
2008; Aras et al., 2009).  Sub-lethal ischemic insults can precondition neurons by activating 
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endogenous protective mechanisms that render cells tolerant to subsequent lethal ischemic injury 
(Kitagawa et al., 1990; Gidday, 2006).  Neuronal Zn2+ accumulation following sub-lethal 
ischemia was necessary and sufficient for inducing tolerance in multiple preconditioning models 
(Lee et al., 2008; Aras et al., 2009).  Thus, in contrast to Zn2+ accumulation in the acute phase of 
lethal ischemia, an early Zn2+ rise following sub-lethal ischemia triggers cell survival cascades.  
One such adaptive survival cascade may involve the modulation of K+ channel kinetics: transient 
increases in overall K+ current can hyperpolarize neurons limiting neuronal excitability 
following ischemia.  The delayed rectifier Kv2.1 channel, similar to other K+ channels that are 
modulated in response to changes in the metabolic state (KATP channels) or [Ca]i (Ca2+-activated 
BK channels), can play an important role in limiting excitability following ischemia (Du et al., 
2000; Misonou et al., 2005).  In light of the critical role of Zn2+ in mediating neuroprotection, we 
hypothesized that the ischemic change in K+ channel activation kinetics may also be Zn2+ 
dependent.  While a role for Ca2+ and calcineurin in the modulation of Kv2.1 channel activation 
following ischemia has been described (Misonou et al., 2005), recent evidence has shown that a 
Zn2+ rise occurs immediately upon onset of ischemia and even precedes, and may contribute to, 
Ca2+ deregulation (Stork and Li, 2006; Medvedeva et al., 2009).  Indeed, we found that the cell-
permeable Zn2+ chelator, TPEN, significantly attenuated the hyperpolarizing shift in the voltage-
dependent activation of Ik to the same extent as calcineurin inhibition.  Further, we found that the 
Zn2+ rise was not altered by calcineurin inhibition, suggesting that the early Zn2+ rise may 
precede Ca2+-dependent calcineurin activation or perhaps occur concurrently.  Thus, Zn2+ plays a 
critical early role in the modulation of K+ channel kinetics following ischemia.   
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Kv2.1 channels are localized to large clusters found over the soma and proximal 
dendrites of cortical neurons (Trimmer, 1991).  The assembly of Kv2.1 into large surface clusters 
restricted to the cell body and proximal dendrites of neurons is likely mediated by a proximal 
restriction and clustering (PRC) domain located within the last 318 amino acids of the 
intracellular C terminus (Lim et al., 2000; Mohapatra and Trimmer, 2006).  The cellular 
components involved in cluster maintenance are currently an intense line of investigation.  For 
example, an actin cytoskeleton-based dynamic perimeter fence may regulate cluster size and 
localization (O'Connell et al., 2006).  Remarkably, although clusters themselves exhibit little 
lateral mobility, single Kv2.1 channels are mobile within and even between clusters (Tamkun et 
al., 2007), arguing against the presence of a sustained physical association between Kv2.1 and a 
scaffolding protein.  Tamkun and co-workers propose a model in which retention proteins 
interact with the Kv2.1 C terminus, perhaps in a phospho-dependent manner, to maintain 
individual channels from crossing the perimeter fence (O'Connell et al., 2006).  While the role of 
Zn2+ in individual Kv2.1 channel mobility is not clear, the liberation of neuronal Zn2+ from 
intracellular stores has been shown to be an important upstream signaling event in the phospho-
dependent surface delivery of new Kv2.1 channels in apoptosis (McLaughlin et al., 2001; Pal et 
al., 2003; Redman et al., 2007).  The results presented here suggest that neuronal Zn2+ may also 
regulate existing Kv2.1 cluster activity and localization following ischemia.  The functional 
significance of maintaining Kv2.1 channels in clusters also remains unclear.  A recent report by 
Misonou and colleagues suggest that Kv2.1 clusters are strategically situated at junctions 
between astrocytic and neuronal membranes to achieve rapid modulation following ischemia 
(Misonou et al., 2008).  The authors speculate that glutamate accumulation in the extracellular 
space following ischemia may activate ionotropic glutamate receptors, leading to elevated 
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[Ca2+]i, calcineurin activation, and modulation of Kv2.1 (Misonou et al., 2008).  Here, we 
provide evidence for an additional signaling event, the calcineurin-independent transient rise in 
neuronal Zn2+, in mediating the dispersal of channel clusters following ischemia.  Thus, a rise in 
Zn2+, along with Ca2+ may be necessary for modulation of Kv2.1 following ischemia.  
  
Finally, although both altered kinetics and localization of Kv2.1 following chemical 
ischemia were dependent on calcineurin, we observed that the Zn2+ rise occurred even in the 
presence of calcineurin inhibition.  Calcineurin is a protein serine/threonine phosphatase that is 
regulated by Ca2+- and calmodulin-binding (King and Huang, 1984).  In addition, calcineurin is a 
Fe2+- and Zn2+- metalloenzyme containing both metals in its catalytic domain, which are required 
for full phosphatase activity (Goldberg et al., 1995).  Along these lines, Zn2+ chelation by TPEN 
may prevent full calcineurin activation following ischemia, preventing Kv2.1 modulation.  It 
should be noted that, like many phosphatases, calcineurin activity can be inhibited with excess 
exogenous Zn2+ in in vitro assays (Takahashi et al., 2003; Huang et al., 2008a).  In light of this, 
direct modulation of calcineurin by Zn2+ is not likely.  Instead, Zn2+ may either be necessary for 
full calcineurin activation following ischemic injury or may mediate a parallel signaling pathway 
leading to Kv2.1 modulation.       
 
The data presented here strongly implicate a rise in free neuronal Zn2+ in the modulation 
of Kv2.1 channel activity and localization following ischemia.  This study represents an 
intersection of emerging evidence implicating Zn2+ in triggering neuroprotective mechanisms 
and Kv2.1 modulation in limiting neuronal excitability following ischemia.         
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4.0  GENERAL DISCUSSION 
The goal of this dissertation was to investigate the role of Zn2+ in endogenous signaling 
pathways that contribute to neuronal tolerance.  Until now, the intracellular accumulation of free 
Zn2+ has been largely identified as a characteristic of degenerating neurons. However, sub-lethal 
activation of cell death molecules can trigger important survival mechanisms that protect neurons 
from lethal injury mediated by those same factors.  Data presented here show that sub-lethal Zn2+ 
signals are necessary and sufficient for limiting subsequent Zn2+-dependent neuronal injury.  
Intracellular Zn2+ release, facilitated by PKC modulation of MT, activated Zn2+-regulated gene 
expression and conferred long term neuronal tolerance.  Additionally, Zn2+ was required for the 
modulation of Kv2.1 activity and localization following sub-lethal ischemic injury, suggesting 
that the metal plays a role in mediating acute cellular responses to stress. Together, these 
findings critically implicate Zn2+ signals in the adaptive neuroprotective response to cellular 
injury.  In this final chapter, I will discuss potential mechanisms of Zn2+-mediated 
neuroprotection and highlight important questions that remain in our understanding of neuronal 
tolerance.   
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4.1 A DUAL ROLE FOR NEURONAL MT III 
Metallothioneins contain 20 sulfur-donating cysteine residues that bind seven Zn2+ ions in Zn3S9 
and Zn4S11 configurations on its two metal-binding domains (Maret and Vallee, 1998).  In order 
for MTs to buffer cellular free Zn2+, these high-affinity ligands for Zn2+ must not be saturated 
with metal under normal conditions.  Indeed, biochemical analysis revealed that three of the 
Zn2+-binding sites on MT bind Zn2+ with low or intermediate affinity, suggesting that under 
normal conditions MT may not be saturated with all seven Zn2+ ions (Krezel and Maret, 2007).  
In addition, differential fluorescent labeling of the MT cysteine clusters from rat kidney, liver, 
and brain tissue extracts showed that tissues contain almost as much of the apo-protein thionein 
as metal-bound metallothionein (Yang et al., 2001).  Thus, the Zn2+ buffering capacity of MTs is 
very high under control conditions and is critically dependent on the amount of Zn2+-lacking 
thionein and unsaturated species of MT in cells.  To examine the Zn2+-buffering capacity of 
neurons, I measured the change in intracellular free Zn2+ following exposure to Cd2+ using a 
MRE-luciferase reporter.  Any free Zn2+ released from MT by Cd2+ (Zhang et al., 2003) that is 
not immediately buffered will trigger luciferase expression.  I found that MT III-overexpressing 
neurons have diminished MRE activation compared to vector-expressing neurons following Cd2+ 
exposure (Figure 7).  This result suggests that transfected neurons actually overexpress metal-
deficient forms of MT and thus have a surplus of available binding sites for buffering the rise in 
free Zn2+ caused by Cd2+ exposure.  Importantly, when the expression of endogenous neuronal 
MT III was reduced by an MT3shRNA construct, I found that intracellular free Zn2+ was 
elevated following the Cd2+ stimulus compared to vector-expressing neurons (Figure 7).  Thus, 
depletion of endogenous MT III impairs the Zn2+-buffering capacity of neurons and allows 
increased levels of free Zn2+ to activate MRE gene transcription.  This result is significant 
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because it suggests that under normal conditions, the Zn2+ binding capacity of neurons is high 
due to the presence of Zn2+-deficient MT III molecules.  Thus, because of the presence of Zn2+-
lacking species along with apo-thionein, MT III serves a significant role in buffering neuronal 
free Zn2+.    
 
On the other hand, MT III may also be a significant source of labile Zn2+ in neurons.  The 
unique coordination environment of MT, consisting of sulfur-containing cysteines that can 
undergo reversible redox reactions, allows the cellular availability of Zn2+ to be closely tied to 
the redox environment of the cell (Maret and Vallee, 1998).  In HT-29 cells, it was found that as 
the intracellular redox potential became more oxidizing, the buffering capacity of MT was 
lowered, leading to a pronounced elevation in free Zn2+ (Krezel and Maret, 2006; Krezel et al., 
2007).  Oxidant-induced liberation of Zn2+ from MT has been demonstrated in cell-free systems 
(Maret and Vallee, 1998) and in cortical neurons (Aizenman et al., 2000b; Zhang et al., 2004).  
In mouse hepatoma (Hepa) cells, exposure of oxidants H2O2 or tert-butylhydroquinone 
sufficiently activated MRE-binding by MTF-1 (Andrews, 2000).  Nitric oxide can also liberate 
Zn2+ from MT from neurons in vivo (Cuajungco and Lees, 1998) and in pulmonary artery 
endothelial cells, which effectively activates MTF-1 and transcription of MT (St Croix et al., 
2002; Spahl et al., 2003; Stitt et al., 2006).  Nitrosylation can occur by transnitrosation, a transfer 
of NO from N-nitrosothiols to the sulfur donor of Zn2+ ligands (Chen et al., 2002).  Other redox 
signals including superoxide/peroxide, selenium compounds, and NADPH have also been shown 
to release Zn2+ from MT (Fliss and Menard, 1992; Maret, 1994; Jacob et al., 1999; Chen and 
Maret, 2001; Stoyanovsky et al., 2005; Sagher et al., 2006).  Thus, because of its susceptibility to 
redox signaling, MT is a significant source of labile Zn2+.   
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While oxidative- and nitrosative-stress mediated liberation of neuronal Zn2+ has been 
previously described as a characteristic of cell death (Aizenman et al., 2000; Bossy-Wetzel et al., 
2004), a similar mechanism may account for the Zn2+ signal in preconditioned neurons.  Indeed, 
sub-lethal oxidative signaling has been shown to be required for tolerance in several models of 
preconditioning (Pain et al., 2000; Forbes et al., 2001), including KCN-induced excitotoxic 
tolerance used in this dissertation (McLaughlin et al., 2003).  In preconditioned neurons, sub-
lethal reative oxygen species generation can modify redox-sensitive protein kinases, 
phosphatases, or redox-sensitive transcription factors, such as nuclear factor-B and activator 
protein-1, modulating gene expression and conferring neuronal tolerance (Perez-Pinzon et al., 
2005).  Similarly, NO generation, triggered by the influx of Ca2+ through NMDA receptors, has 
been shown to play a central role in preconditioning signal transduction by activating 
downstream kinases that ultimately modulate gene transcription (Gonzalez-Zulueta et al., 2000).  
Thus, multiple redox signals known to trigger Zn2+ release from MT are activated in 
preconditioned neurons.  Evidence presented in this dissertation suggests that the predominant 
source of the preconditioning-induced Zn2+ rise is intracellular, as both tricine and the AMPA 
receptor blocker CNQX had little effect on KCN-induced increase in FluoZin-3 fluorescence 
(Figure 6).  Thus, it is likely that the preconditioning-induced Zn2+ signal is mediated by the 
redox modulation of the MT/Zn2+ interaction.   
 
While intracellular MTs represent a major source for labile Zn2+, it is also conceivable 
that other Zn2+ bound proteins are susceptible to oxidant-induced Zn2+ liberation.  Indeed, PKC, 
which contains a cysteine-rich Zn2+-finger motif in the regulatory C1 region, has been shown to 
release Zn2+ in the presence of thiol oxidants, leading to auto-activation of the enzyme (Knapp 
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and Klann, 2000).  Under these conditions, oxidant-induced Zn2+ release occurred prior to PKC 
activation.  In contrast, I found that inhibiting PKC activity attenuated KCN-induced Zn2+ 
accumulation (Figure 6), suggesting that PKC is activated prior to the Zn2+ rise in preconditioned 
neurons.  The PKC inhibitors used in the present studies compete with ATP at the PKC catalytic 
domain (Martiny-Baron et al., 1993) and thus, would not be expected to block potential Zn2+ 
release from the regulatory C1 region.  The results presented here support an indirect relationship 
between PKC and the preconditioning-induced Zn2+ rise.  PKC may interact with a source of 
labile Zn2+, promoting an increase in the intracellular concentration of the metal.  To this end, I 
found evidence for a novel role for PKC in modulating the MT/Zn2+ interaction to facilitate Zn2+ 
release from the metal-binding protein.  I identified a highly conserved, putative PKC 
phosphorylation site on MT at serine 32 (S32).  S32 is located in the linker region of MT 
between the two metal-binding domains containing the Zn2+/thiolate clusters.  Mutation of S32 to 
a non-phosphorylatable alanine (S32A) prevented the increase in PKC-dependent serine 
phosphorylation of MT, attenuated metal-stimulated activation of the MRE, and diminished the 
neuroprotective effect of preconditioning (Figure 7).  However, in fluorescence resonance energy 
transfer (FRET)-based cell-free biochemical studies, the mutation of S32 to a cysteine residue or 
a fluorophore did not alter the overall structure of the protein, or its ability to bind Cd2+ (Hong 
and Maret, 2003).  The effect of mutating S32 on the Zn2+-binding properties of cellular MT was 
not examined (Hong and Maret, 2003).  In the functional assays presented here, I found that 
modulation of S32 to a non-phosphorylatable alanine or a phospho-mimicking aspartic acid had 
a significant impact on neuronal free Zn2+ and Zn2+-regualated gene expression.  Thus, 
phosphorylation of MT on residue S32 by PKC may prevent efficient binding of Zn2+, allowing 
for enhanced Zn2+ regulated gene expression and neuroprotection.  Together, these data strongly 
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suggest that MT III plays a dual role in regulating neuronal free Zn2+ homeostasis.  Depending 
on the availability of unoccupied Zn2+ binding sites as well as the intracellular redox 
environment, MT III can serve as an important buffer for, and source of, neuronal free Zn2+.  
Another major implication of these studies is that signaling kinases can serve as regulating 
factors in neuronal Zn2+ homeostasis.  Thus, other protein kinases, besides PKC, or protein 
phosphatases may interact with MT, ultimately regulating neuronal free Zn2+ and cell viability.   
4.2 ZINC AND CALCIUM SIGNALS IN PRECONDITIONED NEURONS 
Preconditioning triggers a transient increase in neuronal free Zn2+, which is both necessary and 
sufficient to confer tolerance against subsequent Zn2+-mediated injury (Figures 2, 3; Lee et al., 
2008).  Like the Zn2+ rise described here, an accumulation of Ca2+ has also been shown to play 
an important role in the initiation of survival pathways in preconditioned neurons.  In models of 
cerebral tolerance, removing extracellular and cytoplasmic Ca2+ or preventing its influx through 
NMDA receptors by MK-801 [(+)-5-methyl-10,11-dihydro-5H-dibenzo [a,d] cyclohepten-5,10-
imine maleate] severely attenuated neuroprotection (Kato et al., 1992; Kasischke et al., 1996; 
Grabb and Choi, 1999; Raval et al., 2003).  The neuroprotective signal transduction pathway has 
been shown to stimulate Ca2+-dependent enzymes, including PKC (Raval et al., 2003) and nitic 
oxide synthase (NOS; Nandagopal et al., 2001).  While PKC and NOS activation in 
preconditioned neurons required NMDA receptor-dependent Ca2+ influx, downstream targets for 
these enzymes may ultimately regulate intracellular [Zn2+].  Here, I show that PKC can directly 
interact with MT and may play a significant role in promoting Zn2+ release from the metal 
binding protein (Figure 7).  Furthermore, NO, produced by the activation of NOS, can readily 
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trigger the release of Zn2+ from MT (Cuajungco and Lees, 1998).  Thus, the influx of Ca2+ may 
actually contribute to the accumulation of free Zn2+ in preconditioned neurons, mediated by the 
activation of Ca2+-dependent enzymes. 
  
Another Ca2+-dependent enzyme that has been implicated in mediating neuroprotection 
following ischemic injury is protein phosphatase 2B (PP2B or calcineurin).  Rather than 
mediating delayed neuronal tolerance via activation of protein synthesis, calcineurin may play a 
central role in the acute cellular response to injury.  Following sub-lethal ischemic injury, an 
increase in [Ca2+]i, mediated by release from intracellular stores, led to the activation of 
calcineurin and the modulation of the delayed rectifier potassium channel Kv2.1 (Misonou et al., 
2005).  Specifically, sub-lethal ischemia led to calcineurin-dependent dephosphorylation of 
Kv2.1, which was accompanied by dispersal of surface clusters and a shift in the voltage-
dependent activation of neuronal potassium current (Misonou et al., 2005).  In turn, these altered 
Kv2.1 channel properties are thought to protect neurons against sustained hyperexcitability, 
limiting ischemic cell death (Surmeier and Foehring, 2004).  While stimulation of calcineurin 
activity may require Ca2+, I found that chelation of Zn2+ during sub-lethal ischemia partially 
blocked the hyperpolarizing shifts in the activation kinetics as well as prevented Kv2.1 
declustering (Figures 9, 10).  Ischemia-induced Zn2+ accumulation was not prevented by a 
calcineurin inhibitor (Figure 11), suggesting that the Zn2+ rise may be upstream of, or 
independent of, calcineurin activity.  Alternatively, Zn2+ chelation with TPEN may have 
sequestered the metal from the catalytic domain of calcineurin (Goldberg et al., 1995), 
preventing full enzymatic activity.  The exact role of Zn2+ in modulating calcineurin activity, 
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whether direct or indirect, remains unclear.  Regardless, these data provide another example of 
the convergence of Zn2+ and Ca2+ mediated signaling pathways in neuroprotection.   
 
 While it is clear that both Zn2+ and Ca2+ can accumulate in preconditioned neurons and 
trigger converging neuroprotective signaling cascades, the exact roles of the two cations in 
neuronal tolerance needs to be delineated.  Indeed, determination of the contribution of Zn2+ 
versus Ca2+ signaling has been an area of intense investigation in models of neuronal injury.  
Careful examination of indicators traditionally used to detect changes in cellular [Ca2+] revealed 
that they actually respond with higher affinity to Zn2+ (Stork and Li, 2006).  Live cell detection 
of free Zn2+ has only become feasible through recent developments of Zn2+ sensitive and 
selective fluorophores (Gee et al., 2002; Thompson et al., 2002).  By loading neurons with a low-
affinity ratiometric Ca2+-sensitive indicator (e.g., Fura-2FF) and a high-affinity Zn2+-sensitive 
indicator (e.g., FluoZin-3), Devinney and colleagues (2005) provided a novel method for 
simultaneous detection of both divalent cations in living cells.  Using this approach, Dineley and 
colleagues (2008) examined changes in free Zn2+ following extracellular glutamate stimulation 
in cortical neurons in culture.  They found that the glutamate-induced release of intracellular 
Zn2+ was dependent on an influx of extracellular Ca2+ and subsequent production of reactive 
oxygen species (Dineley et al., 2008).  On the other hand, in acute hippocampal slices loaded 
with both Zn2+ and Ca2+ indicators, oxygen-glucose deprivation (OGD) led to a progressive 
increase in neuronal Zn2+ (5-10 min following OGD onset), which preceded and may have 
contributed to Ca2+ deregulation (Medvedeva et al., 2009).  As brief exposure to OGD is a 
prototypical preconditioning stimulus (Grabb and Choi, 1999), a similar temporal profile 
between Zn2+ and Ca2+ accumulation may exist in KCN preconditioned neurons.  A Zn2+ rise 
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prior to Ca2+ deregulation was also observed in a model of spreading depression in hippocampal 
slices (Dietz et al., 2008).  This Zn2+ rise was largely attributed to extracellular Zn2+ entry 
through L-type Ca2+ channels (Dietz et al., 2008).  Thus, simultaneous detection of [Zn2+] and 
[Ca2+] using the dual dye approach provides great insight into how these two divalent cations 
respond to cellular changes.  Similar to injury paradigms, neuroprotective pathways also involve 
critical contributions from, and intersection of, Zn2+ and Ca2+ signals. 
4.3 ZINC-REGULATED GENE ACTIVATION IN NEURONAL TOLERANCE  
One of the hallmark characteristics of delayed neuronal tolerance is its dependence on de novo 
protein synthesis elicited by the preconditioning stimulus (Barone et al., 1998).  However, the 
genomic response to preconditioning may not simply involve an immediate activation of 
quiescent survival genes.  Instead, DNA oligonucleotide microarray analysis has shown that a 
large number of genes may be repressed following preconditioning (Stenzel-Poore et al., 2003).  
Nevertheless, protein synthesis inhibition by cyclohexamide prior to, or during preconditioning 
blocks neuronal tolerance in vivo and in vitro (Barone et al., 1998; McLaughlin et al., 2003), 
suggesting a major role for gene activation and protein synthesis in neuroprotection.  Changes in 
gene expression/repression may occur along several temporal profiles. Some genes are altered 
within minutes or hours (e.g., adenosine A2a receptor, vascular endothelial growth factor), 
whereas others are affected days following the preconditioning stimulus (e.g., calbindin, 
serine/threonine protein kinases; Bernaudin et al., 2002a; Tang et al., 2006).   Thus, the highly 
regulated modulation of gene expression in preconditioned neurons is an important cellular 
response that may ultimately confer neuronal tolerance.  
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In this dissertation, I found evidence suggesting that a preconditioning-induced Zn2+ rise 
triggers the activation of processes that can prevent subsequent toxic Zn2+ accumulations (Figure 
3).  Interestingly, Matsushita and colleagues (1996) reported that exogenous ZnCl2 pretreatment 
reduced neuronal death following in vivo global ischemia when Zn2+ was administered 24 and 48 
hours, but not one hour, prior to ischemia.  In light of the requirement of new protein synthesis in 
neuronal tolerance, and that proteins involved in buffering free Zn2+ are regulated at the level of 
transcription, it is likely that preconditioning triggers the upregulation of proteins involved in 
maintaining cellular Zn2+ homeostasis.  To this end, I found that KCN preconditioning 
sufficiently activates the MRE in transfected cortical neurons (Figure 5), suggesting that Zn2+ 
regulated gene expression can be stimulated in preconditioned cells.  Thus, the Zn2+-induced 
upregulation of Zn2+-regulated proteins, such as MT I/II and ZnT1, may play a role in neuronal 
tolerance.      
 
Indeed, upregulation of MT I and II have been shown in multiple models of 
preconditioning (Bernaudin et al., 2002a; Carmel et al., 2004; Dhodda et al., 2004; Tang et al., 
2006).  A two-fold induction of MT I/II mRNA can be detected as early as three hours following 
preconditioning, peaking at 12 hours with a 6-fold change in expression, and returning to 
baseline levels 24 hours following preconditioning (Carmel et al., 2004; Dhodda et al., 2004).  
The upregulation of MT I/II expression as a general mechanism mediating neuroprotection from 
lethal injury has received some attention.  The induction of MT by application of transition 
metals protects the heart against oxidative damage (Satoh et al., 1988) and cortical cells against 
irradiation damage (Cai et al., 2000).  Mice overexpressing MT I have reduced lesion volume 
and sensorimotor deficits following in vivo ischemia compared to wild-type mice (van Lookeren 
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Campagne et al., 1999). On the other hand, mice lacking MT I/II suffer worse outcomes 
compared to wild-type mice following a range of CNS injuries, including focal cryolesion 
(Penkowa et al., 1999), experimental autoimmune encephalomyelitis (an experimental model of 
multiple sclerosis; Penkowa and Hidalgo, 2001), motor neuron disease, (Puttaparthi et al., 2002), 
and stroke (Trendelenburg et al., 2002).  MT I/II double knockout mice had approximately three-
fold larger infarcts and significantly worse neurological outcome than wild-type mice following 
transient ischemia (Trendelenburg et al., 2002).  Along these lines, I found that neurons 
overexpressing MT III were more resistant to NMDA excitotoxicity compared to vector-
expressing neurons (Figure 2).  Thus, MT plays an important neuroprotective role in response to 
cellular injury.   
 
Despite the abundance of data describing the upregulation of MTs in limiting neuronal 
injury, the inducible isoforms MT I and II are predominantly expressed in astrocytes (Hidalgo et 
al., 1994; Kramer et al., 1996b; Kramer et al., 1996a; Suzuki et al., 2000).  Thus, if MT I/II 
buffer lethal neuronal free Zn2+ in models of neuronal tolerance, then brain astrocytes must 
respond to preconditioning by upregulating MT I/II and secreting it into the extracellular space.  
In fact, accumulating evidence has supported the injury-induced secretion of astrocytic MT 
(Chung et al., 2008), the presence of MT in the extracellular space (Chung and West, 2004), and 
a potential receptor that may mediate MT uptake in neurons (Ambjorn et al., 2008).  However, in 
response to brain injury, extracellular MT has been only shown to promote axonal regeneration 
and neurite outgrowth (Chung et al., 2008). It is conceivable that, in addition to its effects on 
neuronal proliferation, secreted MT could also chelate Zn2+ released into the extracellular space 
from injured neurons.  By chelating extracellular Zn2+, MT may be able to indirectly reduce 
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[Zn2+]i.  In addition, the internalization of astrocytic MT by neurons (Chung et al., 2008) may 
directly buffer lethal Zn2+ accumulations.  Thus, the recently described extracellular actions of 
MT I/II may provide exciting new potential neuroprotective mechanisms.   
  
A more likely target of preconditioning-induced Zn2+-regulated gene expression may be 
neuronal ZnT1.  ZnT1 expression has been found in neurons (Tsuda et al., 1997) and can be 
induced by Zn2+ in an MTF-1 dependent pathway (Andrews, 2000; Langmade et al., 2000).  
ZnT1 facilitates Zn2+ efflux (Palmiter and Findley, 1995, but also see Ohana et al., 2006), and 
may actually be more efficient than MTs in regulating intracellular accumulation of Zn2+ 
(Palmiter, 2004).  Using in situ hybridization, ZnT1 mRNA expression has been shown to be 
upregulated in gerbil CA1 pyramidal neurons 12 hours following transient forebrain ischemia 
(Tsuda et al., 1997).  However, not all changes in ZnT1 mRNA have been realized as 
proportional changes in protein levels (Tsuda et al., 1997; McMahon and Cousins, 1998), 
indicating possible post-translational regulation of ZnT1 protein expression.  It is also unclear 
whether blocking ZnT1-mediated Zn2+ efflux following ischemia exacerbates neuronal injury.  
Unlike MT, changes in ZnT1 mRNA and protein expression in preconditioned neurons have not 
been extensively investigated.  However, a conceptually similar investigation has been 
performed in astrocytes (Nolte et al., 2004).  In a pure astrocytic culture, sub-lethal exogenous 
Zn2+ exposure induced ZnT1 protein expression and conferred resistance to subsequent lethal 
Zn2+ toxicity (Nolte et al., 2004).  Further, in non-preconditioned astrocytes, heterologous 
expression of ZnT1 reduced toxic intracellular Zn2+ accumulations and induced Zn2+-tolerance 
(Nolte et al., 2004).  ZnT1 may play a similar role in neurons.  Data presented here show that 
preconditioning can activate Zn2+-regulated gene expression in neurons and implicate the 
 109 
upregulation of proteins involved in limiting toxic Zn2+ accumulations in tolerant cells.  The 
upregulation of ZnT1 represents an attractive mechanism for mediating Zn2+-induced 
neuroprotection in preconditioned neurons.   
4.4 CONCLUDING REMARKS 
Currently, the most effective therapy for ischemic stroke is timely reperfusion.  Intravenous 
administration of human recombinant tissue plasminogen activator (tPA) within three hours of 
ischemic stroke onset can restore blood flow before major brain damage has occurred (Albers, 
2001; Wardlaw et al., 2003).  However, thrombolytic drugs must be used with caution, as lethal 
intracranial bleeding may result.  In light of the serious side effects and limited time window of 
efficacy, it is imperative that alternative therapeutic strategies for ischemic stroke be developed.  
Over a decade of experimental evidence has described a central role for a toxic accumulation of 
intracellular Zn2+ in ischemic neuronal death.  However, the results presented in this dissertation 
suggest that an increase in neuronal free Zn2+ may also trigger pathways that limit cell injury 
following injury and confer long-term tolerance.  I found that the source of the Zn2+ rise was 
largely intracellular, and may be critically influenced by the activity of signaling kinases.  Data 
presented here also suggest that sub-lethal Zn2+ signals may have diverse cellular effects, 
including the activation of gene transcription and the modulation of cellular excitability.  
Together, the identification of the source of the Zn2+ rise and potential downstream targets 
mediating neuroprotection may provide novel therapeutic targets for regulating intracellular Zn2+ 
signals, and ultimately cell survival.  These results provide a new, neuroprotective role for 
increases in free Zn2+ that could aid in the development of future therapies for ischemic stroke. 
 110 
Appendix A 
 
Supplementary Figure 1 – Verification of MT3shRNA construct 
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Supplementary Figure 1.  Verification of MT3shRNA construct.  Experiments performed by 
Hirokazu Hara, Ph.D.  (A) CHO cells were plated at a density of 5.6 X 104 cells/well on 
coverslips in 24-well plates.  Twenty-four hours later, CHO cells were transfected with either the 
parent pSuppressorNeo (vector; top row) or MT3-shRNA targeting plasmid (0.2 g/well; bottom 
row), together with both pEGFP-MT3 (0.04 g/well) and pDsRed-MT1 (0.04 g/well) for 4 
hours in serum-free medium (F12 nutrient medium with 10mM HEPES) with a total of 1.2 L of 
Lipofectamine (Invitrogen) and 0.28 g of DNA per well.  Forty-eight hours later, cells were 
fixed and visualized for EGFP (green) and DsRed (red) fluorescence.  Note the suppression of 
green fluorescence by MT3-shRNA.  (B) CHO cells were plated at density of 280,000 cells/well 
on 6-well plates.  Twenty-four hours later, cells were transfected with either MT1-shRNA or 
MT3-shRNA targeting vectors (1.36 g/well) together with either pEGFP-MT3 or a plasmid 
encoding EGFP only (0.04 g/well).  Cell lysate samples were harvested 24 hours post-
transfection in lysis buffer [1% Triton X-100, 0.1% SDS, 0.25% Na deoxycholate, 50mM 
HEPES, 150mM NaCl, protease inhibitor mixture (Roche Diagnostics, Indianapolis, IN), pH 7.5] 
after two washes with PBS. Cell lysate samples were combined in a 1:1 ratio with reducing 
sample prep buffer and incubated for 5 min at 100°C to denature proteins before gel 
electrophoresis.  SDS/PAGE was carried out by standard procedures using the Mini Protean 3 
System (Bio-Rad, Hercules, CA).  Equal amounts of cell lysate (10 g) were separated by 
reducing 15% SDS/PAGE gels.  Separated protein bands were transferred onto a 0.2 m 
nitrocellulose membrane.  The membranes were then blocked with 1% BSA in PBS with 0.05% 
Tween 20 at room temperature for 1 h and probed with a GFP monoclonal primary antibody 
(Sigma).  Blots were then incubated with goat secondary antibody conjugated to HRP (1h, room 
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temperature) and were visualized with a SuperSignal CL-HRP Substrate System (Pierce 
Biotechnology, Rockford, IL).  Note the decrease in MT3-eGFP signal induced by MT3-shRNA. 
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Appendix B 
OBLIGATORY ROLE OF ASK1 IN THE APOPTOTIC SURGE OF K+ CURRENTS 
 
Mandar A. Aras and Elias Aizenman 
Department of Neurobiology, University of Pittsburgh School of Medicine, 
 Pittsburgh, PA 15261. 
 
 
ABSTRACT 
 
Apoptosis signal-regulating kinase 1 (ASK1) is a critical component of mitogen-activated 
protein kinase signaling pathways leading to cell death in response to cytokines and cellular 
stress.  We use a dominant-negative (DN) form of ASK1 to show that this enzyme is necessary 
for the delayed surge in neuronal K+ channel activity, a required step in apoptosis.  Furthermore, 
expression of ASK1 DN also suppresses the apoptotic increase in Kv2.1 currents transiently 
expressed in Chinese hamster ovary cells.  Finally, over-expression of thioredoxin, an inhibitory 
binding partner of ASK1, is sufficient to halt the apoptotic current surge in neurons.  Thus, 
ASK1 is an obligatory component of the pro-apoptotic modulation of K+ channels.  
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INTRODUCTION 
 
Apoptosis signal-regulating kinase 1 (ASK1) is a ubiquitously expressed mammalian 
mitogen-activated protein (MAP) kinase kinase kinase (MAPKKK) that activates both the p38 
and c-JUN NH2-terminal kinase (JNK) by directly phosphorylating their respective MAPKKs 
(MKK3/6 for p38 and MKK4/7 for JNK; Matsukawa et al., 2004).  ASK1 has been shown to be 
an important signaling kinase in apoptotic cell death in response to various stimuli, including 
oxidative stress, tumor necrosis factor, endoplasmic reticulum stress, low-potassium, and 
amyloid β (Ichijo et al., 1997; Liu et al., 2000; Nishitoh et al., 2002; Tobiume et al., 2002; 
Yamagishi et al., 2003; Kadowaki et al., 2005).  Although ASK1 activation has been repeatedly 
linked to neuronal apoptosis (Nishitoh et al., 2002; Sarker et al., 2003; Yamagishi et al., 2003; 
Kadowaki et al., 2005), the specific downstream molecular cascades leading to cell death in 
these systems have yet to be fully characterized.     
 
Cellular potassium efflux is a common, required feature in many apoptotic programs 
(Hughes and Cidlowski, 1999; Yu, 2003).  In cortical neurons, the loss of intracellular potassium 
occurs through a delayed surge in voltage-dependent K+ currents (Yu et al., 1997b) that is 
mediated by Kv2.1-encoded ion channels (Pal et al., 2003).  This increase in K+ currents can be 
triggered by classical apoptogens, such as staurosporine, serum deprivation, and amyloid β (Yu 
et al., 1997b; Yu et al., 1998), as well as by oxidants like 2,2’-dithiodipyridine (DTDP; 
Aizenman et al., 2000b; McLaughlin et al., 2001) and peroxynitrite (Bossy-Wetzel et al., 2004; 
Pal et al., 2004).  We have previously observed that the apoptotic K+ current surge is protein 
synthesis independent and precedes caspase activation (McLaughlin et al., 2001).   Importantly, 
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activation of the MAPK p38 is required for this process as both chemical inhibitors of this 
enzyme (McLaughlin et al., 2001) and expression of p38 dominant negative (DN) vectors 
(Bossy-Wetzel et al., 2004; Pal et al., 2004) can completely abolish the increase in K+ currents.   
 
In addition to ASK1, p38 activation can be induced by other MAPKKK, including 
transforming growth factor-β-activated kinase 1 (TAK1), mixed-lineage protein kinase 3 
(MLK3) and mitogen-activated protein three kinase 1 (MTK1; Zarubin and Han, 2005).  
Furthermore, it has been reported that p38 can also be activated via a MAPKKK-independent 
mechanism (Ge et al., 2002).  We report here that ASK1 represents the principal, if not the only, 
upstream signaling MAP kinase linking oxidative injury to the apoptotic increase in Kv2.1-
mediated currents in neurons.  
 
MATERIALS AND METHODS 
 
Experiments were performed on cultures of embryonic rat cerebral cortex and on Chinese 
hamster ovary cells.  Cortical cultures were prepared from embryonic day 16 Sprague-Dawley 
rats and grown on 12 mm glass coverslips as previously described (Hartnett et al., 1997).  
Pregnant rats were sacrificed with the approval of the University of Pittsburgh School of 
Medicine and in accordance with National Institutes of Health protocols.  Enhanced green 
fluorescent protein (eGFP) (pCMVIE-eGFP; Clontech, Palo Alto, CA) was used as a marker for 
positively transfected neurons and was combined with the ASK1 DN or Trx cDNAs (gifts from 
H. Ichijo, Tokyo, Japan), or vector, at a 1:1 ratio. At DIV19-23, cortical cultures were transfected 
using Lipofectamine 2000 (Invitrogen, Carlsbad, CA; Pal et al., 2003).  Briefly, 1.5 g of cDNA 
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was diluted in 50 l Opti-Mem I medium and combined with 50 l of Opti-Mem I medium 
containing 2 l Lipofectamine 2000.  Complexes were allowed to form for 30 min before 
addition to the cultures.  Cortical cells were maintained for 48 hours at 37oC, 5% CO2 before 
electrophysiological recordings.  Chinese hamster ovary (CHO) cells were seeded at 2.8 x 105 
cells per well into six well plates 24 hours before transfection.  Cells were transfected with a 
Kv2.1eGFP-myc tagged cDNA plasmid (a gift from E. Levitan, Pittsburgh, PA) and ASK1 DN, 
or vector, at a 1:1 ratio in serum-free medium with 6 l of Lipofectamine reagent (Invitrogen), 
and a total of 1.4 g of DNA per well.  Electrophysiological recordings from eGFP-positive 
CHO cells were performed 24 hours after transfection.  All recordings were performed using the 
whole-cell configuration of the patch-clamp technique as described previously (McLaughlin et 
al., 2001).  The extracellular solution contained (in mM):  115 NaCl, 2.5 KCl, 2.0 MgCl2, 10 
HEPES, 10 D-glucose; pH was adjusted to 7.2 with concentrated KOH; 0.25 M TTX was 
added to inhibit voltage gated sodium channels.  The intracellular (electrode) solution contained 
(in mM):  100 K-gluconate, 11 EGTA, 10 KCl, 1 MgCl2, 1 CaCl2 x 2H2O, 10 HEPES; pH was 
adjusted to 7.2 with concentrated KOH; 0.22 mM ATP was added and osmolarity was adjusted 
to 280 mOsm with sucrose.   All measurements were obtained under voltage clamp with an 
Axopatch 1C amplifier (Axon Instruments, Foster City, CA) and pClamp software (Axon 
Instruments) using 2 MOhm electrodes.  Partial compensation (80%) for series resistance was 
performed in all instances.  Currents were filtered at 2 kHz and digitized at 10 kHz (Digidata; 
Axon Instruments).  Potassium currents were evoked with a series of 80 ms voltage steps from a 
holding potential of   –70mV to 35mV, in 15mV increments.  Steady-state amplitudes were 
measured relative to baseline and normalized to cell capacitance.   
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Neurons were treated with DTDP (100 μM) for 10 min at 37oC, 5% CO2, a condition that 
induces a well-characterized p38-dependent increase in K+ currents approximately 3 hours later, 
followed by caspase activation at 5-7 hours and subsequent cell death (McLaughlin et al., 2001; 
Pal et al., 2003).  Kv2.1-expressing CHO cells were co-treated with DTDP (25 M) and Boc-
aspartate-fmk (BAF, 10 M), a broad-spectrum cysteine protease inhibitor, for 5 min in 37oC, 
5% CO2.  Subsequently, CHO cells were maintained in BAF (10 M) for three hours.  We have 
previously reported that BAF prevents Kv2.1-expressing CHO cells from dying following DTDP 
exposure (Pal et al., 2003), and here we found the caspase inhibitor necessary to maintain cells 
sufficiently healthy for successful electrophysiological recordings.  All data are expressed as 
mean  s.e.m.  Current densities were analyzed using one-way ANOVA followed by a Bonferoni 
Multiple Comparisons Test.  P-values less than 0.05 were considered significant. 
 
RESULTS AND DISCUSSION 
 
We expressed an ASK1 DN vector in cortical neurons to investigate the role of this 
MAPKKK in the delayed apoptotic K+ current surge.  The ASK1 DN vector (ASK1 K709M) is 
rendered catalytically inactive by a lysine to arginine mutation and has been well characterized in 
prior studies (Ichijo et al., 1997; Jibiki et al., 2003; Machino et al., 2003; Yamagishi et al., 2003).  
Control and ASK1 DN-transfected cultures were treated with either vehicle or with 100 M 
DTDP for 10 min to induce apoptosis (Aizenman et al., 2000a; McLaughlin et al., 2001; Pal et 
al., 2003).  Electrophysiological recordings were performed from these neurons approximately 
three hours later, the time it normally takes to observe a pronounced K+ current surge 
(McLaughlin et al., 2001).  DTDP-treated control neurons had very pronounced K+ currents, 
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when compared to vehicle-treated cells (Figs. 1A and 1C), reflecting the dramatic increase in 
channel activity that accompanies the apoptotic process (Yu et al., 1997b; McLaughlin et al., 
2001).  In contrast, K+ currents in ASK1 DN-expressing neurons were essentially identical 
between the vehicle and DTDP treatment groups (Figs. 1B and 1C), suggesting that this 
MAPKKK was critical for the apoptotic K+ current surge.  As a positive control, 
electrophysiological recordings were also performed on DTDP-treated, untransfected neurons 
from the same coverslip where recordings from ASK1 DN-expressing cells had been obtained.  
In these untransfected cells, a clear K+ current enhancement was measured (Figure 1C), 
confirming that the DTDP treatment had been effective in triggering the apoptotic program in 
those cultures, and reinforcing the notion that ASK1 was a critical component of the current 
surge process. 
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Figure 1.  ASK1 is required for the apoptotic K+ current surge in cortical neurons. (A) Whole-
cell K+ currents were evoked by a series of voltage steps from –70 mV to +35 mV in 15 mV 
increments in two representative control neurons exposed to either vehicle (VEH, left) or 2,2’-
dithio-dipyridine (DTDP; right, 100 M for 10 min).  Note the substantial difference in current 
amplitudes between the two treatment groups.  Also note that the current evoked by the last 
voltage step (+35 mV) in the DTDP-treated neuron was beyond the ability of our amplifier to 
appropriately hold under voltage clamp.  Scale bars 5 nA, 20 ms.  (B) Similar recordings were 
performed from ASK1 dominant negative (DN)-expressing neurons exposed to either vehicle 
(left) or DTDP (middle).  Note the lack of an effect of DTDP on K+ current amplitudes under 
these circumstances.  As a positive control, recordings were also performed from a DTDP-
treated untransfected neuron from the same coverslip where the measurement from the ASK DN-
expressing cell had been performed (right).  The large K+ currents present in this type of cell 
confirmed that DTDP had triggered the apoptotic program in the culture dish.  (C) Mean ± s.e.m. 
current densities from vehicle and DTDP treated control (black bars) and ASK1 DN-expressing 
(green bars) neurons.  The blue bar represents the current densities obtained from DTDP-treated 
untransfected neurons in the same coverslip containing the ASK1 DN-expressing cells.  Currents 
were evoked with a voltage step to +5 mV from a holding potential of –70 mV and normalized to 
cell capacitance (*p<0.05; ANOVA, Bonferoni).  The voltage step to +5 mV was always under 
adequate voltage clamp.   
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Functional expression of Kv2.1 in Chinese hamster ovary (CHO) cells was used to firmly 
establish the role of ASK1 in mediating the apoptotic current surge via the channel known to be 
responsible for the increase in K+ currents in neurons (Pal et al., 2003).  CHO cells do not 
express native Kv channels (Yu et al., 1998), but can be rendered susceptible to DTDP-induced 
apoptosis following the expression of Kv2.1 (Pal et al., 2003).  Electrophysiological recordings 
were performed from control and ASK1 DN-expressing CHO cells 3 hours after a 5 min 
exposure to vehicle or 25 M DTDP.  K+ currents in control cells exposed to DTDP were 
substantially larger than vehicle-treated cells, without a noticeable change in the voltage-
dependence of channel activation, which was determined from current-voltage relationships 
(Figs. 2A and 2C).  In contrast, the K+ currents in ASK1 DN-expressing CHO cells were 
virtually indistinguishable between the vehicle and DTDP-treated groups (Figs. 2B and 2C).  
These data indicate that Kv2.1 is a downstream target of the apoptotic pathway triggered by 
ASK1 activation, even in cells that do not normally express the channel.  This strongly suggests 
that a fairly direct and ubiquitous pathway exists between the downstream signaling cascades 
activated by ASK1 and the mechanism responsible for the enhanced currents mediated by Kv2.1. 
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Figure 2.  Apoptotic increase in Kv2.1 currents in Chinese hamster ovary (CHO) cells requires 
ASK1.  (A) Current-voltage (I-V) relationships of K+ currents evoked by a series of voltage steps 
from –70 mV to +35 mV in 15 mV in 2 representative Kv2.1-expressing CHO cells exposed to 
either vehicle (circles) or DTDP (25 M, 5 min; black squares).  Note the increase in the current 
amplitude in the DTDP-treated cell, without a change in the voltage-dependence of activation. 
(B) Similar measurements were performed in ASK1 DN-expressing CHO cells exposed to either 
vehicle (circles) or DTDP (black squares).  Note the virtually indistinguishable I-V curves 
between the two representative cells. (C) Mean ± s.e.m. Kv2.1-mediated current densities from 
vehicle and DTDP treated control (black bars) and ASK1 DN-expressing (green bars) CHO cells. 
Currents were evoked with a voltage step to +5 mV from a holding potential of –70 mV and 
normalized to cell capacitance (*p<0.05; ANOVA, Bonferoni.) 
In non-stressed cells, ASK1 is bound at its N-terminal region to thioredoxin (Trx) via a 
protein-protein interaction, deeming the kinase inactive.  Trx is a redox-regulatory protein 
containing two sulfhydryl groups near its catalytic center.  Under cell stress, reactive oxygen 
species can oxidize these sulfhydryl groups, inducing the release of ASK1, which becomes 
activated following oligomerization and autophosphorylation (Saitoh et al., 1998; Liu and Min, 
2002).  We have previously observed that a free-radical spin trap can inhibit DTDP-mediated 
activation of p38 in neurons (McLaughlin et al., 2001), suggesting a role for reactive oxygen 
species in the activation of the MAPK.  DTDP is known to trigger neuronal apoptosis by first 
liberating zinc from intracellular binding proteins (Aizenman et al., 2000b).  Zinc, in turn can 
generate reactive oxygen species by modulating mitochondrial function (Sensi et al., 1999; Sensi 
et al., 2003) or activating 12-lipoxygenase (Zhang et al., 2004).  We thus hypothesized that over-
expression of Trx may prove sufficient to halt the DTDP-induced K+ current surge by providing 
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an excess of the inhibitory binding partner of ASK1.  As such, electrophysiological 
measurements were performed from vehicle and DTDP (100 M, 10 min)-treated neurons 
previously transfected with a plasmid containing Trx.  We observed virtually identical current-
voltage relationships and K+ current amplitudes (Figs. 3A and 3B) in both vehicle and DTDP-
treated neurons expressing Trx.  In contrast, recordings performed on DTDP-exposed cells not 
over-expressing Trx, but obtained from the same coverslip, revealed a pronounced K+ current 
surge, indicating that the exposure to the apoptogen had been effective across the culture.  These 
results indicate that over-expression of Trx, a suppressor of ASK1 activation, can halt the 
apoptotic increase in K+ currents in neurons.  It is possible, however, that over-expression of Trx 
may have other, non-specific effects, including a direct interaction with DTDP.  The fact that 
DTDP activates p38 in a ROS-dependent fashion (McLaughlin et al., 2001) despite the presence 
of many endogenous thiol groups does suggest, however, that Trx directly suppresses ASK1 
function.  
 
Consistent with reports involving oxidative injury (Song and Lee, 2003; Takeda et al., 
2003), we have found that ASK1 is a requisite upstream signaling kinase in a critical step of 
neuronal apoptosis; namely, an increase in voltage-dependent K+ currents.  In important recent 
studies, a link was established between Ca2+ signaling and p38 activation in neurons via the 
interaction of Ca2+/calmodulin-dependent protein kinase II (CaMKII) and ASK1 (Sensi et al., 
1999; Sagasti et al., 2001; Takeda et al., 2003).  CaMKII is a well-known regulator of synaptic 
function (Colbran and Brown, 2004), and p38 has recently been implicated in certain forms of 
synaptic plasticity (Thomas and Huganir, 2004), including an NMDA (a Ca2+-permeable 
glutamate receptor) receptor-dependent form of long-term depression that is mediated by the 
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internalization of glutamate receptors specific for AMPA (Zhu et al., 2002.  It is thus appealing 
to speculate that, based on our present findings, calcium signaling may be linked in future studies 
to long-term changes in neuronal excitability via ASK1/p38-dependent alterations in voltage-
dependent K+ currents.  
 
 
 
 
 
 
 
 126 
  
 
 
 
 
 
 127 
Figure 3.  Over-expression of thioredoxin (Trx) prevents the apoptotic current surge in neurons. 
(A) I-V relationships of K+ currents evoked by a series of voltage steps from –70 mV to +35 mV 
in 15 mV in representative Trx over-expressing neurons exposed to either vehicle (black 
triangles) or DTDP (100 M, 10 min; black squares).  Note the very similar I-V curves in these 
two cells.  An I-V relationship was also established from a DTDP-treated untransfected neuron 
from the same coverslip where the measurements from the ASK DN-expressing cell had been 
performed (black circles), demonstrating the current surge. (B) Mean ± s.e.m. current densities 
from vehicle and DTDP-treated ASK1 DN-expressing neurons (green bars).  The blue bar 
represents the current densities obtained from DTDP-treated untransfected neurons in the same 
coverslip containing the ASK1 DN-expressing cells.  Currents were evoked with a voltage step 
to +5 mV from a holding potential of –70 mV and normalized to cell capacitance (statistically 
different from the Trx+ groups, *p<0.05; ANOVA, Bonferoni).  
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Appendix C 
ASSESSMENT OF CELL VIABILITY IN PRIMARY NEURONAL CULTURES 
 
Mandar A. Aras, Karen A. Hartnett, Elias Aizenman 
Department of Neurobiology, University of Pittsburgh School of Medicine,  
Pittsburgh, PA 15261. 
 
ABSTRACT  
 
This unit contains five protocols for assaying cell viability in vitro using primary 
neuronal cultures, including a novel method for use with transfected neurons. Three of the assays 
are based on the principle that cell death cascades alter membrane permeability. The lactate 
dehydrogenase (LDH) release assay measures the amount of the cytoplasmic enzyme released 
into the bathing medium, while the trypan blue and propidium iodide assays measure the ability 
of cells to exclude dye from their cytoplasm. The 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay measures the mitochondrial activity of viable cells by 
quantifying the conversion of the tetrazolium salt to its formazan product. Finally, the fifth assay 
details the measurement of luciferase expression as an indication of neuronal viability within a 
relatively small population of transfected neurons.  
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TOPIC INTRODUCTION 
 
Research aimed at studying the cellular and molecular mechanisms of neuronal cell death 
and the development of novel neuroprotective strategies are critically important areas of modern 
neuroscience. Understanding the complexities of cell death processes has therapeutic 
implications for a variety of neurodegenerative pathologies, including stroke, trauma, epilepsy, 
Parkinson’s disease (PD), and Alzheimer’s disease (AD). As such, rapid, accurate and 
reproducible assays for measuring cell death in vitro are vital.  
 
Historically, neurobiologists have distinguished two broad categories of cell death: 
apoptosis and necrosis. In 1972, John Kerr and colleagues first coined the term apoptosis to 
describe a set of morphological features associated with cell death in pathological as well as in 
normal physiological states (Kerr et al., 1972). These characteristics, also described in the central 
nervous system (Pender et al., 1991), include chromatin condensation, nuclear DNA 
fragmentation, cell shrinkage, apoptotic body formation, and ultimate phagocytosis. On the other 
hand, necrosis follows severe pathological insults and involves cytoplasmic swelling, loss of 
membrane integrity, and cell lysis. Since the initial description distinguishing apoptosis from 
necrosis, many forms of cell death have been described combining features of both death 
programs (Bredesen et al., 2006; Unit 3.8). Importantly, as mechanisms involved in cell death 
become elucidated, additional cellular, biochemical and molecular characteristics (altered 
intracellular ion homeostasis, mitochondrial protein release, and caspase activation) are more 
appropriately used to describe this process (Pettmann and Henderson, 1998; Bredesen et al., 
2006). Neuronal cell culture models have been important tools for the elucidation of signaling 
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cascades relevant to cell death following a variety of insults, and have also provided important 
platforms for the screening of novel neuroprotective interventions. As such, rapid, reliable, and 
inexpensive methods to monitor cell death in these models have allowed researchers to provide 
key insights into the cellular and molecular basis of several neurodegenerative diseases.    
 
Although there are many methods to measure cell viability, most assays are based on a 
few guiding principles (Table 7.18.1). These principles include, but are not limited to, cell 
morphology, membrane permeability, and mitochondrial activity. Selection of the most 
appropriate protocol is driven by the specific goals of the experiment and the relative advantages 
and disadvantages of the assay. In this unit, five protocols are described in detail; the first four 
are to be used in non-transfected neuronal cultures, while a fifth, novel assay is used in 
transfected primary neural cells.  
 
The lactate dehydrogenase (LDH) release assay (Basic Protocol 1) is based on the 
principle that cell death processes in vitro eventually lead to an increase in membrane 
permeability, allowing the release of cytoplasmic enzymes into the bathing medium. This assay 
is simple, quick, and non-destructive, but it is not specific to neuronal cell death if the cultures 
contain additional cell types such as astrocytes.  Alternatively, if the cells are lysed prior to 
assaying the medium, total cytoplasmic LDH can be measured as an indication of the number of 
viable cells remaining in the culture (Alternative Protocol 1).  The tetrazolium salt, 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), is used to measure mitochondrial 
activity in viable cells (Basic Protocol 2). The MTT assay utilizes spectrophotometry to provide 
rapid and reproducible results, but provides no morphological information. The trypan blue and 
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propidium iodide assays (Basic Protocols 3 and 4, respectively) are based on the same membrane 
permeability principle as the LDH assay. However, rather than measuring the release of 
cytoplasmic contents, the trypan blue and propidium iodide assays quantify the extent to which 
cells are unable to exclude these two dyes from their cytoplasm. Although these two assays 
provide morphological information, they can be time-consuming due to manual cell counting. 
However, propidium iodide is a fluorescent biomarker and can also be quantified using a plate 
reader. Cell counting has the added advantage that it can measure cell death of neurons in mixed 
cultures when accompanied by a neuronal marker.  Support Protocol 1 provides a procedure that 
can be used to extend the time window between staining and counting cells in the trypan blue 
and propidium iodide assays.  Finally, Basic Protocol 5 describes a novel method that can be 
used to assess cell viability among positively transfected neurons. By co-transfecting neurons 
with a firefly luciferase reporter, this assay measures viability in cells with a manipulated 
genome. Although this assay selects for a relatively small population of cells that is transfected, 
it has the advantage of being able to use molecular probes to provide important mechanistic 
information about cell signaling pathways involved in the cell death process.    
 
All assays described in this unit utilize primary rat cortical neurons obtained from 
embryonic day 16 Sprague-Dawley rats (Charles River laboratories, Wilmington, MA).  Cortices 
are dissociated and the resultant cell suspension is adjusted to a density of 670,000 cells/well 
(six-well tissue culture plates containing 5, 12mm poly-L-ornithine-treated coverslips per well).  
Cultures are maintained at 37oC, 5% CO2 in 500 µl bathing medium/well composed of a volume-
to-volume mixture of 80% Dulbecco’s modified minimal essential media (MEM), 10% Ham’s 
F12 nutrients, 10% bovine calf serum (heat-inactivated, iron-supplemented; Hyclone, Logan, 
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UT) with 25 mM HEPES, 24 U/mL penicillin, 24 μg/mL streptomycin, and 2 mM L-glutamine 
(Hartnett et al., 1997).   Cultures are inhibited on in vitro day 15 with cytosine arabinoside to 
inhibit non-neuronal cell proliferation.  Cultures are normally utilized at 21-25 days in vitro 
(DIV).  All incubations are performed in a humidified 37oC, 5% CO2 chamber, unless otherwise 
noted.   
 
STRATEGIC PLANNING  
 
To facilitate data interpretation, it is useful to divide a 24-well plate into a vehicle treated 
group, experimental treatments, as well as complete-kill wells (Figure 7.18.1). Cell viability is 
often presented in the literature as percent cell death, which can be calculated as follows: 
 
 % cell death =             (ei result  -  mean vehicle result)            X  100                                              
    (mean complete kill result  -  mean vehicle result) 
 
In the above formula, ei refers to the result of individual experimentally treated wells. 
Mean vehicle result can be obtained by averaging the results from each of the vehicle-treated 
wells. Similarly, mean complete-kill result is obtained by averaging the results from each of the 
wells treated with a substance that produces 100% neuronal cell death conditions. If the 
complete-kill insult is selective for neurons, then the data can be expressed as percent neuronal 
death. For example, 24 hour exposure of cortical cultures containing neurons and glia to 300 µM 
N-methyl-D-aspartate (NMDA) or 1 mM kainate will cause 100% neuronal death while sparing 
astrocytes (Koh and Choi, 1988; Sinor et al., 2000). 
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Figure 1.  Experimental setup. Typically, 24-well plates are divided into vehicle (VEH) treated 
wells, experimental treatments (e1-4), and complete-kill (CK; 100% cell death) treated wells. 
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BASIC PROTOCOL 1:  ASSAY OF CELL VIABILITY BY MEASUREMENT OF 
LACTATE DEHYDROGENASE (LDH) RELEASE 
 
The release of lactate dehydrogenase (LDH) into the bathing medium is an indication of 
compromised membrane integrity (Koh and Choi, 1987). The quantification of LDH release is a 
rapid, reliable, and reproducible method for detecting cell toxicity without disrupting or 
destroying the cell in culture, which can also be assessed morphologically. In this assay, a 
sample of the bathing medium is combined with the assay mixture containing cofactor, substrate, 
and dye solutions. The Tox-7 assay kit (Sigma Chemical Company, St. Louis) is based on the 
conversion of the tetrazolium dye to a soluble, colored compound by nicotinamide adenine 
dinucleotide (NADH). The change in color can be easily quantified using a microplate 
spectrophotometer, with greater LDH activity indicating greater cell damage (Figure 7.18.2).   
 
Materials 
LDH-Based In Vitro Toxicology Assay Kit (Sigma, product# TOX7-1KT) 
Minimal essential media (MEM, without phenol red; Gibco, Grand Island, NY) 
Cells in 24-well culture plate, 500 µl bathing medium/well 
96 well flat bottom, clear microtiter plate 
Microplate spectrophotometer (e.g., Wallac 1420 Victor2 multilabel counter; 
PerkinElmer, Waltham, MA) 
Repeater pipette 
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1. Transfer duplicate (or greater) samples of 40 µl from each culture well to a well of a clear 
96-well plate (Figure 7.18.3). 
a. Include 40 µl samples of MEM for blank wells, 40 µl samples from vehicle 
treated wells and 40 µl from complete-kill samples. 
2. Prepare LDH mixture by combining equal amounts of LDH cofactor, substrate, and dye 
solutions (all supplied in the Tox7 kit).  For example, to assay a single 24 well plate, mix 
500 µl cofactor solution with 500 µl each of the substrate and dye. 
3. Using a repeater pipette, add 20 µl of LDH mixture per blank, vehicle, sample, and 
complete-kill well. 
4. Protect the 96-well plate from light and incubate at room temperature for 10-20 minutes. 
5. Using the plate reader, measure the absorbance at 490 nm (0.1 second) followed by 
measurement of the background absorbance at 690 nm (0.1 second).  Subtract the 
absorbance measurements at 690 nm from the primary measurements at 490 nm. Finally, 
subtract blank measurements from all vehicle, sample, and complete-kill measurements. 
6. Background-subtracted absorbance measurements from control and treatment samples 
can be expressed as % cell death (see Strategic Planning) or as the ratio, LDHTREATMENT / 
LDHCONTROL.  Differences in % cell death or the LDH ratio, expressed as a mean ± 
S.E.M, can be compared among treatment groups for statistical significance.   
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ALTERNATIVE PROTOCOL 1:  ASSAY OF CELL VIABILITY BY MEASUREMENT 
OF TOTAL CYTOPLASMIC LDH 
 
 Rather than assaying cell toxicity via the efflux of LDH into the bathing medium 
(Basic Protocol 1), this assay quantifies the number of viable cells left in the tissue culture plate 
by measuring total cytoplasmic LDH. Cells are lysed prior to sampling, allowing cytoplasmic 
contents to be released into the bathing medium. Here, a greater cell number will provide greater 
LDH activity, increasing the amount of substrate converted to colored product. This method is 
obviously destructive to the cells, so that no morphological information can be obtained. 
 
Additional Materials (also see Basic Protocol 1) 
LDH Lysis Solution (Sigma, product #L2152)   
 
1. Add 50 µl of Lysis Solution to each well of the 24-well culture plate and incubate for 
45 min at 37oC. 
2. Prepare samples and measure LDH activity according to Basic Protocol 1, Steps 1-5. 
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Figure 2.  NMDA-mediated neuronal death characterized by trypan blue (TB) cell counts and 
LDH release. Cortical cultures (21-25 DIV) containing neurons resting on an astrocyte 
monolayer were exposed to increasing doses of NMDA for 10 min. Cell counts (EC50 74.56 ± 
6.15) and LDH release (EC50 98.14 ± 18.84) were assayed 18-20 hours following treatment 
(mean ± s.e.m.; n=3 cultures).         
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BASIC PROTOCOL 2:  ASSAY OF CELL VIABILITY BY MEASUREMENT OF 
MITOCHONDRIAL ACTIVITY (MTT REDUCTION) 
 
The conversion of the yellow tetrazolium salt, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) to its purple formazan product is an indication of 
mitochondrial activity (Mosmann, 1983).  This assay provides a rapid and precise method of 
quantifying cell viability by measuring, via spectrophometry, the ability of living cells to reduce 
the MTT reagent. Following incubation of cells with the MTT reagent, lysis buffer is added to 
dissolve the insoluble purple formazan product to yield a colored solution, which is quantified 
using a microplate spectrophotometer. The relative absorbance directly correlates with cell 
number, that is, more purple color indicates more viable cells.   
 
Materials 
5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma, 
product #M2003-1G) in phosphate buffered saline (PBS; see recipe in Appendix 2A) 
Cells in 24-well plate, 500 µl bathing medium/well 
Lysis Buffer (see recipe in Reagents and Solutions) 
Microplate spectrophotometer (e.g., Wallac 1420 Victor2 multilabel counter; 
PerkinElmer, Waltham, MA) 
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1. Remove the entire volume of cell culture medium by gently aspirating each well. 
Immediately add 50 µl /well 5mg/ml MTT solution. Incubate at 37oC for 4 hours. 
2. Add 500 µl lysis buffer (equal volume to original bathing medium) and incubate 
overnight at 37oC or until the formazan precipitate is completely solubilized. 
3. Measure the absorbance of the wells at 570 nm and 630 nm (reference wavelength) with 
microplate spectrophotometer.  
4. Calculate ratio of A570/A630, which is directly related to the number of live cells in each 
well.  Differences in % cell death (see Strategic Planning), expressed as a mean ± S.E.M, 
can be compared among treatment groups for statistical significance.   
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Figure 3.  A typical 96-well setup for LDH Assay. Samples from vehicle (V) treated, complete 
kill (CK), and experimental (e1-4) wells are assayed in duplicate. Additionally, blank samples 
(B) containing MEM are used for background subtraction. Multiple 24-well plates or a greater 
number of replicate samples (e.g., triplicate, quadruplicate) can be assayed on a single 96-well 
plate.  
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BASIC PROTOCOL 3:  ASSAY OF CELL VIABILITY BY COLLOIDAL DYE 
(TRYPAN BLUE) EXCLUSION 
 
Healthy living cells contain plasma membranes that effectively exclude most large 
hydrophilic molecules. However, injured cells with compromised membrane integrity can allow 
hydrophilic molecules, such as trypan blue, into their cytoplasm. This assay is based on the 
simple principle that viable cells will exclude the trypan blue dye, whereas dead or dying 
neurons will not and thus, will appear blue. Live and/or dead cells are incubated with the dye and 
then counted in situ using bright field optics with a grid containing eye-piece. Dead cells may 
sometimes disintegrate or detach from the culture so most experimenters count live cells, which 
exclude the dye (Figure 7.18.4).  In mixed cortical cultures, a neural-specific marker (e.g., mouse 
anti-NeuN; Chemicon, Cat# MAB377) can be coupled with standard immunocytochemistry 
staining methods to facilitate the identification and counting of neurons.  As Figure 7.18.2 
indicates, cell counts using trypan blue correlate inversely with LDH release following an 
NMDA insult.   
 
Materials 
HEPES-buffered salt solution (HBS, see recipe in Reagents and Solutions) 
0.4% Trypan Blue solution (Sigma, product #T8154) 
Cells plated in 24-well culture plate, 500 µl bathing medium/well 
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1. Rinse each well with 2 ml HBS. Add 0.5 ml 0.2% Trypan Blue solution (prepared in 
HBS) to each well and incubate for 2 min at room temperature. 
2. Wash each well with 2 ml HBS to remove Trypan Blue solution.   
3. Count cells in 10 random fields per well using the grid-containing eye piece by a person 
blinded to the treatment arrangement. Express the number of dead or live cells per unit 
area. If cells cannot be counted immediately following staining, fix cells using 
paraformaldehyde (Support Protocol 1). 
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Figure 4.  NMDA-mediated neuronal death characterized by Trypan blue (TB) exclusion. Phase 
contrast images of cortical cultures (21-25 DIV) containing neurons resting on an astrocyte 
monolayer exposed to vehicle (top panel) or 50μM NMDA (bottom panel) for 10 min.  Cultures 
were fixed with phosphate-buffered 4% paraformaldehyde 24 hours following treatment.  Note 
the uptake of TB in NMDA treated cultures and the lack of TB staining in vehicle-treated 
cultures.         
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BASIC PROTOCOL 4:  ASSAY OF CELL VIABILITY USING PROPIDIUM IODIDE 
 
Propidium iodide is a cell-impermeant fluorescent biomarker that stains DNA. This assay 
is similar in principle to the trypan blue assay in that healthy viable cells will be able to exclude 
the dye from their cytoplasm, whereas dead and dying cells will not. In this assay, cells are 
incubated in propidium iodide, which will fluoresce upon binding nuclear chromatin. This 
increase in fluorescence can be measured using a multiwell plate reader or by simply counting 
fluorescent (non-viable) cells.  Importantly, propidium iodide is a potential mutagen, so special 
handling is required.  
Materials 
1 mg/ml propidium iodide (Molecular Probes, Eugene, OR; product #P3566) 
Cells in 24-well culture plates, 500 µl bathing medium/well 
Fluorescence multiwell plate reader (e.g., Wallac 1420 Victor2 multilabel counter; 
PerkinElmer, Waltham, MA) 
530 ± 25 nm excitation filter and a 645 ± 40 nm emission filter 
 
1. Add 0.1 mg/ml propidium iodide (prepared in dH2O) to culture medium for final 
concentration of 5 µg/ml. 
2. Incubate for 1 to 2 hours, 37o C. 
3. Either a) determine fluorescence of each well using a fluorometric multiwell plate 
reader equipped with a 530 ± 25 nm excitation filter and a 645 ± 40 nm emission 
filter or b) count stained cells using a fluorescence microscope. 
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a. Measure initial fluorescence of each well before applying treatments. Repeat 
steps 1-3 as needed following treatment to monitor time dependency of cell 
death. 
4. Express cell death as emission at 617 nm or percent cell death:  
% cell death = (# stained cells / # total cells)  100 
 
SUPPORT PROTOCOL 1:  PRESERVATION OF STAINED CELLS 
 
This protocol will extend the time that can be taken between staining and counting cells.  
The time window can be extended for 2-3 months, provided that the appropriate measures are 
taken (see below).  
Materials 
Stained cells (see Basic Protocols 3 & 4) 
Phosphate buffered saline (PBS; see recipe in Appendix 2A) 
Phosphate-buffered 4% Paraformaldehyde (FD NeuroTechnologies Inc., Baltimore, MD.)  
 
1. Remove stain solution and rinse each well with 2 ml PBS.  
2. Add 1 ml/well ice-cold 4% paraformaldehyde.  
3. Incubate for 5 min at 4oC and then at room temperature for an additional 10 min. 
4. Remove the fixative solution completely and rinse each well 3 x 5 min with 2 ml PBS. 
5. Store cells in the dark at 4oC until ready to count. Plates should be wrapped in parafilm 
and/or tin foil during storage to prevent evaporation of solutions.  These measures can 
extend the time window between staining and counting up to 2-3 months.     
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BASIC PROTOCOL 5:  ASSAY OF TRANSFECTED CELL VIABILITY BY FIREFLY 
LUCIFERASE ACTIVITY 
 
Mammalian firefly luciferase reporters, which generate enzymatic luciferase activity in 
transfected, surviving cells, can be used as an index of cell viability (Boeckman and Aizenman, 
1996). Because, in general, transfection efficiency is low in primary neuronal cultures, the 
luciferase assay system offers the advantages of being highly sensitive for detecting cell viability 
in a small population of transfected neurons. In spite of the low transfection efficiencies 
observed in neuronal cultures (<10%), multiple plasmids transfected together have a 90% chance 
of being expressed together by the same neurons; this being true of as many as five separate 
plasmids introduced at the same time (Santos and Aizenman, 2002). Twenty-four to forty-eight 
hours following transfection of the luciferase reporter plasmid and any other plasmids of interest, 
cultures are treated with control and experimental conditions and assayed for luciferase-mediated 
luminescence. Cell viability is proportional to luciferase luminescence. This should be initially 
confirmed with cell counts of neurons positively transfected with a green fluorescent protein 
(GFP)-expressing plasmid (Figure 7.18.5), as some experimental conditions may interfere with 
the gene expression assay.  As shown in Figure 7.18.5, luciferase activity in transfected cells 
correlates directly with GFP-positive cell counts and inversely with LDH release following an 
NMDA insult.      
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Materials 
Minimal essential media (MEM, without phenol red; Gibco, Grand Island, NY) 
SteadyLite Luciferase assay reagent (PerkinElmer, Waltham, MA; product #6016981)  
Firefly luciferase (e.g., pGL2, Promega; product #E1611) transfected cells in 24-well 
culture plate (see Appendix 1F for cationic-lipid based transfection protocols), 24-48 
hours post-transfection   
96-well white opaque plate (Corning Life Sciences, Corning, NY) 
Microplate luminometer (e.g., Wallac 1420 Victor2 multilabel counter; PerkinElmer, 
Waltham, MA) 
 
1. Bring MEM (without phenol red) and SteadyLite reagents (light sensitive) to room 
temperature 
2. Reconstitute 1 vial of lyophilized steadylite HTS substrate solution (Perkin Elmer) with 
10 ml of steadylite HTS substrate buffer solution (Perkin Elmer).  
Unused reagent can be stored at -70oC for 1 month.  
3. Remove the entire volume of cell culture medium by gently aspirating each well. 
Immediately add 100 µl /well MEM. 
4. Add 100 µl /well steadylite substrate using a repeater pipette, and incubate at room 
temperature in the dark for 5 minutes. 
5. Transfer the entire 200 µl sample volume to the well of a 96- well white opaque plate. 
6. Measure luminescence (counts per second) using microplate luminometer.  Differences in 
% cell death (see Strategic Planning), expressed as a mean ± S.E.M, can compared 
among treatment groups for statistical significance.    
 148 
REAGENTS AND SOLUTIONS 
 
Use deionized, distilled water in all recipes and protocol steps. For common stock solutions, see 
APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX. 
HEPES-buffered salt solution, pH 7.4 
 135 mM NaCl 
 10 mM KCl 
 0.4 mM MgCl2  
 1 mM CaCl2 
 10 mM HEPES  
Adjust pH to 7.4 with 1 N NaOH and filter sterilize.  Store at 4oC for up to 6 months. 
Lysis Buffer 
 10 g sodium dodecyl sulfate (SDS) 
 25 ml N,N-dimethylformamide (DMF) 
 25 ml H2O  
 1 ml glacial acetic acid 
 1.25 ml 1 N HCl 
Dissolve 20% w/v SDS into combined water/DMF solution. Adjust pH to 4.7 with 
acetic acid or 1 N HCl (Hansen et al., 1989). Store at room temperature for up to 1 month.  
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Figure 5.  LDH release assay verifies cell toxicity in positively transfected neurons. A&B)  
Cortical cultures were co-transfected with firefly luciferase (pUHC13-3) and blank vector 
(pBKCMV) at a ratio of 1:5. Forty-eight hours following transfection, cells were exposed to 
vehicle, 200 µM NMDA, or 200 µM NMDA in the presence of the non-competitive NMDA 
receptor antagonist, MK-801 (10 µM) for 30 minutes. Luciferase activity and LDH release were 
measured 24 hours following treatment (mean ± s.e.m.of 4 samples; *p<0.001; ANOVA, 
Tukey). C&D) Cortical cultures were co-transfected with firefly luciferase (pUHC13-3) and 
eGFP (pCMVIE-eGFP) at a ratio of 1:1. Twenty-four hours following transfection, cells were 
exposed to vehicle, NMDA, or NMDA + MK-801 as above. Cell counts of eGFP-positive cells 
and LDH release were measured 24 hours following treatment (mean ± s.e.m. of 3 samples; 
*p<0.001; ANOVA, Tukey; **p<0.01; ANOVA, Tukey). E) Visualization of GFP-positive 
transfected neurons in situ using fluorescence microscopy. 
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COMMENTARY 
 
Background Information 
LDH assay 
Lactate dehydrogenase (LDH) is a ubiquitous cytoplasmic enzyme responsible for 
reducing pyruvate to lactate with concurrent oxidation of nicotinamide adenine dinucleotide 
(NADH to NAD+). LDH has been shown to be released into the bathing medium of primary rat 
cortical neurons following toxic stimuli and has been correlated well to the number of lysed 
neurons killed by excitotoxicity (Koh and Choi, 1987). The advantages of the LDH release assay 
are that it is simple, rapid, and non-destructive. Since the extracellular medium is sampled, 
repeated measures can be assayed over time. Disadvantages include lack of specificity to 
neurons, LDH release dependency on cell size, and LDH degradation prior to release, or even 
possible uptake of LDH by healthy cells.  
 
MTT assay 
The tetrazolium salt, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT), is a hydrogen acceptor that is reduced to a colored formazan product. The MTT assay 
measures the redox activity of living cells by quantifying the formation of the dark blue 
formazan product at 570 nm. The reduction of the tetrazolium ring is thought to mainly occur in 
the mitochondria of cells through the actions of succinate dehydrogenase (Slater et al., 1963), but 
may also take place in other cellular and extracellular locations (Mosmann, 1983; Burdon et al., 
1993). The MTT assay provides a rapid and precise method for assaying cell viability without 
having to manually count cells. On the other hand, the assay’s disadvantages include the lack of 
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ability to distinguish reversible mitochondrial impairment and injury from cell death. 
Additionally, MTT has been shown to be inherently toxic in an adrenal pheochromocytoma 
(PC12) cell line (Hertel et al., 1996).     
 
Trypan Blue assay 
Trypan blue is an azo dye, which can be absorbed in the cytoplasm of dead or dying cells, 
staining them blue. Healthy cells, with intact cell membranes, will exclude the hydrophilic dye 
and will not change in color. This assay, although non-automated and time consuming, is the 
“gold standard” for assaying viability and is often combined with other viability assays.  
 
Propidium Iodide assay 
Propidium iodide (PI) is a DNA intercalating agent that can bind to double stranded 
nucleic acids of permeable, non-viable cells. The binding of PI to nuclear chromatin causes an 
enhancement and red shift in fluorescence (Trost and Lemasters, 1994). The PI assay is based on 
the same dye exclusion principle as the trypan blue assay, that is, injured cells will absorb dye 
and change color, whereas healthy cells will not. The advantage of using PI over trypan blue is 
that the colorimetric change can be automated due to its higher signal-to-noise ratio and therefore 
can enable rapid, repeated measures of viability over time (Trost and Lemasters, 1994). Both 
dyes, PI and trypan blue, can be used alone or in conjunction with counterstains that detect live 
cells (e.g., fluorescein diacetate). One disadvantage of using PI is that it is a potential mutagen, 
so special handling is required.  
 
 
 153 
Luciferase assay 
Luciferase is a 62 KD monomeric enzyme produced by the North American firefly 
(Photinus pyralis) and catalyzes the oxidation of its substrate, D-luciferin, to produce 
oxyluciferin and light. This assay system quantifies firefly luciferase expression in mammalian 
cells transfected with a luciferase reporter gene. Luminescence, measured by a microplate 
luminometer, is directly correlated with cell viability (Boeckman and Aizenman, 1996). This 
assay is particularly valuable when used in conjunction with other genes of interest to test 
molecular components of cell death pathways (Pal et al., 2003). The advantages of the luciferase 
assay are its reproducibility and exquisite sensitivity for measuring neuronal cell viability in a 
relatively low number of cells. Disadvantages of the assay include inability to perform repeated 
measures, dependency on transfection efficiency, and assay interference with drugs or treatments 
in the bathing medium.  
 
Critical Parameters and Troubleshooting 
LDH assay 
Pipetting seems to be the largest source of error in this assay, causing variability among 
samples. To help resolve this issue, samples should be tested in at least triplicate. Additionally, 
since this assay depends on the amount of LDH released into the bathing medium, ensure that the 
bathing medium volume is consistent among wells. Low LDH values could result from expired 
assay solutions, whereas uncharacteristically high LDH values could result from bacterial 
contamination of the culture medium or the assay solutions. If the LDH signal is completely 
absent in samples, stain cells with trypan blue to verify cell injury.      
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MTT assay 
Ensure that the MTT stock solution is filtered (0.22 µm) to remove insoluble debris and 
stored in a light protective container at 4oC. Also, be sure to set up spectrophotometer to read 
absorbance at 570 nm. If lack of signal is a problem, stain cells with trypan blue to verify cell 
injury. Uncharacteristically large signals may be due to reducing activity of certain treatments, 
leading to cell injury-independent formazan product formation. Again, high variability in this 
assay could result from inconsistent bathing medium volume among wells.  
 
Trypan Blue assay 
Complete lack of staining could be due to presence of serum in media or insufficient 
incubation time with the dye. To resolve these issues, be sure to wash out serum with buffered 
medium prior to staining or increase trypan concentration and/or duration of incubation. If 
staining results in high background, decrease duration and/or concentration of trypan blue and be 
sure to thoroughly remove dye before fixing. If too few cells are stained blue, consider staining 
at an earlier time point, as the dead cells may be detached or degraded. Alternatively, if many 
healthy-looking cells appear blue, decrease incubation time and/or dye concentration. It is very 
important that the experimenter counting cells is blinded to the treatment conditions, as this 
assay depends on the unbiased counting of cells. We recommend counting cells from 10 random 
fields per well at 200X magnification using a 10 x 10 grid-containing eyepiece.  
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Propidium Iodide assay 
For this assay, ensure that the excitation and emission filters are appropriately set in the 
plate reader. Optimization of the dye concentration and incubation time may be required to 
achieve conclusive results. If fluorescence continues to be lower than expected, stain cells with 
trypan blue to verify cell death and/or extend incubation time to allow for complete dye 
absorption. Be sure to prevent dye bleaching by protecting dye stocks from light.  
 
Luciferase assay 
Ensure that the culture medium is free of phenol red or any other colored compounds, as 
these may absorb some of the emitted light. Also, be sure to work under dim light conditions and 
avoid direct sunlight and bright fluorescent light. Optimal room and instrument temperature is 
22oC. Low luminescence values may be due to inefficient transfection of reporter gene, 
interference of treatment with luciferase activity, inefficient mixing of culture medium and assay 
reagents, and/or use of old assay reagents. It is often useful to measure LDH release activity prior 
to performing the luciferase assay to verify assay results (Figure 7.18.5). Additionally, parallel 
experiments with enhanced green fluorescent protein (eGFP; pCMVIE-eGFP, Clontech, Palo 
Alto, CA) -expressing neurons and cell counts can be used to initially verify results (Figure 
7.18.5).       
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Anticipated Results 
LDH assay 
Depending on plating density, after subtracting the absorbance at 690 nm, the LDH 
release values of dead or dying cultures should be at least 5 times greater than those of vehicle-
treated cultures.  
 
MTT assay 
Healthy cultures yield absorbance values of 0.5 to 0.6 units at 570 nm, again, depending 
on plating density.  
   
Trypan Blue assay 
Healthy cells should exclude the dye, whereas the soma of dead cells should be stained 
blue (Figure 7.18.4). Optimization of signal to background may require adjusting the time and 
concentration of trypan blue dye exposure. This assay is often used in parallel to verify cell death 
and assay results in non-transfected neurons.     
 
Propidium Iodide assay 
In general, fluorescence values of dead cultures should be at least twice those of vehicle-
treated cultures.   
 
Luciferase assay 
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We have found that luminescence values of injured cells are less than half those of 
vehicle-treated cultures and correlate well to cell counts of GFP-positive transfected cells, as 
well as LDH assay results (Figure 7.18.5).  
 
Time Considerations 
LDH assay 
The LDH assay can be completed in a very short amount of time. Set up, sampling, and 
clean-up can be performed in 20 minutes. 
 
MTT assay 
Although overnight incubation in lysis buffer ensures the complete solubilization of the 
formazan product, shorter lysis buffer incubation times are possible with thorough mixing or 
vortexing the sample.  
 
Trypan Blue assay 
The counting of stained cells is a time consuming process. If cells cannot be counted 
immediately following staining, fix cells using paraformaldehyde (Support Protocol 1).  
 
Propidium Iodide assay 
By using a fluorometric plate reader, the time required to complete this assay is 
significantly reduced. Nevertheless, manual cell counts can also be performed.  If cells cannot be 
counted immediately following staining, fix cells using paraformaldehyde (Support Protocol 1).  
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Luciferase assay 
Twenty-four or forty-eight hours following transfection with the luciferase reporter gene, 
cells are exposed to various control and experimental conditions. Cells can be assayed for 
luciferase expression following experimental conditions based on time-course of treatment 
toxicity.   
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Table 1 – Methods for assessing neuronal cell viability a  
GUIDING 
PRINCIPLE 
ASSAY MEASURED 
QUANTITY 
FORMAT SAMPLE 
REFERENCES 
Morphology     
 Light,Electron 
Microscopy 
Cell morphology Microscopy Vincent and Maiese, 1999 
Membrane 
Permeability 
    
 Propidium iodide, 
Ethidium homodimer 
Staining of nucleic 
acids 
Fluorometry or 
Microscopy 
Garner et al., 1994 
 Trypan blue Cell morphology Microscopy Perry et al., 1997 
 51Cr Radiolabeled Cr Radioactivity Kingsbury et al., 1985 
 LDH LDH activity Colorimetry Koh and Choi, 1987 
Electrophysiology     
 Membrane potential, 
action potential 
generation, synaptic 
potentials 
Electrophysiological 
response profile of 
cells 
Electrophysiology Pal et al., 2003 
Ionic homeostasis     
 Fura-2, Indo-1, Fluo-
3 
Intracellular free 
calcium 
Fluorometry Mattson et al., 1993 
 Neutral red Lysosomal pH Fluorometry Verdaguer et al., 2002 
Metabolism     
 Luciferase 
expression, eGFP 
expression 
Protein synthesis Luminometry or 
Microscopy 
Pal et al., 2003 
 Glucose utilization, 
lactate production 
Substrate utilization Biochemistry Mills et al., 1995 
 Fluorescein diacetate, 
calcein-AM 
Esterase activity Fluorometry Bozyczko-Coyne et al., 
1993 
Mitochondrial 
function 
    
 MTT, XTT Succinate 
dehydrogenase 
Colorimetry Slater et al., 1963 
 Rhodamine 123 Mitochondrial 
membrane potential 
Fluorometry Mattson et al., 1993 
DNA damage     
 TUNEL Cleaved DNA Microscopy Perry et al., 1997 
 Gel electrophoresis Cleaved DNA Electrophoresis Ormerod et al., 1992 
 Hoechst staining Staining of DNA Microscopy Ormerod et al., 1992 
Signal 
Transduction 
    
 Caspase Assays Caspase activity Fluorometry or 
colorimetry 
McLaughlin et al., 2001 
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 Annexin V Extracellular 
Phosphatidylserine 
Flow cytometry Vincent and Maiese, 1999 
a Assays indicated in bold are detailed in this document.  
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